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General introduction 





Esophageal atresia (EA) with or without tracheoesophageal fistula (TEF) is a relatively common 
congenital anomaly involving the esophagus and trachea. It is the most common congenital 
anomaly of the esophagus, which was first described in twins by Durston in 1670 1. In Europe, 
one in 4,000 newborns is born with EA 2. In the Netherlands each year around 35-55 newborns 
are born with EA 3. 
The Gross classification distinguishes five types of EA based on the presence and location of 
atresia and TEF: isolated EA (type A), EA with proximal TEF (type B), EA with distal TEF (type C), 
EA with dual TEF’s (type D), and isolated TEF (type E)  figure 1.1 4. EA type C (EA with a distal TEF) 
is the most common form (85.8%), followed by type A (7.8%), E (4%), D (1.4%) and B (0.8%) 4.
Early surgical intervention is needed as EA results in a collection of saliva in the blind proximal 
esophageal pouch, causing regurgitation, coughing and choking. In types B to D – depending 
on the location of a coexisting TEF – food, saliva or acid stomach contents passes through the 
fistula into the trachea and lungs, inducing respiratory problems, aspiration pneumonia or 
even acute upper respiratory tract obstruction with a subsequent respiratory arrest.
Surgery and survival
In 1939, Ladd and Leven performed the first successful surgical corrections of EA 5, 6. These first 
two long-term survivors of EA underwent staged repair with delayed esophageal replacement: 
an antethoracic skin-tube conduit of the thoracic esophagus and a jejunal interposition. The 
first successful primary repair (end-to-end anastomosis) of EA was performed by Haight in 
1941 7. In the following decades the survival of children born with EA showed spectacular 
improvement  figure 1.2  8, 9. Nowadays, with improvement of surgical techniques and 
intensive care treatments, survival after EA repair is approaching 95%-100% in dedicated 
centers. Only children with extensive comorbidity – due to severe prematurity, major other 
congenital abnormalities or chromosomal defects – die 10, 11.
As the majority of children survives surgical correction of EA beyond the neonatal period, 
focus has shifted from short-term mortality to long-term morbidity. EA is no longer a medical 
problem in just young infants, but a lifelong problem in all patients born with EA. Besides 
direct disease related gastrointestinal and respiratory morbidity, growth impairment and 
neurodevelopmental problems are frequently seen in EA patients 12-14. A multidisciplinary 
approach to morbidity in EA patients is necessary as most of these problems are multi-
factorial. A structured follow-up may help to reduce overall morbidity and improve quality  
of life of children with EA and their families 15. 
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Figure 1.1 Normal esophageal development and the fi ve types of esophageal atresia 
(Gross types A, B, C, D and E).
Figure 1.2 Children born with EA and treated between 1948 and 1972 in the Erasmus MC-Sophia 
Children’s Hospital in Rotterdam (Figure adapted from EUR thesis van Walleghem 1973). 
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In The Netherlands surgical repair of EA and TEF takes place in all university hospitals involved 
in neonatal surgery. Each year around 10-15 newborns with EA and/or TEF are admitted to the 
Intensive Care Unit of the Erasmus MC-Sophia Children’s Hospital in Rotterdam. Since 1999, 
all children born with EA have joined a longitudinal follow-up program at the Pediatric 
Surgery department, with scheduled visits until 18 years of age and transfer for adult care 16, 17. 
Researchers of our center previously published data on growth up to 5 years of age, long-term 
respiratory problems, long-term neurodevelopmental problems and genetics in EA patients 18-25. 
This thesis focuses on gastrointestinal morbidity after EA repair.
Gastroesophageal reflux and associated  
gastrointestinal problems
After EA repair, esophageal dysmotility is present in almost all patients 26. Several patho-
physiological mechanisms underlying disturbed esophageal motility in EA patients have  
been suggested. Inborn deficient esophageal innervation and abnormal esophageal smooth 
muscle development seem to play a role, but also surgical injury to the vagal nerve and 
esophageal damage caused by surgical complications (e.g. anastomotic leakage, anastomotic 
strictures and subsequent dilation procedures) are thought to be related to dysmotility in EA 
patients 27-33.
Esophageal motility disorders might lead to aspiration, gastroesophageal reflux (GER), 
complaints of dysphagia and feeding problems with associated growth impairment.  
A systematic review of chronic long-term problems in EA patients found a high prevalence  
of GER symptoms of 40.2% compared to 10%-20% in the general population 34, 35. However,  
no uniform definition to define GER was used which complicates comparing results from 
different studies. The gold-standard test for the diagnosis of GER is pH monitoring with or 
without impedance monitoring 36. Both pH and impedance monitoring measure the acid 
reflux burden. The additional value of impedance monitoring is the ability to detect non-acid 
reflux and is therefore a good diagnostic tool to evaluate the correlation between symptoms 
and (acid and non-acid) reflux events 36-38. 
Since it is unlikely that there is an absolute cut-off value that distinguishes pathologic from 
physiologic GER, the NASPGHAN-ESPGHAN guideline on GER suggests to consider a reflux 
index between 3% and 7% to be indeterminate (abnormal and normal index: >7% and <3%,  
respectively) 36. A Danish study found an abnormal reflux index in 32/58 (55%) children with  
EA aged 5-15 years 39. 
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As gastrointestinal problems – including GER – are prevalent in EA patients, recent 
NASPGHAN-ESPGHAN guidelines for the management of gastrointestinal complications in 
children with EA were developed 38. GER is already present in the neonate and often continues 
into early childhood and adulthood. Long-term exposure of the esophagus to GER might lead 
to esophageal damage including esophagitis, esophageal strictures, Barrett’s esophagus (BE) 
and eventually esophageal adenocarcinoma 40-43. To diminish associated complications early 
diagnosis and treatment of GER is important. 
The recommendations in the recent guidelines for the management of gastrointestinal 
complications in children with EA (published in 2016) are mainly based on expert opinions,  
as only a few randomized controlled trials in EA patients were available 38. The guidelines 
recommend to treat all EA patients with acid suppression in the neonatal period up to the age 
of one year 38. At time of discontinuation of acid suppression, it is recommended to monitor 
GER using combined impedance and pH monitoring to evaluate the need for continuation of 
acid suppression 38. Since GER can be asymptomatic, it is advised to perform three routine 
endoscopies in asymptomatic children: one after discontinuation of acid suppression, one 
before the age of 10 years and one at transition to adulthood 38. 
Anastomotic stricture formation is the most frequent complication after EA repair, present in 
up to 59% of EA patients 44. The newest ESGE-ESPHGAN guideline on pediatric endoscopy 
defines a refractory stricture of the esophagus as ‘an anatomic stricture without endoscopic 
inflammation that results in dysphagia after a minimum of five dilations at maximally 
four-week intervals’ 45. Frequent dilation procedures in these children result in a high burden 
for both child and parents. 
As GER is present since early childhood, concerns in adult EA patients include development of 
BE and esophageal carcinoma. Eight esophageal carcinoma have been reported in young adult 
EA patients 46-52, but it was not until recently that esophageal surveillance has been suggested 
in this group of patients. The recent guidelines recommend surveillance endoscopy every five 
to ten years to detect early signs of esophageal metaplasia or malignancy, but the ideal 
endoscopic surveillance strategy has yet to be determined 38.
Due to the absence of clinical practice guidelines on care for EA patients beyond childhood, 
hospitals have lost sight of adult EA patients over the years 53. This is enhanced by the fact that 
EA patients do not easily seek medical help for gastrointestinal complaints, as they may have 
gotten used to these symptoms over the years. As a result, the burden of long-term 
gastrointestinal problems in adult EA patients is still unclear.
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Aims and outline of the thesis
This thesis aims to optimize long-term gastrointestinal follow-up of EA patients. 
As described above, many EA patients – both children and adults – experience GER. GER results 
in gastrointestinal problems such as dysphagia, feeding difficulties, esophageal strictures, 
esophagitis, BE, and esophageal cancer. Since gastrointestinal and pulmonary problems can 
compromise growth, this thesis will start with a longitudinal evaluation of growth of EA 
patients from infancy up to school age in chapter          . In addition, this chapter focuses on 
determinants associated with growth impairment.
Chapter            gives an overview of the prevalence of esophagitis, BE, and esophageal cancer in 
EA patients. The few strategies for esophageal surveillance programs suggested in literature 
are shortly mentioned in this chapter.
At present, it is recommended to monitor GER at time of discontinuation of acid suppression 
and during long-term follow-up in symptomatic children born with EA. The results of routine 
evaluation of GER in EA patients aged ≤18 months and 8-years old using combined impedance 
and pH monitoring are evaluated in chapter          .
Chapter            describes the incidence of refractory strictures of the esophageal anastomosis in 
a large national multicenter cohort of children born with EA. Determinants of refractory 
stricture formation are discussed in more detail in this chapter.
GER can result in chronic damage to esophageal mucosa. Chapter            assesses the prevalence 
of BE and esophageal carcinoma in a prospective screening and surveillance program in adult 
EA patients.
Four EA patients that developed carcinoma in the gastrointestinal tract at a relatively young 
age are described in more detail in chapter          .
In chapter            the main findings and conclusions of the studies are placed in broader 
perspective and suggestions for future research are discussed. 
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Previous studies reported diminished growth after oesophageal atresia (OA) repair.  
We evaluated long-term follow-up data on growth.
Methods
Longitudinal cohort study up to 12 years. Patients with OA, born 1999-2013, who participated 
in a longitudinal follow-up programme were included. Children with genetic syndromes 
associated with growth disorders were excluded. SD scores (SDS) for height-for-age (HFA), 
weight-for-height (WFH) and distance-to-target-height were calculated for routine visits 
(0.5/1/2/5/8/12 years). Linear mixed models were used to estimate SDS until 12 years of age and 
to evaluate explanatory factors for growth.
Results
We included 126/155 children (32% prematurely born, 20% small for gestational age), 32 
reached the age of 12 years. Fundoplication surgery was performed in 24%. SDS-HFA was below 
normal up to 8 years but improved over these years (mean (SE) -0.48 (0.09), -0.31 (0.09) and 
-0.20 (0.13) at 0.5, 8 and 12 years). Scores improved after correction for target height (mean 
(SE) -0.29 (0.10), -0.17 (0.09) and -0.10 (0.14) at 0.5, 8 and 12 years). SDS-WFH was below 
normal from age 1-5 years (mean (SE) -0.53 (0.09), -0.24 (0.09) and 0.03 (0.14) at 1, 5 and 12 
years). Low birth weight and fundoplication surgery were negatively associated with growth.
Conclusions
The growth of patients with OA was below the reference norm during the first years of life, but 
normalised at 12 years. Large longitudinal cohort studies should evaluate if normal growth 
persists into adolescence. Early nutritional assessment with timely dietary intervention 





Oesophageal atresia (OA) is a rare anatomical anomaly which occurs in 2.43 per 10,000 births 
worldwide 1. Over the past decades, survival rates have improved to up to 95% 2, 3. While OA 
outcome research used to focus on respiratory or gastrointestinal morbidity, we have come  
to realise that growth is an important outcome measure too. Many of these children are born 
small for gestational age (SGA) or prematurely 1, 4, and growth might be compromised by 
feeding difficulties, gastrointestinal problems, recurrent pulmonary infections, associated 
congenital malformations and genetic syndromes.
Most studies on growth in patients with OA are cross-sectional or retrospective 5-16. Our group 
previously published longitudinal data on growth, which suggested persisting growth 
impairment up to 5 years 17.
We therefore hypothesised that children with OA face growth problems at the longer term, 
notably if serious comorbidity is present. We longitudinally evaluated the growth of patients 




We included patients with OA born between 1999 and 2013, who after birth were admitted to 
the Intensive Care Unit of the Erasmus MC-Sophia Children’s Hospital, Rotterdam, the 
Netherlands, and since then participate in a longitudinal follow-up programme. Physical 
health, growth, lung function when appropriate and developmental parameters are regularly 
assessed until 17 years of age 17. Parents were informed about the study. The Medical Ethics 
Committee of Erasmus MC concluded that the Medical Research Involving Human Subjects Act 
did not apply to the study protocol (protocol ID MEC-2016-111). Data were included until 
December 2015. Data from children with genetic syndromes known to be associated with 
growth disorders were excluded. 
Study design
The following general data were retrieved: gender, ethnicity, gestational age, birth weight, 
type of OA according to Gross 18, associated anomalies, type of primary oesophageal surgery, 
initial days on ventilator and parental height. In addition, specific data were retrieved related 
to growth status (baseline and at follow-up): height, weight, type of feeding, diagnosis of 
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gastrooesophageal reflux (GOR), therapy for GOR, pulmonary infections, use of antibiotics 
(prophylaxis or therapeutic dose), number and duration of hospital admissions, number of 
surgical interventions and number of dilations of oesophageal stenosis.
Comorbidity was classified as major or minor. Major comorbidities included Ravitch’ 
paediatric surgical index diagnoses 19, cardiac malformations requiring surgical correction or 
follow-up by a paediatric cardiologist, other congenital malformations requiring major 
surgical interventions, and malformations seriously affecting normal function (eg, tethered 
cord with neurogenic bladder function). All other anomalies were considered minor (eg, 
small atrial septal defect closing spontaneously). VACTERL association was defined according 
to Solomon et al. 20 Prematurity was defined as a gestational age <37 weeks. SGA was defined 
as a birth weight 2 SDs below normal 21. High-calorie nutrition included fortified breastmilk, 
additives such as soybean fat, and concentrated formula. GOR was considered clinically 
significant if fundoplication surgery was performed, if pH monitoring showed pathological 
reflux or if upper endoscopy showed typical reflux-induced mucosal lesions 22. Besides, 
spontaneous GOR extending to the proximal oesophagus at contrast oesophagography with 
typical symptoms was diagnosed as GOR. GOR was classified as either adequately treated 
(fundoplication surgery performed, medical therapy without symptoms or normal pH 
monitoring during treatment) or insufficiently treated (ie, clinical symptoms, symptomatic 
spontaneous GOR in proximal oesophagus or presence of GOR during pH monitoring despite 
medical therapy). Pulmonary infections were defined as lower respiratory tract infections 
requiring antibiotics and/or hospital admission.
Physical growth
Physical growth was evaluated by weight and height measurements at 0.5, 1, 2, 5, 8 and 12 
years of age. SD scores (SDS) were calculated for height-for-age (HFA) using the 
populationspecific reference data from the Fifth Dutch Growth Study (2009) 23. SDS for 
weight-for-height (WFH) were calculated using normative references 24. SDS-HFA was 
corrected for Moroccan or Turkish ethnicity if applicable 25. We corrected for prematurity until 
2 years of corrected age. Target height (TH) and its SDS were calculated with parental heights 
as previously described 26. SDS for distance-to-target-height (SDS-DTH) was calculated as 
SDS-HFA minus SDS-TH. Wasting (acute malnutrition) and stunting (chronic malnutrition) 
were defined as, respectively, WFH and HFA >2 SD below normal 27.
Data analysis 
Data are summarised as percentages, mean (SD or SE) or median (range), as appropriate. To 
evaluate growth longitudinally, we used linear mixed models for the repeated measurements 
of growth SDS 28. In the linear mixed models, the dependent variable consisted of SDS for 
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HFA, DTH and WFH at 0.5, 1, 2, 5, 8 and 12 years of age. The following variables were considered 
for inclusion as explanatory variables: assessment age (coded as a categorical variable), birth 
weight, OA Gross type A, VACTERL association or major anomalies, thoracotomy, duration of 
initial ventilation, fundoplication surgery (coded as a time-dependent dichotomous variable: 
negative before and positive after fundoplication), number of surgeries, history of GOR, 
occurrence of pulmonary infections in the previous year and number of dilation procedures. 
Three models (for SDS-HFA, SDS-DTH and SDS-WFH) were fitted using a stepwise backward 
approach (p-value cut-off of 0.20). An unstructured covariance matrix was used to account for 
the within-subject correlations. After the stepwise backward variable selection, statistically 
significant interaction effects of assessment age and each of the other selected explanatory 
variables were included. Multicollinearity was assessed using variance inflation factors (VIFs). 
All VIFs were <2.5, suggesting that multicollinearity was not a problem 29.
For each growth parameter two other linear mixed models were estimated, one with only 
assessment age, and one with assessment age, fundoplication and their interaction term 
included as explanatory variables. The results of these linear mixed models were summarised 
using the estimated marginal means, which are the mean predicted values of the dependent 
variable (growth SDS) adjusted for the effect of explanatory variables. These estimated 
marginal means were used to compare the mean SDS for growth parameters with the norm in 
the reference population (SDS=0).
The statistical analyses were performed using SPSS V.21.0 for Windows (IBM, Chicago, Illinois, 
USA) with a two-sided significance level of 0.05.
results
Demographic characteristics
Of the 155 children born with OA in the study period, 126 were included (see exclusion details 
in  figure 2.1 ). Reasons for missing growth data were refusal (n=11), emigration (n=7), follow-
up performed at another age for organisational reasons (n=3), follow-up at other hospital 
(n=1), lost to follow-up (n=1) and no length measurement available (n=1). Variation in age of 
all children attending visits is available in  supplementary table 2.1 .  table 2.1  summarises 
demographics. Male sex predominated; almost one-third were born prematurely and almost 
one-fifth were born SGA. Vertebral anomalies, anal atresia, cardiac anomalies, tracheo-
oesophageal fistula, renal anomalies, and limb defects (VACTERL) association or major 
anomalies were reported in 32 (25.4%) children. Nearly half of the children (n=59; 46.8%) were 
extubated on the first postoperative day. Fifty-four children were extubated after 2-7 days, 8 
after 8-14 days, 2 after 14 days and 3 after more than a month (37, 41 and 43 days, respectively).
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Figure 2.1 Enrolment of patients with oesophageal atresia (OA) (N=126). For each routine visit, the 
actual number of patients of whom growth data were obtained and the number of patients who 
reached the specified age of the visit are shown. CHARGE, coloboma, heart defects, atresia of the 
choanae, retardation of growth, genital and urinary abnormalities, ear abnormalities and/or hearing 
loss.
In 12 (9.5%) children primary surgery consisted of a gastrostomy (Gross type A/B/C in 5/1/6, 
respectively). Anastomosis was obtained in all but one child at a median age of 78 (30-143) 
days.
Thirty-nine (31.0%) children used high-calorie nutrition. Tube feeding or parenteral nutrition 
was discontinued in 29 (60.4%) children before the 6-month visit. At 5 years of age, 4 (4.1%) 
children still used high-calorie nutrition and 2 (2.1%) children still needed (supplemental) 
tube feeding.
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Table 2.1 Patient demographics (N=126) 
  n (%)
Males 78 (61.9)
Ethnicity 
- Dutch 109 (86.5)
- Moroccan 6 (4.8)
- Turkish 5 (4.0)
- Other 6 (4.8)
Gestational age (weeks); median (range) 38.3 (25.6-42.3)
Prematurity 40 (31.7)
Birthweight (kilogram); median (range) 2.830 (0.725-4.505)
SGA 25 (19.8)
Type of OA 
- Type A 5 (4.0)
- Type B 1 (0.8)
- Type C 114 (90.5)
- Type D 3 (2.4)
- Type E 3 (2.4)
Type of oesophageal correction 
- Primary anastomosis 111 (88.1)
- Delayed anastomosis 11 (8.7)
- Gastrostomy  [a] 1 (0.8)
- Ligation of tracheo-oesophageal fistula 3 (2.4)
Type of surgery 
- Thoracoscopy 42 (33.3)
- Thoracotomy 81 (64.3)
- Converted 3 (2.4)
Associated problems 
- Major associated problems 28 (22.2)
- VACTERL association 16 (12.7)
- Minor associated problems 38 (30.2)
Initial days on ventilator; median (range) 2 (0-73)
Initial hospitalization (days); median (range) 23 (7-464)
Hospital admissions in first 2 years of follow-up; median (range) 
- Number of admissions 3 (1-19)
- Duration (days) 41 (8-467)
Feeding type at initial discharge 
- No tube feeding 78 (61.9)
- (supplemental) tube feeding  [b] 47 (37.3)
- Parenteral nutrition 1 (0.8)
History of GOR  [c] 56 (44.4)
Fundoplication surgery  [d] 30 (23.8)
Dilation of oesophageal stenosis  [e] 75 (59.5)
History of pulmonary infection(s) 102 (81.0)
Prophylactic antibiotics  [f] 54 (42.9)
GOR, gastro-oesophageal reflux; OA, oesophageal atresia; SGA, small for gestational age.
a No oesophageal continuity was obtained in one patient with a long-gap OA. 
b Discharge with (supplemental) nasal gastric tube (n=35), nasal jejunal tube (n=1), gastrostomy (n=10) or jejunostomy (n=1) 
feeding.
c First diagnosis of GOR: fundoplication surgery performed (n=25), pathological pH monitoring (n=28), typical reflux-induced 
lesions during endoscopy (n=1), pathologic contrast oesophagography with typical symptoms (n=2).
d Nissen (n=29) or Thal fundoplication (n=1) performed at a median age of 175 (range 54–1343) days. Redo-fundoplication 
was needed in four patients, with a median time interval after initial fundoplication surgery of 253 (range 91–434) days.  
Two redo-fundoplication surgeries were performed in one patient.
e Median of 2 (range 1–15) dilations.
f Number of patients with prophylactic antibiotic treatment for respiratory and/or urinary tract infections. 
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At each routine visit until the 8-year visit, half of the children received antibiotic treatment for 
respiratory tract infections (prophylaxis or therapeutic dose); at the 12-year visit this was the 
case for only 21.9%. Prophylactic antibiotics for respiratory or urinary tract infections were 
given to 42.9% of the children, mostly in the first 2 years.
Eighty-three per cent (n=105) of children had been readmitted before the 6-month visit. 
Readmission rates since their last visit were around 30% for the periods 0.5-1, 1-2 and 2-5 years. 
Only 16% had been admitted between 5-8 and 8-12 years. 
Fundoplication surgery was needed in 30 (23.8%) children. Indications were apparent 
life-threatening events suspected of GOR (n=15), recurrent oesophageal strictures in 
combination with oesophagitis (n=5) or feeding difficulties (n=6), vomiting with oesophagitis 
(n=2) and persistent acidic GOR despite adequately dosed anti-acid drug therapy (n=2). In 24 
patients, a reliable pH monitoring was obtained prior to fundoplication, in 70.8% (n=17) GOR 
was confirmed. Surgeries other than fundoplication procedures (eg, aortopexy, 
reconstruction of anorectal/cardiac/limb malformations, pyloromyotomy or closure of 
recurrent tracheo-oesophageal fistula) were performed in 48.4% (n=61).
Physical growth
 table 2.2  summarises all biometric results. SDS-HFA was below the population norm in the 
first 8 years, but improved over these years. Chronic malnutrition (stunting) was reported in 
5%-8% of children (depending on age). After correction for TH, results of HFA were more 
favourable. SDS-DTH <−2 SD was present in 3%-5% of children. Mean SDS-WFH declined in the 
first 2 years, after which it improved and normalised at 8 years. Mean SDS-WFH was below the 
population norm at the ages of 1, 2 and 5 years. Wasting was present in 3%-12% of children.
Determinants of growth impairment
Results of the multivariable linear mixed models are listed in  table 2.3 . One or more 
explanatory variables were missing in 0.5% of the visits, and these visits were excluded from 
the longitudinal analyses. Lower birth weight and fundoplication surgery, after adjustment 
for other factors, were associated with lower SDS for all three growth parameters. Children 
who underwent fundoplication surgery had significantly lower SDS-WFH at their subsequent 
visits, but this association was age-dependent (interaction term; illustrated in  figure 2.2 ) see  
 supplementary figures 2.1 and 2.2  illustrating individual trajectories and for each patient 
the change in SDS compared with the previous time point). The number of surgeries and 
history of pulmonary infections were positively associated with WFH.
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Table 2.2 Biometric results for all age groups
Age SDS-HFA   SDS-DTH   SDS-WFH 
   Stunting   SDS-DTH <-2   Wasting
years mean (SE) p-value n (%) mean (SE) p-value n (%) mean (SE) p-value n (%)
0.5  -0.479 (0.087) <0.001 10 (7.9) -0.288 (0.100)   0.005 6 (4.8) -0.164 (0.099)   0.100 9 (7.1)
1  -0.446 (0.090) <0.001 9 (7.2) -0.280 (0.097)   0.005 6 (4.8) -0.534 (0.094) <0.001 11 (8.8)
2  -0.343 (0.089) <0.001 8 (6.6) -0.172 (0.095)   0.074 4 (3.3) -0.624 (0.094) <0.001 15 (12.3)
5  -0.412 (0.092) <0.001 5 (5.2) -0.271 (0.098)   0.007 4 (4.2) -0.236 (0.093)   0.013 3 (3.1)
8 -0.310 (0.090) <0.001 3 (4.8) -0.173 (0.093)   0.066 2 (3.2) -0.179 (0.109)   0.104 2 (3.2)
12  -0.197 (0.133)   0.146 2 (6.3) -0.102 (0.139)   0.468 1 (3.1) 0.028 (0.144)   0.849 1 (3.1)
SDS-HFA, SDS-DTH and SDS-WFH = SD scores for height-for-age, distance-to-target-height and weight-for-height. For each 
growth parameter, a separate linear mixed model including only assessment age as explanatory variable was estimated.  
The estimated marginal means were used to compare the mean SDS with the norm in the general population (SDS=0).  
Bold typeface indicates significance level of 0.05.
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The linear mixed models did not reveal any significant associations between the growth 
parameters and OA Gross type A, VACTERL association or major anomalies, thoracotomy, 
duration of initial ventilation, history of GOR or number of dilation procedures.
Table 2.3 Estimated coefficients of the mixed models for SDS for HFA, DTH and WFH
Mixed model  Estimated coefficient (95% CI) p-value
SDS-HFA Assessment age [a] 0.001
 Birthweight; kilogram 0.3791 (0.1807 – 0.5775) <0.001
 Fundoplication surgery performed -0.3615 (-0.6147 – -0.1082) 0.005
 Initial days on ventilator -0.0147 (-0.0303 – -0.0009) 0.064
SDS-DTH Assessment age [a] 0.001
 Fundoplication surgery performed -0.4621 (-0.7364 – -0.1879) 0.001
 Birthweight; kilogram 0.3218 (0.1182 – 0.5254) 0.002
 Initial days on ventilator -0.0159 (-0.0331 – 0.0012) 0.069
SDS-WFH Assessment age [a] 0.001
 Interaction fundoplication surgery with age [a,b] <0.001
 Number of surgeries performed 0.1277 (0.0411 – 0.2143) 0.004
 Birthweight; kilogram 0.2457 (0.0479 – 0.4435) 0.015
 History of pulmonary infection(s)  [c] 0.1517 (0.0254 – 0.2779) 0.019
 Thoracotomy performed  [d] -0.2787 (-0.5911 – 0.0338) 0.080
 VACTERL association or major anomalies -0.3033 (-0.6552 – 0.0487) 0.091
SDS-HFA, SDS-DTH and SDS-WFH = SD scores for height-for-age, distance-to-target-height and weight-for-height.
Bold typeface indicates significance level of 0.05.
a Estimated coefficients with 95% CIs are not shown for this categorical variable.
b The interaction term represents the age-dependent effect of fundoplication surgery on SDS-WFH after adjustment for the 
main effect of age and other explanatory variables, but without adjustment for the main effect of fundoplication surgery.  
The interaction term would also contribute significantly to the model after adjustment for the main effects of both age and 
fundoplication surgery.
c Occurrence of lower respiratory tract infection(s) requiring antibiotics and/or hospital admission in previous year.
d Thoracotomy performed during primary oesophageal atresia repair. 
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Figure 2.2 Biometric results for SDS-HFA (A), SDS-DTH (B) and SDS-WFH (C) of children with and 
without fundoplication surgery. Symbols represent the estimated marginal means of the SD scores (SDS) 
with associated 95% CIs (error bars) for the different growth parameters at the different time points, 




In this study in 126 children born with OA, we found a significantly lower weight and height in 
the first 5 and 8 years of life compared with the general population. Weight and height had 
normalised, however, at 12 years of age. To our knowledge, our study is the first to address 
DTH in patients with OA. TH can be useful to discriminate the influence of disease on growth 30. 
When height was corrected for individual TH, the SDS for height (SDS-DTH) improved. This 
finding shows the importance of structurally recording parental height, as a child’s 
nutritional status can be underestimated when only interpreting SDS-HFA. Stunting was 
present in a minority of children and was seen less frequently when children got older. Two of 
the studied explanatory variables were negatively associated with growth, that is, low birth 
weight and fundoplication surgery.
Previous studies reported reduced HFA in patients with OA 5, 7-9, 11, 12, 14-16. Longitudinal data 
showed growth problems up to 5 years of age with catch-up between 2 and 5 years 17, 31. HFA 
was significantly lower in the first 2 years of patients who underwent thoracoscopic repair 31. 
The small sample size in the latter study (n=37) limits the strength of the evidence, however.
In our cohort, WFH was found to decline in the first 2 years, indicating acute weight loss.  
After this age, WFH recovered and had normalised at 8 years of age. Several retrospective and 
cross-sectional cohort studies described weight below the reference norm in patients with  
OA 5, 7-9, 11, 12, 15, 16. Longitudinal data published by our group showed a weight-for-age below 
the norm during the first 5 years 17. WFH was significantly lower in a small series of patients 
with thoracotomic repair 31. These results warrant early dietary management, as a good 
nutritional status in the first years of life is crucial for normal brain and immune system 
development 32, 33.
In this study, patients with OA showed catch-up growth before puberty. We suspect that fewer 
pulmonary infections and shorter duration of hospitalisation after the first 2 years of life 
contributed to an early growth spurt 17, 34.
We found two of the studied explanatory variables to be negatively associated with growth. 
For one, children with a low birth weight were more likely to have a short stature and to be 
underweight, which is in concordance with previous studies 35. Second, many children who 
underwent fundoplication surgery, typically performed in the first 6 months, had height and 
weight below the reference norm after this surgery (at 12 years only mean SDS-WFH was 
improved to normal). We suspect that these children have persistent feeding problems 
preventing catch-up growth. Moreover, they may have had more extreme disease severity 
posing a risk for failure to thrive. The SDS-WFH of these children increased from 1 to 2 years, 
which we assume can be ascribed to adequate treatment of severe GOR.
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Our finding that number of surgeries and history of pulmonary infections were positively 
associated with WFH was unexpected. We speculate that children with recurrent 
hospitalisations more often received dietary interventions. Close involvement of 
multidisciplinary nutrition support teams was indeed found to prevent failure to thrive in 
patients with congenital diaphragmatic hernia 36. It is worth recommending to have such 
teams, including dietitians and speech-language pathologists, available to support 
hospitalised children in general, and continue supporting high-risk patients after discharge 
to home.
Previous studies reported long-gap OA, oesophageal substitution and a history of GOR as 
explanatory variables for growth impairment 6, 7, 12. We also evaluated these factors, but did 
not find associations with growth impairment, perhaps because the sample size is relatively 
small for multivariable analyses.
The strengths of our study are the longitudinal design and the large cohort (considering the 
rarity of OA) followed in a highly structured follow-up programme. Still, some limitations of 
our study should be addressed. First, not all children appeared at all scheduled visits to the 
outpatient clinic, resulting in missing data for these visits. With linear mixed models, we 
accounted for these missing data. Second, the overall nutritional intake of the children is 
unknown because a dietitian was not structurally involved in the follow-up programme. 
Finally, dietary management, GOR diagnostics/therapy, motility studies and use of antibiotics 
were not recorded prospectively. To our knowledge, there is no literature on the effect of poor 
gastrointestinal motility on growth in patients with OA. It would be interesting to correlate 
motility and growth in future studies in patients with OA.
In conclusion, we found physical growth in patients with OA to be compromised during the 
first 5 or 8 years of life. Still, at 12 years of age, growth parameters had improved to normal 
values in most children, but children who underwent fundoplication surgery had SDS-HFA 
and SDS-DTH significantly below SDS=0 at 12 years  figure 2.2 . The question is whether 
growth remains normal during puberty or whether nutritional intervention is needed in 
adolescence. Therefore, structural follow-up of all patients with OA, especially those who 
underwent fundoplication surgery, should be considered up to adulthood. Dietitians, as part 
of a multidisciplinary team, should be involved during (initial) hospitalisation and follow-up 
to optimize nutritional status in early years, which is crucial for normal brain and immune 
system development. Future multicenter studies should focus on optimisation of nutritional 




1 Pedersen, R.N., et al., Oesophageal atresia: prevalence, prenatal diagnosis and associated anomalies 
in 23 European regions. Arch Dis Child, 2012. 97(3): p. 227-32.
2 Wang, B., et al., A nationwide analysis of clinical outcomes among newborns with esophageal atresia 
and tracheoesophageal fistulas in the United States. J Surg Res, 2014. 190(2): p. 604-12.
3 Sulkowski, J.P., et al., Morbidity and mortality in patients with esophageal atresia. Surgery, 2014. 
156(2): p. 483-91.
4 Cassina, M., et al., Prevalence, characteristics, and survival of children with esophageal atresia: A 
32-year population-based study including 1,417,724 consecutive newborns. Birth Defects Res A Clin 
Mol Teratol, 2016.
5 Faugli, A., et al., Mental health and psychosocial functioning in adolescents with esophageal atresia. J 
Pediatr Surg, 2009. 44(4): p. 729-37.
6 Legrand, C., et al., Long-term outcome of children with oesophageal atresia type III. Arch Dis Child, 
2012. 97(9): p. 808-11.
7 Lacher, M., et al., Early and long term outcome in children with esophageal atresia treated over the last 
22 years. Klin Padiatr, 2010. 222(5): p. 296-301.
8 Seo, J., et al., An 18-year experience of tracheoesophageal fistula and esophageal atresia. Korean  
J Pediatr, 2010. 53(6): p. 705-10.
9 Little, D.C., et al., Long-term analysis of children with esophageal atresia and tracheoesophageal 
fistula. J Pediatr Surg, 2003. 38(6): p. 852-6.
10 Somppi, E., et al., Outcome of patients operated on for esophageal atresia: 30 years’ experience.  
J Pediatr Surg, 1998. 33(9): p. 1341-6.
11 Chetcuti, P. and P.D. Phelan, Gastrointestinal morbidity and growth after repair of oesophageal 
atresia and tracheo-oesophageal fistula. Arch Dis Child, 1993. 68(2): p. 163-6.
12 Puntis, J.W., et al., Growth and feeding problems after repair of oesophageal atresia. Arch Dis Child, 
1990. 65(1): p. 84-8.
13 Lindahl, H., Long-term prognosis of successfully operated oesophageal atresia-with aspects on physical 
and psychological development. Z Kinderchir, 1984. 39(1): p. 6-10.
14 Andrassy, R.J., et al., Long-term nutritional assessment of patients with esophageal atresia and/or 
tracheoesophageal fistula. J Pediatr Surg, 1983. 18(4): p. 431-5.
15 Presse, N., et al., Insufficient Body Weight of Adults Born With Esophageal Atresia. J Pediatr 
Gastroenterol Nutr, 2016. 62(3): p. 469-73.
16 Menzies, J., et al., Prevalence of Malnutrition and Feeding Difficulties in Children With Esophageal 
Atresia. J Pediatr Gastroenterol Nutr, 2016.
17 Gischler, S.J., et al., A prospective comparative evaluation of persistent respiratory morbidity in 
esophageal atresia and congenital diaphragmatic hernia survivors. J Pediatr Surg, 2009.  
44(9): p. 1683-90.
18 Gross, R.E., The Surgery of Infancy and Childhood. Philadelphia: W. B. Saunders Company, 
1953: p. 441-444.
30 chapter 2
19 Ravitch, M.M. and B.A. Barton, The need for pediatric surgeons as determined by the volume of work 
and the mode of delivery of surgical care. Surgery, 1974. 76(5): p. 754-63.
20 Solomon, B.D., et al., An approach to the identification of anomalies and etiologies in neonates with 
identified or suspected VACTERL (vertebral defects, anal atresia, tracheo-esophageal fistula with 
esophageal atresia, cardiac anomalies, renal anomalies, and limb anomalies) association.  
J Pediatr, 2014. 164(3): p. 451-7 e1.
21 Visser, G.H., et al., New Dutch reference curves for birthweight by gestational age. Early Hum Dev, 
2009. 85(12): p. 737-44.
22 Vandenplas, Y., et al., Pediatric gastroesophageal reflux clinical practice guidelines:  
joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and 
Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and 
Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr, 2009. 49(4): p. 498-547.
23 Schonbeck, Y., et al., The world’s tallest nation has stopped growing taller: the height of Dutch 
children from 1955 to 2009. Pediatr Res, 2013. 73(3): p. 371-7.
24 Talma, H., et al., Groeidiagrammen 2010: Handleiding bij het meten en wegen van kinderen en het 
invullen van groeidiagrammen. 2010, Leiden: TNO innovation for life. 64.
25 Schonbeck, Y., et al., Trend in height of Turkish and Moroccan children living in the Netherlands. 
PLoS One, 2015. 10(5): p. e0124686.
26 van Dommelen, P., Y. Schonbeck, and S. van Buuren, A simple calculation of the target height. 
Arch Dis Child, 2012. 97(2): p. 182.
27 WHO, Nutrition Landscape Information System (NLIS) country profile indicators: interpretation guide. 
10 October 2012 ed. 2010, Geneva: WHO Document Production Services. 38.
28 Fitzmaurice, G.M., N.M. Laird, and J.H. Ware, Applied Longitudinal Analysis, 2nd Edition.  
2011: John Wiley & Sons. 740 pages.
29 Hair, J.F.J., et al., Multivariate data analysis (4th ed.): with readings. 1995: Prentice-Hall, Inc. 745.
30 Joosten, K.F. and J.M. Hulst, Malnutrition in pediatric hospital patients: current issues. Nutrition, 
2011. 27(2): p. 133-7.
31 Spoel, M., et al., Respiratory morbidity and growth after open thoracotomy or thoracoscopic repair of 
esophageal atresia. J Pediatr Surg, 2012. 47(11): p. 1975-83.
32 Wachs, T.D., et al., Issues in the timing of integrated early interventions: contributions from nutrition, 
neuroscience, and psychological research. Ann N Y Acad Sci, 2014. 1308: p. 89-106.
33 Marques, A.H., et al., The influence of maternal prenatal and early childhood nutrition and maternal 
prenatal stress on offspring immune system development and neurodevelopmental disorders. Front 
Neurosci, 2013. 7: p. 120.
34 van der Cammen-van Zijp, M.H., et al., Motor-function and exercise capacity in children with major 
anatomical congenital anomalies: an evaluation at 5 years of age. Early Hum Dev, 2010. 86(8): p. 
523-8.
35 Berglund, S.K., et al., Marginally low birth weight increases the risk of underweight and short stature 
at three and a half years of age. Acta Paediatr, 2016.
36 Haliburton, B., et al., Nutritional Intake, Energy Expenditure, and Growth of Infants Following 
Congenital Diaphragmatic Hernia Repair. J Pediatr Gastroenterol Nutr, 2016. 62(3): p. 474-8.
31chapter 2
Supplementary table 2.1 Variation in age of all children attending visits
Routine visit Age in years; median (IQR)
0.5 year visit 0.5 (0.5-0.6)
1 year visit 1.0 (1.0-1.1)
2 years visit 2.0 (2.0-2.1)
5 years visit 5.2 (5.1-5.5)
8 years visit 8.2 (8.1-8.3)
12 years visit 12.1 (12.0-12.2)
supplementary material
32 chapter 2
Supplementary figure 2.1  
Individual trajectories for SDS-HFA (a), 
SDS-DTH (b) and SDS-WFH (c) plotted 
against assessment age (patients without  
a fundoplication in green, patients with a 
fundoplication in red).
Supplementary figure 2.2  
Change in SDS-HFA (a), SDS-DTH (b) and SDS-WFH (c) 
in children with (red) and without (green) 
fundoplication surgery between two successive visits:  
A= change between 0.5-1 years;  
B= change between 1-2 years,  
C= change between 2-5 years,  
D= change between 5-8 years;  
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abstract
Esophageal atresia (EA) is a rare congenital anomaly. Enhanced operative techniques and 
intensive care treatment have improved survival among children with repaired EA (range, 
93-95%). Many (up to 67%) suffer from gastroesophageal reflux (GER). The high incidence of 
GER and improved survival among EA patients raises concerns about an increased risk of 
developing Barrett esophagus (BE) and esophageal cancer. This review provides an overview of 
the prevalence of esophagitis, BE, and esophageal cancer in EA patients and outlines 
suggestions for future research. A literature search indeed revealed a higher prevalence of BE 
in EA patients than in the generalized population and that this condition occurs at a much 
younger age. It should be noted that in some studies gastric metaplasia without intestinal 
metaplasia is defined as BE. Gastric-type mucosa in columnar-lined esophagus is probably of 
less clinical importance in terms of the likelihood of malignant transformation. Its inclusion 
therefore confounds the risk of esophageal adenocarcinoma. A total of eight cases of 
esophageal carcinoma at a young age, either squamous cell carcinoma or adenocarcinoma, 
have been reported. These observations bear important implications prompting for early 
onset lifelong BE/esophageal cancer surveillance to facilitate the diagnosis of (pre)neoplastic 




Esophageal atresia (EA) with or without tracheoesophageal fistula (TEF) is a rare anatomical 
anomaly, with a prevalence of 2.55 per 10,000 pregnancies in Europe 1. Advancements in 
surgery and modern intensive care have led to survival rates up to 93 to 95% in dedicated 
centers, and more children nowadays reach adulthood 2, 3.
After surgical repair, many EA patients experience gastroesophageal reflux (GER) 4-8. If 
untreated, chronic GER may lead to esophagitis, anastomotic strictures, metaplastic epithelial 
changes (gastric metaplasia or intestinal metaplasia), and esophageal adenocarcinoma (EAC). 
When the squamous mucosa in the distal esophagus is damaged, usually by GER, it is replaced 
by metaplastic columnar mucosa, so-called Barrett esophagus (BE). A study has suggested that 
metaplasia is found in approximately 42% of EA patients 9. In case intestinal metaplasia is 
present in the metaplastic columnar mucosa, BE becomes an important risk factor for 
developing EAC, with an estimated incidence rate of 0.5% per year during follow-up 10. In the 
general population, BE is reported in 1.6% of adults and is predominantly diagnosed in 
middle-aged white males 11. It is suggested that the prevalence of BE in EA patients is higher 
and that it occurs at a much younger age 7. Cancer in the upper gastrointestinal tract in EA 
patients has been described in 10 cases, of which 8 were esophageal carcinoma  table 3.1  and 
2 squamous cell carcinoma not related to the native esophagus (related to the lung and to a 
subcutaneous skin tube reconstruction) 12-18.
Given the high prevalence of BE, the early development of esophageal cancer, and the possible 
absence of alarm symptoms in EA patients, surveillance programs seem warranted. 
Prospective long-term follow-up cohort studies, including endoscopic data of adult EA 
patients, are limited and guidelines for follow-up are lacking. The aim of this review is to give 
an overview of the prevalence of esophagitis, BE, and esophageal cancer in EA patients and 
outline suggestions for future research.
Gastroesophageal reflux
Gastroesophageal reflux disease (GERD) is considered a motility disorder, with transient lower 
esophageal sphincter relaxations as its main underlying mechanism in healthy premature 
infants, healthy adults, GERD patients, and EA patients (shortly after primary anastomosis and 
in adulthood) 19. In EA patients several anatomic and functional causes can explain the 
increased occurrence of GER.
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First, by pulling the distal esophagus more cranial during atresia repair the lower esophageal 
sphincter is displaced, resulting in sphincter incompetence and an increase in retrograde 
movements of gastric contents into the esophagus. The altered angle of His of the stomach 
fails to prevent GER 20, 21. Second, surgical injury to the vagal nerve leads to dysmotility, and 
despite careful connection of the different muscle layers the esophageal peristaltic wave is 
disrupted at the anastomosis 19, 20. Third, disturbed motility seems to be present before 
atresia repair as a result of deficient extrinsic and intrinsic innervation 19, 20. Finally, delayed 
gastric emptying in EA patients and upper airway obstruction in EA patients with 
tracheomalacia or tracheal stenosis can also facilitate GER 19, 20.
Table 3.1 Reported esophageal cancer in EA patients (n=8) 
References
Adzick et al. (1989) 14
Deurloo et al. (2001) 12
Alfaro et al. (2005) 15
Pultrum et al. (2005) 16
Jayasekera et al. (2012) 13
Jayasekera et al. (2012) 13
Jayasekera et al. (2012) 13
Jayasekera et al. (2012) 13
Gender, age, type of EA, type of surgery
 
Female, 20 years
Gross type C, primary repair
Male, 38 years
Gross type C, primary repair
Female, 46 years
Gross type E, primary TEF repair
Female, 22 years
Gross type C, primary repair (high tension 
with post-operative mediastinal leakage  
and mediastinitis)
Female, 44 years
Gross type C, primary repair 
Female, 46 years
Gross type C, primary repair
Male, 46 years
Gross type C, delayed primary repair  
(day 49)
Male, 44 years
Gross type C, primary repair, recurrent TEF
Type and location of esophageal cancer
 
EAC, at GEJ with extension to lower 
esophagus and cardia
ESCC, at 2cm distal of the anastomosis
EAC, in BE (18-35 cm)
EAC, at anastomosis
ESCC, at anastomosis (23cm) with metastasis
in frontal lobe and mediastinum
ESCC, mid-esophageal at 20-28 cm with 
reactive mediastinal and subcardinal lymph 
nodes
ESCC, in BE (19-21 cm) with reactive 
para-aortic lymph node
ESCC, tumor mass eroding through sternum 
and ribs
BE: Barrett’s esophagus, EA: esophageal atresia, EAC: esophageal adenocarcinoma, ESCC: esophageal squamous cell carcinoma, 






Since age of 5 years
Hiatus hernia with GER and 
aspirations
Gastrostomy at age of 3 years  




Hiatus hernia with GER and 
aspirations
Gastrostomy at age of 1 year and 











Yes, twice resection of 
stenosis and multiple 
dilatations










Esophagitis and a 16cm 
long BE with low grade 
dysplasia
Not reported











The reported prevalence of GER in EA patients after neonatal repair ranges from 32.8 to 54.2% 
during infancy and childhood, and from 5.9 to 66.7% during adolescence and adulthood  
 table 3.2  4, 6-9, 22-39. These wide ranges are probably explained by the different definitions 
used. A recent systematic review on long-term problems in EA patients found a high 
prevalence of GER, based on GER symptoms, of 40.2% compared with 10 to 20% in the general 
adult Western population 40, 41. Typical symptoms of GER are heartburn and acid 
regurgitation, which are reported by 7.7 to 27% and 6.3 to 16%, respectively, of the general 
Western population 41. In EA patients, the prevalence of these symptoms ranges from 14 to 38% 
and 7 to 34%, respectively 28, 38. Dysphagia is present in 50.3% of the patients 40. GER symptoms 
are not well correlated with the severity of esophageal damage: up to two-thirds of the 
patients with GER-related symptoms do not have mucosal erosions 42. Most EA patients do 
not recognize GER symptoms as troublesome, as they have had these for years, resulting in 
chronic esophageal injury such as erosions, ulcerations, anastomotic strictures, BE, and 
eventually EAC.
The gold standard for diagnosing GER is ambulatory pH monitoring, completed with 
impedance. During pH monitoring acid reflux is measured, while esophageal impedance can 
also identify nonacid reflux. At endoscopy typical reflux-induced erosions can be observed. 
However, as mentioned above, not all patients with GER have mucosal damage, resulting in  
a low sensitivity of endoscopy as a diagnostic tool for GER 42, 43. Also, esophageal biopsies, 
for assessment of histological changes and number of eosinophils, have not been proven  
to be useful, because of their low sensitivity and specificity and overlap with eosinophilic 
esophagitis and various other esophageal diseases (eosinophilic gastrointestinal diseases, 
celiac disease, drug hypersensitivity, and infection) 43, 44. The basal zone normally 
compromises no more than 15% of the total epithelial thickness, the papillae reach up till 
two-thirds of the normal epithelium, and the maximum number of eosinophils in a normal 
esophageal biopsy specimen is 15 per high-power field 44, 45. Eosinophilic esophagitis is 
characterized by eosinophilia, eosinophilic microabscesses, degranulated eosinophilia, basal 
cell hyperplasia, elongated rete pegs, and dilated intercellular spaces, but also in GERD 
patients and even in healthy individuals basal cell hyperplasia, elongated rete pegs, and 
eosinophilia can be found 46. Therefore, histological assessment is often not conclusive to 
discriminate between the various esophageal diseases 43.
Treatment options for GERD are lifestyle modification, acid suppression and surgery. In view 
of the high occurrence of (severe) GER in EA patients, most newborns with EA receive medical 
therapy directly after birth. Medical treatment is often successful by reducing gastrointestinal 
and respiratory symptoms, but antireflux surgery, such as Nissen fundoplication, is still 
needed in up to 44% of the cases   table 3.2  4, 6-8, 24-27, 29, 30, 32, 34-37, 39, 47. The wrap fails in many 
patients. A review of 2013 reported a redo-fundoplication rate of 18% in EA patients, a much 
higher percentage than the 7% in GERD patients in the general population 20. Another study 
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found an ever higher percentage of redo-Nissen procedures of 25% 48. The modified anatomy 
in EA patients and the persistent dysmotility after medical or surgical anti-GERD treatment 
may explain the high occurrence of wrap failures 20, 49.
Abnormal reflux of gastric contents into the esophagus (and beyond) can cause serious 
esophageal problems (inflammation, erosions, ulcerations, anastomotic strictures, BE, and 
EAC) and pulmonary problems (asthmatic complaints, inflammation, and respiratory distress 
of apparent life-threatening events). The disturbed esophageal motility in EA patients reduces 
acid clearance and increases the adverse effects of GER in this population. Early diagnosis and 
treatment of GER in EA patients may influence the onset of GER-related complications.
Esophagitis
Chronic GER may lead to esophagitis with mucosal breaks, especially when untreated. Upper 
endoscopy is the most sensitive diagnostic tool for assessment of GER-related mucosal injury. 
During upper endoscopy, esophagitis is classified using the Los Angeles Classification 50. For 
histological examination, the Ismail-criteria have long been considered one of the most 
reliable criteria for diagnosing reflux esophagitis and these are still used 45. Although 
histology can be useful to assess the individual therapeutic response in GERD, routine 
biopsies cannot be recommended as a diagnostic tool for GERD as the correlation between 
histological findings and GERD in the absence of mucosal lesions is poor 43.
In EA patients, the prevalence of esophagitis observed during an endoscopy is considerably 
higher than that in the general population: 25.1 versus 12 to 15%  table 3.2  6, 7, 22, 24, 27-32, 35, 36, 
38, 39, 51, 52. An endoscopic diagnosis of erosive esophagitis is made in 31.5% of the infants and 
children with EA, with histology revealing moderate-to-severe esophagitis in 8.5%  table 3.2  
22, 24, 27. In adolescents and adults with EA, esophagitis is observed during endoscopic and 
histological evaluation in 26.4 and 20%, respectively  table 3.2  6, 7, 28-32. A recent systematic 
review found a prevalence of histological esophagitis of 56.5% in EA patients 40. This can 
hardly be interpreted as mild inflammation, as findings included minimal basal hyperplasia, 
subtle reactive changes, and slight amounts of lymphocytic, eosinophilic, and neutrophilic 
infiltration in the epithelium, which are also present in healthy individuals 43, 46.
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Table 3.2 Literature reports on the prevalence of GER symptoms, pH-measurements, esophagitis, 
gastric metaplasia, Barrett’s esophagus and fundoplication surgery in EA patients: children(A), adults (B) 
and both children and adults (C) 
A
References
Pedersen et al. (2013) 22
Catalano et al. (2011) 23
Castilloux et al. (2010) 24
Kawahara et al. (2009) 25
Koivusalo et al. (2007) 26
Deurloo et al. (2002) 4
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Gatzinsky et al. (2015) 28
Huynh-Trudeau et al. 
(2015) 29
Sistonen et al. (2010) 6
Deurloo et al. (2008) 30
Taylor et al. (2007) 7
Deurloo et al. (2003) 32
Krug et al. (1999) 31
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5/45 (11.1)  [c]
NR
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24/61 (39.3)  [e,f]
23/52 (44.2)  [e,f]
22/43 (51.2)  [e,f]
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7/17 (41.2)  [e,h]
NR
33/165 (20)
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EA: esophageal atresia, GER: gastroesophageal reflux, GERD: gastroesophageal reflux disease, NR: not (clearly) reported
a GERD diagnosis defined as: fundoplication surgery performed, pH-measurement positive or endoscopic esophagitis 
(according to the ACG guidelines) 43.
b No official classification used for endoscopic grading of esophagitis.
c Histological diagnosis of three biopsies was unspecified.
d Fundoplication surgery and pH-measurement.
e To exclude selection bias, these numbers are not used to calculate the total prevalence of the features, see below the 
different reasons.
f Fundoplication surgery, pH-measurement, and histological esophagitis (moderate-to-severe).
g Biopsies (n = 12) taken in presence of endoscopic abnormalities: Barrett esophagus (n = 10) and/or esophagitis (n = 6).
h Biopsies (n = 17) taken in presence of esophagitis and/or Barrett epithelium (n = 8) or normal mucosa (n = 9).
i Patients with a history of fundoplication surgery or severe/obvious symptoms were excluded from this study.
References
Koivusalo et al. (2013) 34
Schneider et al. (2013) 9
Burjonrappa et al. (2011) 35
Deurloo et al. (2005) 36
Schalamon et al. (2003) 37
Tomaselli et al. (2003) 38
Somppi et al. (1998) 39
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The diagnosis BE is made if normal squamous epithelium of the distal esophagus has been 
replaced by metaplastic columnar mucosa 10, 53, 54. Three types of esophageal metaplastic 
columnar epithelium are distinguished: gastric fundic type epithelium (surface mucus, 
parietal, and chief cells), gastric cardiac type epithelium (mucus secreting cells), and intestinal 
type epithelium (goblet cells) 55. Intestinal metaplasia is the most biologically unstable type 
of metaplastic columnar epithelium with the greatest risk of neoplastic progression through 
dysplasia to adenocarcinoma 54. The annual incidence of EAC in BE patients, defined as the 
presence of columnar-lined esophagus with intestinal metaplasia, is 0.5% 10. Whether gastric 
metaplasia (fundic or cardiac type epithelium) is associated with malignant transformation 
remains unclear 27, 36, 39, 56. Importantly, the definition of BE differs between guidelines in 
respect of whether or not intestinal metaplasia is present 10, 53, 54.
The estimated prevalence of BE in the general population is 1.6% 11. In EA patients, the 
prevalence of BE varies between 0 and 12.5% and that of gastric metaplasia between 0 and 
40.9%  table 3.2  6-9, 22, 24, 26-29, 32, 35-37, 39. The great variety in BE prevalence in EA patients can 
be ascribed to different definitions used. It should be noted that in several studies gastric 
metaplasia without intestinal metaplasia also is defined as BE. This illustrates the importance 
of using a uniform working definition of BE, so as to prevent overdiagnosis and 
overtreatment. While in the general population BE patients are usually middle-aged white 
males, in EA patients BE is diagnosed at a remarkably younger age. In a study from Taylor et al, 
BE was diagnosed in 7/62 (11.3%) patients with a median age of 37 years (range, 21–43 years) 7. 
There is some evidence that EA patients with TEF recurrence, long gap EA, esophageal stricture 
resection in childhood, esophageal stricture present in adulthood, severe reflux symptoms, 
and age above 30 years are at an increased risk for developing BE 6, 7.
To detect BE it is important to identify landmarks such as the Z-line (transition line of 
squamous to columnar epithelium) and the gastroesophageal junction (GEJ) 53. Normally, the 
Z-line corresponds to the GEJ and is in line with the diaphragm. After EA repair, especially after 
a gastric pull-up, the GEJ is located proximal of the diaphragm. This modified anatomy may 
complicate landmark recognition.
The purpose of reducing acid exposure in BE is to prevent the development of high-grade 
dysplasia and EAC. Acid suppression drugs are prescribed in almost all BE patients for 
chemoprevention and symptom control. Antireflux surgery is not superior to medical therapy 
to prevent malignant progression of BE 10, 54. Moreover, it does not fully protect GERD patients 
against BE development. Sistonen et al found that 40% of the EA patients with prior anti-
reflux surgery developed esophageal gastric or intestinal metaplasia 6.
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Endoscopic resection with or without ablation therapy can be offered with curative intent 
when BE with high-grade dysplasia or early stage esophageal cancer is detected. The treatment 
of choice depends on the tumor stage, patient’s age, comorbidity, preferences, and local 
expertise 53, 54, 57-59.
Esophageal cancer
The two commonest types of esophageal cancer are EAC deriving from the columnar mucosa 
and esophageal squamous cell carcinoma (ESCC) originating from the squamous mucosa. 
Dysphagia is often the first symptom of esophageal cancer. However, dysphagia is common  
in EA patients (prevalence 48-72%) and patients therefore are not necessarily alarmed by this 
symptom 5. Because of the association between BE and EAC, EA patients with prolonged GER 
and BE may have an increased risk for malignant progression.
Over the last decades, survival of EA patients has increased and many more patients reach 
adulthood. Long-term follow-up studies in adult EA patients are scarce. To date, eight cases of 
esophageal cancer in adult EA patients have been reported: three EAC and five ESCC  table 3.1  
12-16. The tumors were mainly located in the middle esophagus and diagnosed at a young age 
(median, 38 years; range, 20-46 years). A few articles about cancer risk in this population have 
been published, but large follow-up cohort studies in patients throughout adolescence and 
adult life are needed for proper risk assessment and stratification. Two Scandinavian studies, 
both found three cases of cancer (no esophageal cancer) in a cohort of 870 and a cohort of  
272 EA patients, respectively 60, 61. The esophageal cancer prevalence was not higher than in  
the general population, but the median follow-up in both studies was only 16 and 35 years, 
respectively. In an Australian cohort of 309 adult EA patients (age ≥40 years), of whom 76 
underwent endoscopic screening, 4 ESCC were found 13. However, the cause of death or 
long-term outcome was not known in 120 of the 309 patients (38.8%). The cumulative 
incidence of ESCC in EA adults above 40 years of age was 50-fold higher than that in the 
general population.
These findings should be interpreted with caution, however because of the small power of the 
studies and the relatively short follow-up period. To date the relevant literature has reported 
more ESCC than EAC. Possible reasons are the fact that EA patients have a higher risk of 
developing ESCC than EAC, publication bias, or a relatively short follow-up in adulthood.  
With regard to the latter, EAC derived from BE could develop on a longer term than ESCC.  
The follow-up period in most of the studies, including EA patients is relatively short.
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Screening and surveillance
As described above, EA patients appear to have a higher prevalence of BE at a younger age 
compared with the general population. Due to the poor prognosis of patients with 
esophageal cancer, early diagnosis is of utmost importance to make curative and less invasive 
treatment still feasible. For recommendations about endoscopic screening and surveillance 
of BE in EA patients, presence of intestinal metaplasia should be taken into account as gastric 
type mucosa in columnar-lined esophagus is of less clinical importance in terms of the 
likelihood of malignant transformation.
To date guidelines on esophageal follow-up on EA patients are lacking. Several screening 
strategies have been suggested as a clinical screening in all patients aged 15 to 25 years, with 
endoscopy performed if any GER symptoms are present 7. Another study suggested 
endoscopic surveillance at the ages of 15, 30, 40, 50, and 60 years, with intensification of this 
protocol if pathological observations are made: yearly in case of BE and 5-yearly in the 
presence of esophagitis, gastric metaplasia, severe esophageal strictures, recurrent TEF, severe 
GER symptoms, or the need for continuous anti-GERD medication 5. Other endoscopy 
protocols suggest screening in all adults, from the age of 30 years for patients with significant 
primary surgery complications; from the age of 20 years, regardless of symptoms (5-yearly 
until the age of 30 years, 3-yearly until the age of 40 years, 2-yearly after 40 years of age); and 
screening once before adulthood with surveillance through adulthood with 5 to 10 year 
intervals (3-yearly in case of BE or twice a year with dysplasia) 6, 9, 13, 31.
Future prospects
Large cohort studies with longer follow-up focusing on the development of BE and 
esophageal cancer in EA patients are scarce. A few suggestions for endoscopic surveillance 
programs in this population have been put forward, but none of these strategies have been 
validated in a population-based follow-up study. Screening all adult EA patients is labor 
intensive. Moreover, the inconvenience and burden of repeated endoscopies for the patients 
should not be underestimated. Future large prospective follow-up cohort studies are needed 
to define the actual BE and cancer risk in (adult) EA patients. In this regard, it is important to 
identify pivotal risk factors, including genetic predisposition, to focus and intensify 
surveillance in those patients at true risk for developing EAC or ESCC, rendering surveillance 
program more cost-effective and less inconvenient for EA patients overall. 
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To evaluate acid and non-acid gastroesophageal reflux in infants and school-aged children 
with esophageal atresia (EA) using pH-impedance (pH-MII) monitoring.
Methods
Between 2012-2017, all 24-hour pH-MII studies performed in infants (≤18 months) and 8-year 
olds with EA were included. Anti-acid therapy was discontinued before study. Exclusion 
criteria were: isolated tracheoesophageal fistula; esophageal replacement therapy; tube 
feeding; and monitoring <18 hours. Automatically detected retrograde bolus movements 
(RBM) were manually reviewed and modified/deleted if necessary.
Results
We included 57 children (51% male; 2% isolated EA; 44% thoracoscopic EA repair): 24 infants 
(median age 0.6 years) and 33 school-aged children (median age 8.2 years). Of the 
automatically detected 3,313 RBM, 1,292 were manually deleted from the tracings: 52% of 
non-acid RBM and 8% of acid RBM (mainly misinterpreted swallows or one event recognized 
as several events). In infants, median reflux index (RI; pH<4) was 2.6% (abnormal in n=2), 
median RBM was 61 (62% non-acid, 58% mixed) and median of the mean BCT was 11 seconds. 
In older children, median RI was 0.3% (abnormal in n=4), median RBM was 21 (64% non-acid; 
75% mixed) and median of the mean BCT was 13 seconds.
Conclusions 
Most children with EA off medication have a normal RI, yet experience a significant number of 
non-acid RBM. After manual revision of the tracings a high percentage of RBM was deleted. 
Our data show that automated impedance analysis software needs refinement for use in 





Esophageal atresia (EA) with or without a tracheoesophageal fistula (TEF) is a relatively 
common birth defect in which the continuity of the esophagus is interrupted (European 
prevalence: 2.43 per 10,000 births) 1. As a result of inborn deficient esophageal innervation 
and surgical nerve injury, EA patients suffer from esophageal dysmotility 2, 3. Gastroesophageal 
reflux (GER; acid and non-acid) is a physiologic phenomenon. When GER causes troublesome 
symptoms interfering with daily life or complications it is referred to as GER disease (GERD) 4. 
GERD is thought to be common after surgical EA repair in both children and adults 5, 6.  
It results in respiratory and gastrointestinal problems in the short-term (e.g. aspiration 
pneumonia, apparent life-threatening events, dysphagia, feeding problems) and long-term 
(e.g. chronic respiratory symptoms, esophagitis, esophageal strictures, Barrett’s esophagus, 
esophageal cancer) 6-10. Given the high prevalence of GERD in children with EA (up to 54% in 
some studies), it is important to diagnose and manage GERD to reduce associated 
complications 5, 6. 
Although many children with EA are exposed to chronic GER, only a few experience 
troublesome symptoms. Results from pH-impedance (pH-MII) studies as well as endoscopic 
evaluations in children with EA show that asymptomatic children can have severe 
abnormalities 11-14. Therefore, the ESPGHAN-NASPGHAN Guideline (2016) recommends to 
routinely prescribe proton pump inhibitors (PPI) for the first year of life and monitor GER 
using pH-MII monitoring and/or endoscopy at time of discontinuation (regardless of 
symptoms) and during long-term follow-up in symptomatic children with EA 6. 
We hypothesized that GER occurs frequently in children with EA, not only in infancy but even 
thereafter. Moreover, based on clinical interpretation of several pH-MII studies prior to this 
study we assumed that disturbed impedance patterns in EA patients leads to over-detection of 
reflux events in automated analysis. We aimed to evaluate and characterize acid and non-acid 
GER in infants and school-aged children with EA using pH-MII monitoring and to evaluate the 




All children with EA born in our hospital are offered a 24-hour pH-MII study at the age of 0.5 
and 8 years as part of a longitudinal multidisciplinary follow-up program 15. As standard of 
care, all children receive PPI for at least six months after surgical EA repair. We retrospectively 
reviewed all pH-MII studies conducted in children with EA between September 2012 and 
October 2017. Exclusion criteria were: isolated TEF; esophageal replacement therapy (e.g. 
gastric pull-up, jejunal/colonic interposition); use of tube feeding; and pH-MII study duration 
<18 hours. The Medical Research Involving Human Subjects Act was considered not applicable 
to the study protocol (protocol ID MEC-2017-185).
Data collection
Data retrieved from patient records included baseline characteristics (e.g. gender, gestational 
age, type of EA, type of EA repair) and clinical data at time of pH-MII monitoring (e.g. 
symptoms, use of anti-reflux medication, z-scores height and weight-for-height) 16, 17.  
All 8-year old children were asked to fill in an online validated questionnaire for detecting 
GERD by Manterola et al. 18, 19. A cut-off score >3 was used. 
Small for gestational age was defined as a birth weight two standard deviations (SD) below 
normal. Prematurity was defined as gestational age <37 weeks. Pulmonary infections were 
defined as lower respiratory tract infections requiring antibiotic therapy and/or hospital 
admission.
pH-MII monitoring protocol
Children were intubated with an age appropriate pH-MII catheter. We used two available types 
of pH-MII catheters to perform 24-hour pH-MII studies: Greenfield (Dover, USA) single use 
antimony pH-MII catheters (6.4 French, 6 impedance channels, 1-2 pH channels) and Laborie 
ion-sensitive field-effect transistor (ISFET) disposable pH-MII catheters (6 French, 6 impedance 
channels, 1 pH channel). A chest x-ray was performed to ensure correct pH channel position 
(three vertebrae above the diaphragm) 20. All anti-acid and prokinetic therapy was 
discontinued prior to the start of the pH-MII assessment (five and two days, respectively). 
Parents were asked to fill in a diary during pH-MII monitoring to monitor symptoms, body 
position and intake of food and beverages. Patients were instructed not to eat acid foods or 
drink carbonated beverages.
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Manual correction of reflux events
Initial manual review was performed to ensure correct diary records and to delete artefacts. 
Then MMS database software 9.5 (Medical Measurement Systems B.V., Enschede, The 
Netherlands) was used for automated analysis (acid/alkaline limits: pH 4.0 and 7.0; minimum 
reflux duration pH- and MII-results: 5 seconds; air threshold: 5000Ω). All reflux events – 
identified as such by the software – were manually reviewed and modified (duration; number 
of impedance channels involved; liquid/mixed reflux content) by one researcher unaware of 
the clinical symptoms (FV). A second reviewer (MvW) examined inconclusive events. RBM were 
deleted in case both reviewers agreed the RBM was misinterpreted by the software.
Data analysis
Parameters analyzed in this study included number of pH changes to <4; reflux index (RI; acid 
exposure index (%)); number of long (>5 minutes) acid exposures; longest acid exposure 
(minutes); number of retrograde bolus movements (RBM); number of acid/non-acid (pH ≥4) 
RBM; number of liquid/mixed RBM; mean bolus clearance time (BCT; seconds); number of 
proximal bolus exposures (reaching proximal impedance channel); symptom index for reflux 
(SI); and symptom association probability (SAP)(window of 120 seconds before and after a 
reflux event). A RI>7% was considered to be abnormal, <3% to be normal, and 3%-7% to be 
indeterminate 21. SI≥50% and SAP≥95% were considered positive 22.
Data are presented as frequencies, mean (SD) or median (minimum; maximum; inter-quartile 
range (IQR)). Data were analyzed with SPSS 21.0 (SPSS Inc., Chicago, IL) using descriptive 
statistics. Non-parametric Mann-Whitney U test was used to compare continues variables and 
Pearson’s chi-square test or Fisher’s exact test for categorical variables. The two-tailed level of 
significance was set at p=0.05.
results
Demographics   table 4.1 
Of the 69 children born between 2011-2017 (aged ≤18 months in study period), three children 
had died. Sixteen children fulfilled exclusion criteria, mainly because of tube feeding  
 figure 4.1 . We included 24/50 (48.0%) eligible infants (median age 0.6 (range 0.2-1.5) years). 
Reasons for not being included are listed in  figure 4.1 . Of the 74 children born between 
2004-2009 (aged 8 years in study period), six children had died. Nine children fulfilled 
exclusion criteria. We included 33/59 (55.9%) children (median age 8.2 (range 8.0-9.0) years).
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Table 4.1 Patient demographics (N=57)
 Age ≤18 months (N=24) Age 8 years (N=33)
 n (%) / median (min; max; IQR) n (%) / median (min; max; IQR)
Male gender 14 (58.3) 15 (45.5)
Age (years) 0.6 (0.2; 1.5; 0.5-1.1) 8.2 (8.0; 9.0; 8.1-8.4)
Gestational age (weeks) 38.1 (30.4; 41.7; 35.3-40.0) 38.6 (28.9; 42.3; 37.0-40.1)
Prematurity 7 (29.2) 7 (21.2)
Birthweight (gram) 2595 (854; 3630; 1746-3078) 2850 (1080; 3810; 2235-3190)
Small for gestational age 4 (16.7) 4 (12.1)
Type of esophageal atresia  
– Gross type A 0 1 (3.0)
– Gross type C 24 (100.0) 31 (93.9)
– Gross type D 0 1 (3.0)
Type of esophageal correction  
– Primary anastomosis  23 (95.8) 30 (90.9)
– Delayed anastomosis 1 (4.2) 3 (9.1)
Type of surgery  
– Thoracoscopy 17 (70.8) 8 (24.2)
– Thoracotomy 6 (25.0) 25 (75.8)
– Converted 1 (4.2) 0
Z-score for weight-for-height; mean (SD) -0.5 (1.1) -0.3 (1.1)
Wasting (acute malnutrition) 2 (8.3) 2 (6.1)
Use of anti-reflux medication  
– Proton pump inhibitor 11 (45.8) 2 (6.1)
– H2 antagonist ± prokinetic drug 11 (45.8)  [a] 0
– None 2 (8.3) 31 (93.9)
Pulmonary infections  [b] 1 (4.2)  [c] 8 (24.2)  [d]
Prophylactic antibiotics (airways) 2 (8.3) 2 (6.1)
Symptoms  
– Gastrointestinal 2 (8.3)  [e] 6 (18.2)  [f]
– Respiratory 2 (8.3)  [e] 2 (6.1)  [f]
– None 20 (83.3) 25 (75.8)
Gastroesophageal reflux questionnaire (Manterola) - 2 (0; 9; 1-4)
Nissen fundoplication surgery 0 8 (24.2)  [g]
a Five children used Ranitidine and Domperidone.
b Defined as lower respiratory tract infections requiring antibiotics and/or hospital admission since birth (infants) or in the 
previous year (8-year olds). 
c One infection in the previous year. 
d One (n=4) and 2-4 (n=4) infections in the previous year. 
e Vomiting unrelated to food intake/physical activity (n=1), frequent vomiting (n=1), ALTE (n=1), cough (n=1). 
f Regurgitation (n=2), acidic reflux (n=1), nausea (n=1), nausea/abdominal pain (n=1), foetor ex ore and abdominal pain 
related to food intake (n=1), night cough (n=2). 
g Median age of 5 (range 3-87) months at time of Nissen fundoplication.
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Demographics of the 57 included children and the 52 non-included children did not 
significantly differ  supplementary table 4.1 . In 43.9% of included children thoracoscopic EA 
repair was performed. Twenty-four children were using anti-reflux medication (91.7% of 
infants and 6.1% of older children), which was discontinued prior to pH-MII monitoring. 
Nissen fundoplication was previously performed in eight (24.2%) 8-year old children (median 
age 0.5 years).
pH-MII studies
Greenfield catheters were used in 30 (52.6%) and ISFET catheters in 27 (47.4%) of the 57 pH-MII 
studies. Of the 57 included pH-MII studies, we evaluated 52 complete pH-MII studies, three 
studies showed no reliable pH results due to pH-sensor malfunctioning and in two studies 
impedance results were not analyzed (after deleting artefacts, duration of the impedance 
tracing was <18 hours).
Manual correction of reflux events
In total 3,313 RBM were detected by MMS software of which 1,287 (39%) RBM were manually 
deleted from the tracings: 52% of all non-acid RBM (mainly swallows misinterpreted as being 
a RBM) and 8% of all acid RBM (mainly swallowing or a single event being recognized as 
several events by the software)  supplementary figure 4.1 . Median RI was 2.6% in infants and 
0.6% in older children.  table 4.2  shows all other pH-MII parameters.
In infants, pH results were abnormal in 2/22 (10%) evaluated pH studies; one of these had 
apparent life-threatening events suspected to be GER related. Indeterminate pH results were 
found in six (27%) infants, two of whom (33%) suffered from daily regurgitation/vomiting. 
Normal pH results were found in 14 (64%) infants, one was symptomatic (day and night 
cough). A median of 61 (range 0-134) RBM were observed. Four infants had >100 RBM/ 
24 hours 22. 
In older children, pH results were abnormal in 4/32 (12.5%) pH studies, three of them (75%) 
were symptomatic (regurgitation, acid reflux and night cough). None of the older children 
with abnormal pH results had undergone fundoplication surgery prior to the pH-MII study. 
Indeterminate pH results were found in two (6%) children, both asymptomatic, and pH results 
were normal in 26 (81%) children, five (19%) reported symptoms (regurgitation, nausea, 
nausea/abdominal pain, foetor ex ore/abdominal pain and night cough). A median of 21 
(range 0-54) RBM were observed and none of the older children had >70 RBM/24 hours 22.
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Figure 4.1 Flowchart of children included in study.
a Deceased at a median age of 71 (range 3-704) days. Causes: multiple major anomalies (n=5), recurrent sepsis (n=1), 
reanimation complicated with sepsis and severe neurological impairment (n=1), acute apparent life-threatening event based 
on intracerebral bleeding and ischemia (n=1), sudden death with unknown cause (n=1). 
b Clinical reasons for absence of pH-MII studies: absence of symptoms after a recent Nissen fundoplication (n=1); normal 
esophagus observed at endoscopy in an asymptomatic child treated with anti-reflux medical therapy (n=1); and expectative 
management in a child with a short esophagus, intrathoracic stomach and proven gastroesophageal reflux (n=1).
Excluded children (n=16)
6 tracheoesophageal fistula only
10 tube feeding
No pH-MII study performed (n=24)
6 inability to insert nasal catheter
3 refusal of parent/child
10 organisational reasons (6 pH only, 1 at 
another age and 3 outside study period)   
3 clinical reason b
2 unknown reason
Children aged ≤18 months included (n=24)
20 completed pH-MII studies
2 studies without pH results
2 studies without impedance results
pH-MII study unreliable (n=2)
Children eligible for this study
(n=50)
Deceased (n=3) a
Children aged ≤18 months (n=69)




Table 4.2 Results from pH-impedance monitoring in children born with esophageal atresia after  
manual modification of reflux events
 Age ≤ 18 months (N=24)  [a] Age 8 years (N=33)  [b]
 n median min; max; IQR n median min; max; IQR
Monitoring duration (min) 24 1369 1123; 1478; 1334-1407 33 1352 1230; 1511; 1331-1393
pH results
– Number of acid exposures 22 35.0 4.0; 186.0; 17.5-68.5 32 7.5 0.0; 65.0; 2.0-17.8
– Reflux index (%) 22 2.6 0.1; 28.5; 1.1-4.6 32 0.3 0.0; 14.4; 0.1-2.5
– Number of long acid exposures 22 1.0 0.0; 11.0; 0.0-1.3 32 0.0 0.0; 8.0; 0.0-1.0
– Longest acid exposure (min) 22 6.0 0.4; 67.2; 3.3-10.0 32 2.2 0.0; 111.0; 0.6-8.4
Impedance results
– Number of RBM 22 61.2 0.0; 133.7; 16.7-98.3 33 20.7 0.0; 53.7; 11.2-31.6
– Number of acid RBM 20 20.9 0.0; 85.6; 6.8-38.1 32 7.0 0.0; 45.7; 0.3-11.0
– Number of nonacid RBM 20 31.2 0.0; 73.1; 9.9-60.2 32 11.2 0.0; 36.3; 6.9-16.7
– Number of liquid RBM 22 21.1 0.0; 58.3; 5.5-50.0 33 4.2 0.0; 21.2; 2.2-11.8
– Number of mixed RBM 22 30.2 0.0; 92.0; 11.1-60.1 33 12.6 0.0; 44.6; 6.4-23.3
– Mean BCT (sec) 22 11.0 0.0; 13.0; 9.0-12.0 33 13.0 0.0; 18.0; 8.5-14.0
– Number of proximal bolus exposures 22 5.0 0.0; 80.2; 1.1-11.5 33 0.0 0.0; 8.7; 0.0-1.2
BCT: bolus clearance time; IQR: inter-quartile range; RBM: retrograde bolus movements. 
a Children aged ≤18 months (n=24): results from 20 complete pH-MII studies, two studies without pH results and two studies 
without impedance results are shown. 
b Children aged 8 years (n=33): results from 32 complete pH-MII studies and one study without pH results are shown.
Children aged 8 years (n=74)
born 2004 – 2009
Excluded children (n=9)
4 tracheoesophageal fistula only
3 interposition
2 tube feeding
No pH-MII study performed (n=24)
4 inability to insert nasal catheter
12 refusal of parent/child
5 organisational reasons (2 pH only, 2 at 
another age and 1 outside study period)   
3 unknown reason
Children aged 8 years included (n=33)
32 completed pH-MII studies
1 study without pH results
pH-MII study unreliable (n=2)
Deceased (n=6) a





Prior to pH-MII monitoring, 12 children/parents spontaneously reported symptoms (16.7% of 
the infants and 24.2% of the older children)  table 4.1 . Diaries recorded during the 
measurement were missing in two children. Twenty-seven children did experience symptoms 
during pH-MII monitoring, of whom 21 reported non-specific and unlikely to be GER related 
(e.g. sneezing, hiccup) or very few (<3 times per 24 hours) symptoms. As a result, symptom 
analysis was performed in only four infants (coughing, belching and twice crying) and two 
older children (coughing and nausea/burping/regurgitation/vomiting). SI and SAP were 
positive in 1/6 (16.7%) and 3/6 (50.0%), respectively. If only acidic episodes were considered, SI 
and SAP were positive in 0/6 and 4/6 (66.7%), respectively. Without manual correction, only 
three of these latter four children had a positive SAP.
Questionnaire
Twenty-four (72.7%) 8-year old children completed the Manterola questionnaire  
 supplementary table 4.2 . Demographics, RI and number of RBM of these children did not 
significantly differ from the nine children who did not complete the questionnaire  
 supplementary table 4.3 . The score was suggestive for GERD in seven (29.2%) children. 
Nocturnal cough (n=7), regurgitation (n=6, weekly in four), dysphagia (n=5) and heartburn 
(n=5, weekly in one and daily in one) were the most frequently reported symptoms. In only 2/7 
children abnormal pH results were found: a RI of 13% in a child with complaints of heartburn 
at least once a month and an index of 14% in a child with occasional chest pain. pH-MII 
parameters (automated or manual), SI and SAP did not differ significantly between children 
with a high (>3) or low (≤3) score.
Change of anti-reflux treatment  supplementary table 4.4 
The majority (22/24; 91.7%) of infants were using anti-reflux medication prior to the pH-MII 
study. In infants, medication was continued in three (one abnormal and two indeterminate 
pH results), discontinued in 18 (four indeterminate, twelve normal and two unreliable pH 
results), and discontinued in one infant with abnormal pH results who underwent Nissen 
fundoplication.
Of the older children, only 2/33 (6%) were using anti-reflux medication prior to the pH-MII 
study. Medication was discontinued in both (normal pH results). Upper endoscopy was 
performed in three children with abnormal pH results, in 2/3 PPI was started for mild 
esophagitis. In two children (one with abnormal pH results and one with night cough) 
medication was started without endoscopy.
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discussion
In this study we evaluated acid and non-acid GER using pH-MII monitoring in 57 children with 
EA in infancy and at school-age. Observed RBM were mainly non-acid boluses (infants: 62% of 
RBM, older children: 64% of RBM) and mixed boluses (infants: 58% of RBM, older children: 
75% of RBM). 
Compared to available reference values in children without EA (asymptomatic neonates or 
children with symptoms), we found similar results for RI, number of RBM  figure 4.2a  and 
BCT 22-25.
Although several groups have published their pH-MII monitoring results in children with EA, 
reference values are lacking 2, 11, 12, 26-30. Differences in patient selection and study protocols 
makes comparing results difficult. For instance, one study in 35 children with EA continued 
PPI therapy, while medication was discontinued in other studies 26. Moreover, they included 
children of all ages (0.3-17.2 years) while two other studies focused on infants/toddlers 29 and 
school-aged children 11. In the latter study children with non-acid reflux were excluded 11. 
Compared to studies in children with EA, number of RBM in infants in our study was high 
compared to a small group of Dutch children, but similar to other cohorts 2, 11, 30. Results in 
8-year old children were comparable. We found a lower RI in both infants (2.6% vs 5.8-6.1%) 
and older children (0.3% vs 2.5-8.3%)  figure 4.2c . RI was similar in 35 Australian children 
(aged 0-17 years) 26.
In our study, abnormal GER/GERD was diagnosed in 10/57 children (17.5%: RI>7% n=6, positive 
SI/SAP n=4). This is much lower than the 54% of Danish children with EA and abnormal RI 28. 
Others reported 38%-45%, but they used different cut-offs for RI (>4.2% or >5% in children <12 
months; >10% in older children) 13, 29. Tube feeding was an exclusion criteria in the present 
study, which could have resulted in exclusion of children with GERD. When children with 
fundoplication surgery were considered as having GERD, a total of 31.6% of abnormal GER/
GERD was found.
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Figure 4.2 pH-MII parameters (number of retrograde bolus movements (RBM) and reflux index) of 
study cohort compared to available reference values in A) children without esophageal atresia 
(asymptomatic neonates or children with gastrointestinal, pulmonary or neurological symptoms) and B) 
and C) children with esophageal atresia.
63chapter 4
Symptom recording was insufficient for symptom association analysis as in 10/12 
symptomatic children (spontaneously reported prior to pH-MII monitoring) symptoms were 
absent during pH-MII monitoring. A previous study in 20 children found a recording failure in 
52% of coughs and a time lag of 11 seconds between the cough and the recording in the log 31.
The Manterola questionnaire 18 was suggestive for GERD in 29% of 8-year old children, but in 
only 2/7 a RI>7% was found. Compared to symptomatic 130 children without EA (aged 5-10 
years) they had similar number of RBM (21 vs 24), but a lower mean BCT (11 vs 17 second) 22. We 
found similar pH-MII parameters in children with low and high Manterola scores, possibly 
due to a larger day-to-day variability of pH-MII studies in EA patients, or perhaps disturbed 
impedance patterns make pH-MII studies unsuitable for GER detection in EA patients 32. 
Dysphagia was scored positive by 5/7 children with a positive Manterola questionnaire, which 
may be the result of dysmotility, eosinophilic esophagitis or strictures rather than GER. 
Furthermore, regurgitation was also scored often (6/7) which – in children with EA – can also 
be regurgitation from the esophagus rather than the stomach. It may therefore be that the 
Manterola questionnaire is not suitable for EA patients.
After visual validation of RBM identified as such by the software, 39% was deleted from the 
tracings. These were mainly non-acid swallows, which the software incorrectly identified as 
RBM  supplementary figure 4.1 . Abnormal esophageal motility, stasis of fluids and gas 
caused disturbed patterns which were misinterpreted by the software. Stasis of fluids was 
mostly present in Z3-Z4, at the level of the esophageal anastomosis. The software did not 
recognize this stasis and measured a shorter BCT. This is in accordance with previous literature 33. 
In automated analysis, swallows following RBM were sometimes misclassified as proximal 
GER events. Air in the esophagus after a swallow showed a pattern that was recognized as GER 
by the software.
Previous studies show high inter- and intra-observer variability in pH-MII analysis 34, 35. The 
high percentage of deleted RBM raises the question how accurate pH-MII analysis in EA 
patients is. We believe this number is too high to ignore and to perform automated analyses 
without manual revision. Manual revision, however, carries the risk of greater inter-observer 
variability. Refinement of automated software is needed to identify impedance reflux patterns 
in patients with complex motility disorders such as EA.
The recent ESPGHAN-NASPGHAN Guideline recommends to treat all EA patients with anti-acid 
treatment in the first year of life and to monitor GER with pH-MII monitoring and/or 
endoscopy at time of discontinuation (regardless of symptoms) and during long-term 
follow-up in symptomatic children 6. However, no studies have been performed to show 
benefit of routine pH-MII monitoring in EA patients and a recent SR showed evidence – albeit 
of low quality – that prophylactic anti-reflux medication does not prevent stricture formation 
64 chapter 4
after EA repair 36. As discussed above reflux in our patients was mainly non-acid. In infants, 
symptoms were mainly associated with non-acid RBM, while symptoms in older children 
were mainly associated with acid RBM 29. Treatment options of non-acid GER are limited. A 
small double-blinded placebo controlled RCT in children showed that Baclofen inhibits 
transient lower esophageal sphincter relaxation and accelerates gastric emptying, but is 
dissuaded in guidelines as a first-choice therapy in children because of known side effects in 
adults 4, 37. Surgical anti-reflux procedures are available, but have side effects and it is unclear 
which patients would benefit. Further research is needed to determine the optimal duration 
of anti-acid therapy after EA repair.
The strengths of our study are the manual evaluation of RBM, the inclusion of both 
symptomatic as well as asymptomatic children with EA, and both infants and older children. 
International guidelines recommend to monitor GER at time of discontinuation of anti-acid 
treatment (around one year) and during long-term follow-up in symptomatic children with 
EA 6. Our study is the first to show pH-MII results in these two age-groups. Still, some 
limitations need to be mentioned. First, two different pH electrodes were used. Although 
significant differences have been found in acid exposure times between ISFET, glass and 
antimony electrodes, our results from both catheters were similar 38. Second, only 52% of 
eligible children of our follow-up program were included. Since demographics did not differ 
and the majority (79%) was asymptomatic, selection bias does not seem to be a major factor 
influencing our results. Third, only RBM recognized by the software were manually reviewed 
and modified. This method might have resulted in underreporting of reflux events. Although 
the software is designed to over-detect reflux events, we cannot exclude the option that 
episodes were missed. Last, due to the lack of longitudinal data we did not compare results 
between infants and older children. Infants seem to have worse pH-MII parameters compared 
to older children, however differences in type of feeding (liquid vs solid food), body position 
during feeding, and other demographics (i.e. thoracoscopic surgery, use of anti-reflux 
medication and history of fundoplication surgery) would have made the comparison 
unreliable. 
In conclusion, most infants and school-aged children with EA off medication have a normal 
RI, yet experience a significant number of non-acid RBM. After manual revision of the tracings 
a high percentage of RBM was deleted. These were mainly non-acid swallows which the 
software incorrectly identified as RBM. Our data show that automated impedance analysis 
software needs refinement for use in infants and children with EA and question the need for 
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supplementary material
Supplementary figure 4.1 Screenshot: automated analysis of MMS database software misinterprets 
two swallows (arrows) as being a non-acid retrograde bolus movement.
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Supplementary table 4.1 Patient demographics of included children (n=57) and children without 
pH-MII study (n=52)
 Children included (N=57) Children not included (N=52)
 n (%) / median (min; max; IQR) n (%) / median (min; max; IQR) p-value
Male gender 29 (50.9) 34 (65.4) 0.126
Gestational age (weeks) 38.3 (28.9; 42.3; 36.8-40.1) 37.7 (32.0; 41.3; 35.9-39.9) 0.163
Prematurity 14 (24.6) 21 (40.4) 0.077
Birthweight (gram) 2685 (854; 3810; 2150-3125) 2750 (1180; 3995; 1909-3270) 0.785
Small for gestational age 8 (14.0) 8 (15.4) 0.842
Type of esophageal atresia   
– Gross type A 1 (1.8) 5 (9.6) 0.101  [a] 
– Gross type C 55 (96.5) 47 (90.4) 
– Gross type D 1 (1.8) 0 
Type of esophageal correction   
– Primary anastomosis  53 (93.0) 47 (90.4) 0.734
– Delayed anastomosis 4 (7.0) 5 (9.6) 
Type of surgery   
– Thoracoscopy 25 (43.9) 26 (50.0) 0.459  [b]
– Thoracotomy 31 (54.4) 22 (42.3) 
– Converted 1 (1.8) 2 (3.8) 
– Unknown 0 1 (1.9) 
Non-parametric Mann-Whitney U test for continues variables and Pearson’s chi-square test or Fisher’s exact test for categorical 
variables. 
a Esophageal atresia Gross type A versus other types (Gross type C + D). 
b Thoracoscopy versus thoracotomy (including conversion).
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Supplementary table 4.2 Gastrointestinal questionnaire 8-year old children (24/33=72.7%)
Questions to detect gastroesophageal reflux Answer Manterola score n (%)
Do you have complaints of burning reflux (burning sensation
behind your breastbone)? Never 0 16 (66.7) 
 At least once a month 1 5 (20.8)
 At least once a week 2 2 (8.3)
 Daily 3 1 (4.2)
Do you have complaints of regurgitation of stomach contents? Never 0 14 (58.3)
 At least once a month 1 6 (25.0)
 At least once a week 2 4 (16.7)
 Daily 3 0
Do you have problems with swallowing? No 0 18 (75.0)
 Yes 1 6 (25.0)
Do you have complaints of pain on the chest? Never 0 17 (70.8)
 Occasional 1 7 (29.2)
 Daily 2 0
Do you have nightly coughs? Never 0 8 (33.3)
 Occasional 1 16 (66.7)
 Each night 2 0
Do you have complaints of hoarseness? No 0 22 (91.7)
 Yes 1 2 (8.3)
Do you have asthma? No 0 24 (100)
 Yes 1 0
Other questions asked Answer  n (%)
Are you able to eat everything? No  5 (20.8)  [a]
 Yes  19 (79.2)
Are you able to eat as much as your peers? No  7 (29.2)
 Yes  17 (70.8)
Are you able to eat as fast as others? No  13 (54.2)
 Yes  11 (45.8)
Is it necessary to drink while you eat? No  13 (54.2)
 Yes  11 (45.8)  [b]
Do you ever feel nauseous after eating? No  17 (70.8)
 Yes  7 (29.2)  [c]
Are you easily feeling full after eating? No  15 (62.5)
 Yes  9 (37.5)  [d]
Do you ever feel bloated after eating? No  15 (62.5)
 Yes  9 (37.5)  [e]
Manterola score: Manterola et al. Initial validation of a questionnaire for detecting gastroesophageal reflux disease in 
epidemiological settings. J Clin Epidemiol. 2002;55(10):1041-5. 
a Cooked eggs (n=1); hot dogs (n=1); garden peas, beans, cheese and potatoes (n=1); soft drinks (n=1); candy, bananas,  
apples and hot dogs (n=1).
b The Manterola Questionnaire reported dysphagia in two children, chest pain in three children (one also complained of  
dysphagia), and regurgitation in two children. In the other five children none of these symptoms were reported. 
c A few times a week (n=3); a few times a month (n=2); a few times a year or less (n=2). 
d Daily (n=1); a few times a week (n=4); a few times a month (n=1); a few times a year or less (n=3). Two children had a  
history of Nissen fundoplication. 
e Daily (n=1); a few times a week (n=1); a few times a month (n=3); a few times a year or less (n=4).
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Supplementary table 4.3 Patient demographics of 8-year old children who were asked to fill in the 
gastrointestinal questionnaire (N=33)
 Questionnaire completed (N=24) No questionnaire (N=9)
 n (%) / median (min; max; IQR) n (%) / median (min; max; IQR) p-value
Male gender 9 (37.5) 6 (66.7) 0.239
Gestational age (weeks) 39.0 (28.9; 42.3; 37.3-40.7) 37.7 (34.6; 40.1; 36.0-38.7) 
Prematurity 4 (16.7) 3 (33.3) 0.358
Birthweight (gram) 3030 (1080; 3810; 2238-3368) 2615 (1905; 3180; 2143-2925) 
Small for gestational age 3 (12.5) 1 (11.1) 1.000
Type of esophageal atresia   
– Gross type A 1 (4.2) 0 1.000  [a]
– Gross type C 22 (91.7) 9 (100) 
– Gross type D 1 (4.2) 0 
Type of esophageal correction   
– Primary anastomosis  23 (95.8) 7 (77.8) 0.174
– Delayed anastomosis 1 (4.2) 2 (22.2) 
Type of surgery   
– Thoracoscopy 6 (25.0) 2 (22.2) 1.000  [b]
– Thoracotomy 18 (75.0) 7 (77.8) 
Reflux index (%) 0.3 (0; 11.8; 0.1-1.9) 0.3 (0; 14.4; 0.1-2.7) 0.651
Number of RBM 20.7 (5.8; 48.9; 12.7-27.1) 20.9 (0; 53.7; 10.1-35.4) 0.953
Non-parametric Mann-Whitney U test for continues variables and Pearson’s chi-square test or Fisher’s exact test for categorical 
variables. 
a Esophageal atresia Gross type A versus other types (Gross type C + D).
b Thoracoscopy versus thoracotomy (including conversion).
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Supplementary table 4.4 Change of anti-reflux treatment after pH-MII study
 abnormal indeterminate normal unknown
 pH results pH results pH results pH results
Age ≤ 18 months (N=24) n=2 n=6 n=14 n=2
Continuation without anti-reflux medication 0 0 2  0
Discontinuation of anti-reflux medication 0 4 12 2
Continuation of anti-reflux medication 1 2 0 0
Fundoplication surgery + discontinuation of anti-reflux 
medication 1 0 0 0
 abnormal indeterminate normal unknown
 pH results pH results pH results pH results
Age 8 years (N=33) n=4 n=2 n=26  [a] n=1  [b]
Continuation without anti-reflux medication 0 2 23 1
Discontinuation of anti-reflux medication 0 0 2 0
Start anti-reflux medication 1 0 1  [c] 0
Upper endoscopy ± start anti-reflux medication 3  [d] 0 0 0
a Nissen fundoplication surgery was performed prior to the pH-MII study in 7/26 children with normal pH results. 
b Nissen fundoplication surgery performed prior to the pH-MII study. 
c In one child with normal pH-MII results, anti-reflux medication was started to treat night cough. 
d Upper endoscopy revealed normal esophagus in one child (no further actions) and mild esophagitis in two children for which 
treatment with proton pump inhibitors was started. 
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To determine the incidence of refractory anastomotic strictures after oesophageal atresia (OA) 
repair and to identify risk factors associated with refractory strictures.
Methods
Retrospective national multicentre study in patients with OA born between 1999 and 2013. 
Exclusion criteria were isolated fistula, inability to obtain oesophageal continuity, death prior 
to discharge, and follow-up <6 months. A refractory oesophageal stricture was defined as an 
anastomotic stricture requiring ≥5 dilations at maximally 4-week intervals. Risk factors for 
development of refractory anastomotic strictures after OA repair were identified with 
multivariable logistic regression analysis.
Results
We included 454 children (61% male, 7% isolated OA (Gross type A)). End-to-end anastomosis 
was performed in 436 (96%) children. Anastomotic leakage occurred in 13%. Fifty-eight per 
cent of children with an end-to-end anastomosis developed an anastomotic stricture, 
requiring a median of 3 (range 1-34) dilations. Refractory strictures were found in 32/436 (7%) 
children and required a median of 10 (range 5-34) dilations. Isolated OA (OR 5.7; p=0.012), 
anastomotic leakage (OR 5.0; p=0.001) and the need for oesophageal dilation ≤28 days after 
anastomosis (OR 15.9; p<0.001) were risk factors for development of a refractory stricture.
Conclusions 
The incidence of refractory strictures of the end-to-end anastomosis in children treated for OA 
was 7%. Risk factors were isolated OA, anastomotic leakage and the need for oesophageal 




Oesophageal atresia (OA) with or without a tracheo-oesophageal fistula (TOF) is a rare 
anatomical anomaly (2.43:10,000 births) 1. Dedicated centres have reported survival rates up 
to 95% 2, 3. However, anastomotic stricture formation is still the most frequent postoperative 
complication (17%-59%), occurring mostly in the first year of life 4, 5.
Data on oesophageal stricture formation after OA repair and potential risk factors is scarce 6-12. 
A recent single-centre retrospective study found postoperative oesophageal strictures (≥4 
dilations, no interval specified) in 21.5% of OA patients (26/121), thoracoscopic and staged  
OA repair were both associated with stricture formation 6.
A uniform definition of an oesophageal stricture after OA repair is lacking, which makes 
comparing different studies difficult. Most studies define an oesophageal stricture as any 
narrowing of oesophageal lumen requiring at least one dilation 5, 7, 9. However, in current 
literature definitions vary based on frequency of dilations 6, 13-17, luminal diameter 12, or 
symptomatology 8, 10. In some centres patients with OA are routinely subjected to a series of 
three dilations, even when symptoms and luminal narrowing have disappeared.
Refractory strictures require frequent dilations and therefore result in a high burden for both 
child and parents, including frequent anaesthesia, hospital stay and risk of perforation. The 
newest European Society of Gastrointestinal Endoscopy-European Society for Paediatric 
Gastroenterology Hepatology and Nutrition Guideline on Pediatric Endoscopy suggests the 
following definition of a benign refractory oesophageal stricture in children: an anatomic 
restriction without endoscopic inflammation that results in dysphagia after a minimum of 
five dilations at maximally 4-week intervals 18. 
We hypothesised that anastomotic leakage and thoracoscopic OA repair will increase 
refractory oesophageal stricture formation. In a large multicentre cohort of children born 
with OA in the Netherlands, we retrospectively determined the incidence of postoperative 
dilations and refractory anastomotic strictures. We studied possible determinants of 




We included all OA patients born between 1999 and 2013 who were treated for OA in one of  
the participating centres. Data until June 2016 were included, ensuring minimum follow-up 
of 2.5 years. Exclusion criteria were: isolated TOF (Gross type E) 19, inability to obtain 
oesophageal continuity, death prior to discharge, and follow-up less than 6 months. 
Five of the six university hospitals involved in neonatal surgery – all members of the Dutch 
Consortium of Esophageal Atresia (DCEA) Study Group – participated (see  supplementary 
appendix ). The Medical Ethics Committee of Erasmus MC concluded that the Dutch Medical 
Research Involving Human Subjects Act did not apply to the study protocol (protocol ID 
MEC-2016-570). Ethics approval from the local committees in the other participating centres 
was obtained.
Data collection
Baseline demographics and outcome data at follow-up were retrieved from patient records. 
Major associated anomalies included Ravitch’ paediatric surgical index diagnoses 20, major 
cardiac anomalies (cardiac malformations requiring surgical correction or cardiological 
follow-up), other congenital malformations requiring major surgical interventions, and 
malformations seriously affecting normal function (e.g. tethered cord with neurogenic 
bladder function). All other anomalies were considered minor (e.g. small atrial septal defect 
closing spontaneously). Prematurity was defined as gestational age <37 weeks. VACTERL 
(vertebral defects, anal atresia, TOF with OA, cardiac anomalies, renal anomalies and limb 
anomalies) association was defined according to Solomon 21. Type of OA was classified 
according to Gross 19. A child was considered to have gastro-oesophageal reflux disease (GORD) 
if pH monitoring showed pathological reflux, if upper endoscopy showed oesophagitis or if 
antireflux surgery was performed. Furthermore, frequent aspiration, typical symptoms with 
spontaneous reflux present at contrast oesophagography, or symptom relief using antireflux 
drugs were considered to indicate GORD. Anastomotic leakage was defined as leakage visible 
at contrast oesophagography or necessitating placement of a chest tube postoperatively.
Definitions of strictures 
A stricture was defined as a symptomatic stenosis of an anastomosis for which dilation was 
indicated. A stricture requiring dilation ≤28 days after OA repair was considered ‘early’.  
A refractory stricture was defined as an anastomotic (end-to-end, oesophagojejunal or 
oesophagogastric) stricture requiring ≥5 dilations at maximally 4-week intervals 18.
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Data analysis
Data are presented as frequencies or as medians (minimum; maximum; IQR). Pearson’s X2 
test, Fisher’s exact test and the non-parametric Mann-Whitney U test were used for statistical 
comparison between children with and without a refractory stricture of the end-to-end 
anastomosis. Multivariable logistic regression analysis was performed to identify risk factors 
for refractory strictures of the end-to-end anastomosis. Predefined risk factors for refractory 
strictures were (based on previous literature): gestational age, isolated OA (Gross type A), 
thoracoscopic correction, anastomotic leakage and early stricture (≤28 days after 
anastomosis). Centre was also included as an independent variable in the logistic regression 
model. The Hosmer-Lemeshow goodness-of-fit test was used to assess whether the model 
adequately describes the data. Because in several studies a clinically significant stricture – to be 
distinguished from a refractory stricture – is defined as a stricture requiring ≥3 dilations, 
findings from children with and without a stricture requiring ≥3 dilations were also compared 
including identification of risk factors. Data were analyzed with SPSS V.21.0 (SPSS).
results
We included 454/563 (80.6%) children treated in one of the participating centres. Reasons for 
exclusion were: isolated TOF (n=31), no oesophageal continuity obtained (n=2), early death 
(n=59), follow-up <6 months (n=15), and missing data (n=2). Six (1.3%) children who died after 
discharge and after the age of 6 months (median of 576 (range 207-1729) days) were included. 
Demographics 
Thoracotomy with primary anastomosis was performed most frequently (357/454; 78.6%)  
 table 5.1 . Oesophageal continuity was obtained with a jejunal interposition or gastric 
pull-up in 18/454 (4.0%) children. Stricture formation was the reason for oesophageal 
replacement at an older age in three children with isolated OA.
Anastomotic strictures
An anastomotic stricture was documented for 262/454 (57.7%) children: 251/436 (57.6%) 
children with an end-to-end anastomosis (median (minimum; maximum; IQR) of 3 (1; 34; 1-5) 
dilations); 9/13 (69.2%) children with a jejunal interposition (median of 5 (3; 32; 4-16) 
dilations); and 2/5 (40.0%) children with a gastric pull-up (two and five dilations)  table 5.2 . 
 figure 5.1  illustrates the number of dilations performed in children with an end-to-end 
anastomosis.
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Table 5.1 Patient demographics (N=454)
  n (%)
  median (min; max; IQR)
Male gender  277 (61.0)
Age at last follow-up (years)  6.6 (0.6; 16.9; 3.7-10.9)
Gestational age (weeks)  38.0 (25.6; 42.9; 35.9-40.0)
Prematurity  161 (35.5)
Birthweight (gram)  2780 (725; 4505; 2115-3200)
Type of oesophageal atresia Gross type A (isolated OA) 30 (6.6)
 Gross type B (OA with proximal TOF) 3 (0.7)
 Gross type C (OA with distal TOF) 409 (90.1)
 Gross type D (OA with dual TOFs) 12 (2.6)
 Gross type E (isolated TOF) 0
Associated problems Major associated anomaly 140 (30.8)
 Major cardiac anomaly 39 (8.6)
 VACTERL association 71 (15.6)
 Syndromic diagnosis  [a] 33 (7.3)
Type of oesophageal correction  [b] Primary anastomosis 405 (89.2)
 Primary anastomosis with Livaditis lengthening 2 (0.4)
 Delayed anastomosis 28 (6.2)
 Delayed anastomosis with Livaditis lengthening 1 (0.2)
 Oesophageal replacement 18 (4.0)
Type of surgery Thoracoscopy 52 (11.5)
 Thoracotomy 397 (87.4)
 Converted 5 (1.1)
Chest tube postoperatively  143 (31.5)
Anastomotic leakage  [c]  60 (13.2)
Recurrent tracheo-oesophageal fistula  [d]  19 (4.2)
Initial days on ventilator  2 (0; 89; 1-4)
Need for gastrostomy  [e]  95 (20.9)
Antireflux medical therapy after 
oesophageal atresia repair  [f] Yes 399 (87.9)
 Unknown 9 (2.0)
History of gastro-oesophageal reflux  [g]  223 (49.1)
Antireflux surgery  [h]  81 (17.8)
IQR: inter-quartile range; max: maximum; min: minimum; OA: oesophageal atresia; TOF: tracheo-oesophageal fistula.
a Down syndrome (n=13), Goldenhar syndrome (n=8), CHARGE syndrome (n=5), Megarbane syndrome (n=1), Silver-Russell 
syndrome (n=1). Treacher Collins syndrome (n=1), 22q11.2 deletion syndrome (n=1), caudal duplication syndrome (n=1), 
22q11.2 microduplication syndrome (n=1) and Trisomy 18 (n=1).
b Oesophageal continuity obtained at a median of 2 (range 0-2539) days after birth. Oesophageal replacement: jejunal 
interposition (n=13) and gastric pull-up (n=5). 
c At a median of 6 (range 0-63) days after oesophageal continuity was obtained.
d At a median of 107 (range 12-5032) days after initial surgery (primary anastomosis or gastrostomy in staged repair). In two 
children with long gap OA a TOF arose after laryngotracheal reconstruction for a subglottic stenosis (fistula at day 3698) and 
after recurrent anastomotic leakage (fistula at days 203 and 3498).
e At a median of 6 (range 0-3098) days after birth. Reasons: staged repair (n=42), feeding difficulties (n=22), oesophageal 
strictures (n=9), anastomotic leakage (n=7), gastro-oesophageal reflux disease (n=7), decompression tension on stomach 
during ventilation (n=4), prematurity (n=2), access to stomach to retrieve broken bougie tip (n=1), and unknown (n=1).
f H2 antagonist ± prokinetic drug (n=319), proton pump inhibitor ± prokinetic drug (n=47) or prokinetic drug monotherapy 
(n=33). Duration of medical therapy: <3 months (n=51), 3-6 months (n=79), 6-12 months (n=82), >12 months (n=150), 
unknown (n=37). 
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Table 5.2 Dilation procedures of anastomotic strictures (N=1077) in 262 (57.7%) children
  n (%)
  median (min; max; IQR)
Stricture location End-to-end oesophageal anastomosis 973 (90.3)
 Oesophagojejunal anastomosis proximal  [a] 93 (8.6)
 Oesophagogastric anastomosis gastric pull-up 11 (1.0)
Diameter of dilation procedure (mm)  9 (3; 20; 7-10)
Type of dilation procedure Bougie 733 (68.1)
 Balloon (endoscopic) 138 (12.8)
 Balloon (fluoroscopic) 170 (15.8)
 Unknown 36 (3.3)
First type of dilation Bougie 201 (76.7)
 Balloon 50 (19.1)
 Unknown 11 (4.2)
Perforation after bougie/balloon 
dilation procedure Bougie 9 (1.2)
 Balloon 5 (1.6)
Tight stricture Yes 95 (8.8)
 No 664 (61.7)
  Unknown 318 (29.5)
Ability to pass an endoscope through 
the stricture No passage possible  313 (29.1)
 Passage possible 101 (9.4)
 Stricture visible, but passage unknown 220 (20.4)
 No relevant stricture visible  [b] 96 (8.9)
 Unknown 347 (32.2)
a Stricture of proximal anastomosis (n=45), distal anastomosis (n=40) or both proximal and distal anastomosis (n=8).
b No resistance during the dilation procedure and no mucosal tears after the dilation procedure.
g Diagnosis of gastro-oesophageal reflux disease: antireflux surgery performed (n=76), pathological pH-monitoring (n=61), 
pathologic contrast oesophagography with typical symptoms (n=31), oesophagitis (n=21), typical symptoms with good 
response to medical therapy (n=18), and frequent symptoms of aspiration (n=16).
h Nissen (n=56), Thal (n=7), Toupet (n=2), Boix-Ochoa fundoplication (n=1) and Boerema anterior gastropexy (n=15), 
performed at a median of 207 (range 42-2785) days after birth. Redo antireflux surgery was needed in 15 children, with a 
median time interval after initial antireflux surgery of 399 (range 72-2758) days. One child needed a third surgery (interval of 
3317 days) and one child needed a second and third surgery (intervals of 400 and 2640 days).
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Figure 5.1 Anastomotic dilation procedures performed in children with oesophageal end-to-end 
anastomosis (N=436).
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Refractory strictures developed in 32/436 (7.3%) children with an end-to-end anastomosis 
(varying between centres: 1.6%-13.3%, see  supplementary figure 5.1 . A median of 10 (5; 34; 
8-15) dilations were performed; the fifth dilation at a median of 110 (49; 158; 81-124) days after 
anastomosis. Refractory strictures of the oesophagojejunal anastomosis developed in 2/13 
(15.4%) jejunal interpositions: one stricture of a proximal anastomosis requiring 32 dilations 
(fifth dilation at day 86 after anastomosis) and one stricture of a distal anastomosis requiring 
15 dilations (fifth dilation at day 72 after anastomosis).
Eighteen of 81 (22.2%) children who underwent fundoplication surgery had developed a 
refractory stricture prior to antireflux surgery. After antireflux surgery 31 (39.3%) children still 
needed oesophageal dilation, with a median of 3 (1; 29; 1-7) dilations per child. Two (2.5%) 
children developed a refractory stricture after antireflux surgery (Nissen fundoplication and 
Boerema anterior gastropexy with hiatoplasty, respectively).
 supplementary table 5.1  summarises details on other treatments of strictures (i.e. stent 
placement, mitomycin application and stricture resection). 
Determinants of refractory anastomotic strictures
 table 5.3  summarises characteristics of children with and without a refractory stricture of the 
end-to-end anastomosis. Results from multivariable logistic regression analysis (adjusted for 
centre) in children with an end-to-end anastomosis demonstrated that isolated OA (OR 5.7; 
p=0.012), anastomotic leakage (OR 5.0; p=0.001) and an early stricture (OR 15.9; p<0.001) were 
associated with refractory stricture formation  table 5.4 . Thoracoscopic OA repair was not 
significantly associated with refractory strictures. In multivariable logistic regression analysis 
6/436 children were excluded (missing values for gestational age). 
 supplementary table 5.2, 5.3 and 5.4  summarise results from multivariable logistic 
regression analysis for strictures requiring ≥3 dilations (definition of a clinically significant 
stricture in several studies).
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Table 5.3 Strictures of oesophageal end-to-end anastomosis (N=436): characteristics of children with 
and without a refractory anastomotic stricture (≥5 dilations)
 Refractory stricture  [b] No refractory stricture
 (N=32) (N=404)
 n (%) n (%) p-value
 median (min; max; IQR) median (min; max; IQR) 
   
Male gender 21 (65.6) 248 (61.4) 0.635
Gestational age (weeks) 37.6 (25.6; 42.0; 35.6-38.9) 38.1 (25.6; 42.9; 36.0-40.0) 0.170
Prematurity 13 (40.6) 136 (33.7) 0.460
Birthweight (gram) 2650 (725; 3440; 2000-2933) 2795 (735; 4505; 2150-3220) 0.152
Isolated OA (Gross type A) 4 (12.5) 11 (2.7) 0.018
Major associated anomaly 12 (37.5) 121 (30.0) 0.377
Major cardiac anomaly 2 (6.3) 36 (8.9) 1.000
Syndromic diagnosis 3 (9.4) 26 (6.4) 0.461
Thoracoscopy  [a] 5 (15.6) 47 (11.6) 0.567
Staged repair 9 (28.1) 21 (5.2) <0.001
Chest tube 13 (40.6) 116 (28.7) 0.192
Anastomotic leakage 9 (28.1) 49 (12.1) 0.025
Recurrent tracheo-oesophageal fistula 2 (6.3) 14 (3.5) 0.331
History of gastro-oesophageal reflux 23 (71.9) 182 (45.0) 0.001
Antireflux surgery 2 (6.3) 60 (14.9) 0.289
First dilation with a bougie 27 (84.4) 168 (41.6) 0.593
Early stricture (≤28 days after anastomosis)  12 (37.5) 21 (5.2) <0.001
OA: oesophageal atresia. Bold typeface represent statistically significant p values (p<0.05). Non-parametric Mann-Whitney U 
test for continuous variables and Pearson’s X2 test or Fisher’s exact test (if expected counts were <5) for categorical variables. 
a Thoracoscopy was performed in centre A and E: refractory strictures developed in 4/48 (8.3%) and 1/4 (25.0%) 
thoracoscopic repairs, respectively.
b Antireflux surgery was performed in 18 of 32 (56.3%) children with a refractory stricture: two prior to and 16 after 
development of a refractory stricture.
Table 5.4 Multivariable logistic regression analysis for refractory anastomotic stricture (≥5 dilations) in 
children with oesophageal end-to-end anastomosis (N=436)
 OR 95% CI p-value
Gestational age (weeks) 0.98 0.85-1.12 0.711
Isolated OA (Gross type A) 5.71 1.48-22.13 0.012
Thoracoscopy 0.45 0.14-1.50 0.191
Anastomotic leakage 5.03 1.88-13.43 0.001
Early stricture (≤28 days after anastomosis)  15.90 5.89-42.92 <0.001
CI: confidence interval; OA: oesophageal atresia; OR: odds ratio. Bold typeface represents statistically significant p values 
(p<0.05). Adjusted for centre. Hosmer-Lemeshow goodness of fit test p=0.552. Due to missing values for gestational age 6/436 
children were excluded from the multivariable logistic regression analysis.
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discussion 
In this multicentre national cohort of 454 children born with OA the incidence of anastomotic 
strictures after end-to-end anastomosis was 57.6%. Refractory stricture of an end-to-end 
anastomosis requiring ≥5 dilations developed in 7.3% of cases. Isolated OA, anastomotic 
leakage and early stricture (≤28 days after anastomosis) were associated with refractory 
stricture development.
The incidence of anastomotic strictures after OA repair in our study (57.7%) is concordant with 
previous literature (9%-79%) 22. This wide range reflects the lack of a uniform definition of 
refractory strictures. Many clinicians decide to surgically intervene after three consecutive 
dilations. Thus, in several studies a clinically significant stricture is defined as a stricture 
requiring ≥3 or ≥4 dilations 6, 16, 17. We recommend to use a uniform definition for refractory 
anastomotic strictures in future studies: an anastomotic stricture requiring ≥5 dilations at 
maximally 4-week intervals. This definition distinguishes refractory strictures from so called 
recurrent strictures.
Nice et al. found that both thoracoscopic and staged OA repair were associated with stricture 
formation 6. These authors considered strictures refractory and clinically significant after ≥4 
dilations. Unfortunately, information on the interval between dilations and the duration of 
follow-up was not provided, which impedes comparison to our study.
Despite better visualization and usually a more limited dissection during thoracoscopic OA 
repair, opening of the upper pouch can be less than in open surgery which might lead to 
increased stricture formation. We could however not confirm our hypothesis that 
thoracoscopic OA repair is associated with refractory stricture formation. The relatively low 
number of thoracoscopic corrections (n=54 performed in two centres only) may explain this. 
Two recent literature reviews concluded that the incidence of strictures after both 
thoracoscopic and open OA repairs is comparable 23-25.
Both in the present and in earlier studies leakage was predictive of anastomotic stricture 
formation 26, 27. We assume that leakage enhances inflammation and scarring of the 
anastomotic area.
Our finding that isolated OA was a risk factor is supported by others 8, 11, 12. The long gap in 
isolated OA often requires staged anastomosis or oesophageal replacement. Although 
correction of a large gap is thought to result in anastomotic tension with subsequent stricture 
formation, contradictory results have been reported 15, 28. We included only the uniformly 
objective variable isolated OA as a potential explanatory variable, since staged repair, long gap 
OA and oesophageal replacement are correlated to each other. 
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In children with an isolated OA, the current practice to restore oesophageal continuity is 
performing a primary anastomosis, either immediately or delayed. In our study only 15/30 
children with an isolated OA underwent an oesophageal anastomosis. Children with an 
isolated OA in whom a primary anastomosis is performed may be at higher risk of developing 
a refractory stricture than children with other types of OA. Indeed we found that a refractory 
stricture had developed in 26.7% (4/15). This information can be shared in preoperative 
parental counseling.
We also found that an early anastomotic stricture predicted the development of a refractory 
stricture. More severe strictures may occur in the first weeks postoperatively, but early dilation 
in a still vulnerable anastomosis might be an independent risk factor for refractory strictures. 
Our data do not allow to draw any conclusions on this subject. Most of the refractory strictures 
developed within four months postoperatively. We assume that the ‘late onset’ oesophageal 
strictures are related to altered food consistency as more solid formulas can cause dysphagia, 
food impaction, stasis, aspiration or vomiting.
Although others have identified anastomotic tension as a risk factor for strictures, we chose to 
not include tension as a potential determinant 7-11, 26. Anastomotic tension is a subjective 
observation which is usually poorly recorded. Anastomotic leakage is a more objective finding 
and was found to be a predictor for stricture formation in our study.
Another factor thought to increase stricture development is GORD 5, 11, 26, 27. Studies are hard 
to compare as different definitions of GORD are used. Besides, most studies are retrospective 
without use of standardized protocols to diagnose GORD. Interestingly, prophylactic 
antireflux drugs did not always reduce stricture formation in OA patients 29-31. We did not 
include GORD as a possible determinant in our study as participating centres used different 
protocols for diagnosis. In our study, antireflux surgery was more frequent in children with a 
refractory stricture than in those without. It was typically performed after refractory stricture 
development and should therefore be considered as therapeutic management rather than 
being a risk factor for stricture formation.
Prematurity, birth weight and cardiac anomalies have been associated with stricture 
formation, but this was not the case in our study 6, 8, 30.
Several adjuvant treatments are currently available for the treatment of refractory strictures, 
such as stent placement, intralesional steroid injection, mitomycin C application, endoscopic 
needle knife incision and resection surgery. Studying the effectiveness of these treatments 
was outside the scope of our study. 
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The strengths of our study are the large cohort (covering ~80% of all newborns born with OA 
in the Netherlands), the long follow-up period and the small number of missing data. Still, 
some limitations need to be addressed. First, risk factors for refractory strictures after jejunal 
interposition (2/13) or gastric pull-up (0/5) could not be identified due to the limited sample 
size. Second, indications for dilations were not recorded reliably in all cases. One of the 
problems with OA is the associated dysmotility, so some level of stasis is always present. 
Whether feeding can be ameliorated with dilations is usually decided based on the 
combination of clinical symptoms and by radiographic findings in selected cases. Third, the 
method used to open the proximal pouch (monopolar/bipolar electrocautery, knife, scissors) 
and suture techniques for anastomosis were not recorded. Since anastomotic tension and 
ischemia are thought to play a role in anastomotic stricture formation, it would be interesting 
to use innovative new optical techniques to address these aspects in future studies (e.g. 
deformation sensors in (endoscopic) instruments to quantify tension and spectroscopic 
assessment of tissue oxygenation and perfusion). Fourth, due to the retrospective design and 
the absence of uniform protocols for dilations and GORD diagnosis, we were unable to 
reliably study the relation between these factors and stricture development. Besides, 
eosinophilic oesophagitis – known to be associated with oesophageal stricture development 
– could not be included as a risk factor as no standardized upper endoscopies with biopsies 
were performed in our study cohort 32. Last, the participating centres differed with regard to 
the frequencies of thoracoscopic corrections, chest tube placement postoperatively, 
anastomotic leakage, recurrent TOFs and antireflux procedures. Studying a large cohort with  
a higher number of thoracoscopic surgeries is needed to examine whether a learning curve is 
present 32, 33. Numbers of antireflux procedures performed in different centres might reflect 
differences in dilation management and GORD protocols between centres.
We observed an alarmingly high number of refractory strictures after end-to-end anastomosis 
in children with isolated OA (26.7%). Whether these children, those with anastomotic leakage, 
and those with an early stricture may benefit from supportive care (e.g. adequate acid 
suppression) aiming to protect the anastomotic area is still unknown. 
In conclusion, refractory anastomotic strictures requiring ≥5 dilations had developed in 7.3% 
of 436 OA patients with an end-to-end anastomosis. A high number (26.7%) was observed 
after end-to-end anastomosis in children with isolated OA. We observed that isolated OA, 
anastomotic leakage and early anastomotic stricture (≤28 days after anastomosis) are 
associated with refractory anastomotic stricture formation. Future prospective multicentre 
studies should focus on uniform recording of baseline data – including surgical techniques 
used –, standardized protocols for diagnosis of GORD, eosinophilic oesophagitis 32, and 
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Supplementary figure 5.1 Patient per centre: development of refractory strictures (≥5 dilations) of 
oesophageal end-to-end anastomosis
Supplementary table 5.1 Stent placement, mitomycin application and stricture resection
Treatment of stricture  n
Stent placement  [a] Intraluminal solid silicone stent 25
 Self-expanding silicone stent 7
 Stent of unknown type 12
 Mitomycin application  [b] 6
Stricture resection with end-to-end anastomosis  [c]  8
a Forty-four stents were placed in seven children (median of 3 (range 1-25) stents. The initial stent was placed after a median 
of 15 (range 6-26) dilations. In all seven children strictures reoccurred after the first stent placement. 
b Mitomycin was applied in two children, in both cases additional dilations were still required.




Supplementary table 5.2 Strictures of oesophageal end-to-end anastomosis (N=436): characteristics 
of children with and without an anastomotic stricture requiring ≥3 dilations
 Stricture requiring ≥3 dilations  [a] No stricture requiring ≥3 dilations
 (N=61) (N=375)
 n (%) n (%) p-value
 median (min; max; IQR) median (min; max; IQR) 
  
Male gender 35 (57.4) 234 (62.4) 0.454
Gestational age (weeks) 37.3 (25.6; 42.0; 35.9-39.0) 38.3 (25.6; 42.9; 35.9-40.0) 0.036
Prematurity 26 (42.6) 123 (32.8) 0.158
Birthweight (gram) 2600 (725; 4210; 2000-2965) 2800 (735; 4505; 2154-3251) 0.016
Isolated OA (Gross type A) 7 (11.5) 7 (1.9) 0.002
Major associated anomaly 18 (29.5) 115 (30.7) 0.845
Major cardiac anomaly 3 (4.9) 35 (9.3) 0.255
Thoracoscopy 12 (19.7) 40 (10.7) 0.044
Staged repair 14 (23.0) 16 (4.3) <0.001
Chest tube 18 (29.5) 111 (29.6) 0.988
Anastomotic leakage 14 (23.0) 44 (11.7) 0.017
Recurrent tracheo-oesophageal fistula 4 (6.6) 12 (3.2) 0.258
History of gastro-oesophageal reflux 36 (59.0) 163 (43.5) 0.007
Antireflux surgery 1 (1.6)  [a] 49 (13.1) 0.009
Early stricture (≤28 days after anastomosis)  17 (27.9) 16 (4.3) <0.001
OA: oesophageal atresia. Non-parametric Mann-Whitney U test for continuous variables and Pearson’s chi-square test or Fisher’s 
exact test (if expected counts were <5) for categorical variables.
a Anti-reflux surgery was performed in 29 of 61 (47.53%) children with a stricture requiring ≥3 dilations: one prior to and 28 
after the third dilation of the stricture.
Supplementary table 5. 3 Multivariable logistic regression analysis for anastomotic strictures requiring 
≥3 dilations in children with oesophageal end-to-end anastomosis (N=436)
 OR 95% CI p-value
Gestational age (weeks) 0.96 0.86-1.06 0.403
Isolated OA (Gross type A) 5.79 1.80-18.57 0.003
Thoracoscopy 0.72 0.30-1.72 0.460
Anastomotic leakage 2.93 1.33-6.43 0.007
Early stricture (≤28 days after anastomosis)  10.59 4.50-24.90 <0.001
CI: confidence interval; OA: oesophageal atresia; OR: odds ratio. Adjusted for centre. Hosmer & Lemeshow goodness of fit test 
p=0.274. Due to missing values for gestational age 6/436 children were excluded from the multivariable logistic regression 
analysis.
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Supplementary table 5.4 Strictures of oesophagojejunal anastomosis (N=13): characteristics of 
children with and without an anastomotic stricture requiring ≥3 dilations
 Stricture requiring ≥3 dilations  [a] No stricture requiring ≥3 dilations
 (N=6) (N=7)
 n (%) n (%) p-value
 median (min; max; IQR) median (min; max; IQR) 
   
Male gender 5 (83.3) 1 (14.3) 0.029
Gestational age (weeks) 35.1 (31.4; 37.6; 32.6-37.1) 37.1 (27.9; 38.1; 33.4-38.0) 0.431
Prematurity 4 (66.7) 3 (42.9) 0.592
Birthweight (gram) 2203 (1875; 2729; 2020-2509) 2840 (932; 3230; 1642-2905) 0.668
Isolated OA (Gross type A) 6 (100) 6 (85.7) 1.000
Major associated anomaly 2 (33.3) 3 (42.9) 1.000
Major cardiac anomaly 0 1 (14.3) 1.000
Thoracoscopy 0 0 -
Staged repair 6 (100) 7 (100) -
Chest tube 4 (66.7) 5 (71.4) 1.000
Anastomotic leakage 1 (16.7) 0 0.462
Recurrent tracheo-oesophageal fistula 0 0 -
History of gastro-oesophageal reflux 2 (33.3) 4 (57.1) 1.000
Antireflux surgery 0 0 -
Early stricture (≤28 days after anastomosis)  1 (16.7) 0 0.462
OA: oesophageal atresia. Non-parametric Mann-Whitney U test for continuous variables and Pearson’s chi-square test or Fisher’s 
exact test (if expected counts were <5) for categorical variables.
a Anti-reflux surgery was performed in three of six (50.0%) children with a stricture requiring ≥3 dilations, all three were 
performed after the third dilation of the stricture.
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High prevalence of Barrett’s 
esophagus and esophageal 
squamous cell carcinoma after 
repair of esophageal atresia
Clin Gastroenterol Hepatol. 2018 Apr;16(4):513-521
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Esophageal atresia is rare, but improved surgical and intensive care techniques have increased 
rates of survival in children, so there are now many adults with this disorder. Many patients 
with esophageal atresia develop gastroesophageal reflux (GER), raising concerns about 
increased risk of Barrett’s esophagus (BE; prevalence of 1.3%-1.6% in general population) and 
esophageal carcinoma. We assessed the prevalence of BE and esophageal carcinoma in this 
population. 
Methods
We performed a prospective study of 289 patients with esophageal atresia at the Department 
of Gastroenterology and Hepatology at Erasmus MC University Medical Center in The Nether-
lands, from May 2012 through March 2017. One hundred fifty-one (median age, 25.4 years;  
age range, 16.8–68.6 years) underwent upper endoscopies as part of a surveillance program 
for (pre)malignant esophageal lesions. Biopsies were collected and analyzed by histology.  
We collected data on patients’ use of medications, tobacco, and alcohol; gastrointestinal 
symptoms; ability to swallow; complaints of GER; and type of atresia and surgeries. 
Prevalence of esophageal squamous cell carcinoma (ESCC) was determined using data from 
the Netherlands Cancer Registry. The number of persons alive on January 1, 2016 in the 
esophageal atresia cohort and in the general Dutch population were used to calculate the 
10-year prevalence of ESCC per 100,000 persons in both populations.
Results
Forty-seven percent of patients with esophageal atresia had a history of GER and 20.5% had 
undergone fundoplication surgery. Endoscopy revealed normal esophagus in 68.2% of 
patients, esophagitis in 7.3%, and columnar-lined esophagus in 24.5%. Histology revealed 
normal mucosa in 50.3% of patients, esophagitis in 23.2%, gastric metaplasia in 17.2%, and BE 
in 6.6% (at a median age of 31.6 years). A history of fundoplication surgery was associated with 
BE (P=.03). Three ESCCs developed, in 2 men, at ages of 42, 44, and 60 years. This corresponded 
to a prevalence of 0.7% in patients with esophageal atresia – a value 108-fold higher than in 
the same age group in the general population.
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Conclusions 
The prevalence of BE is 4-fold higher in young adults with esophageal atresia, and the 
prevalence of ESCC is 108-fold higher, than in the general population. This finding could  
have important implications for transition of young adults from pediatric care to adult 
gastroenterology departments to receive life-long endoscopic follow up to facilitate early 
diagnosis of relevant lesions.
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introduction
Esophageal atresia (EA) is a rare anatomical anomaly (worldwide prevalence 2.43/10,000 
births) 1. Surgical correction is needed soon after birth. In the last 40 years, improved surgical 
and intensive care techniques have increased survival rates up to 93% in expert centers and 
therefore more of these children have reached adulthood 2.
Many EA patients suffer from gastroesophageal reflux (GER) with a reported prevalence of 
32.8-54.2% in infancy/childhood and 5.9-66.7% in adolescence/adulthood 3. Chronic GER may 
lead to esophageal mucosal injury, resulting in esophagitis, gastric metaplasia (GM) or 
intestinal metaplasia (IM) also called Barrett’s esophagus (BE) 4. In the general adult 
population, the prevalence of BE is 1.3%-1.6% and is predominantly diagnosed in middle-aged 
white males 5-7. BE is a premalignant lesion and predisposes to esophageal adenocarcinoma 
(EAC), with an estimated incidence rate of 0.5% per year of follow-up 8. 
The high prevalence of GER in EA patients raises concerns about an increased risk of 
developing BE and EAC in this population 3. Carcinoma of the upper gastrointestinal tract at a 
relatively young age has been described in EA patients: eight esophageal carcinoma (three EAC 
and five esophageal squamous cell carcinoma (ESCC)) 9-13 and two squamous cell carcinoma 
not related to the native esophagus 14, 15.
Given these findings and the dismal prognosis of patients with symptomatic esophageal 
cancer, endoscopic surveillance in EA patients was recently recommended in an ESPGHAN-
NASPGHAN guideline 16. We assessed the prevalence of BE and esophageal cancer in a 
prospective screening and surveillance program in adult EA patients.
materials and methods
Patients
Since 1999, all EA patients have joined a longitudinal follow-up program at the Pediatric 
Surgery department of our tertiary referral center 17. Since April 2013, all adult EA patients  
(≥17 years) have routinely been referred to the Gastroenterology department for clinical 
assessment and endoscopic screening and surveillance of (pre)malignant esophageal lesions. 
We searched our patient registry system and written surgical records for patients born in 1948 
to 1999 to identify all EA patients treated in our center and invited these patients for our 
endoscopic screening and surveillance program. 
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Ethics
The study protocol was reviewed by the Institutional Review Board of the Erasmus Medical 
Center (MREC Erasmus MC, protocol ID MEC-2015-093). Formal approval was waived since all 
handling to the subjects was part of standard clinical care.
Data collection
All data were prospectively collected. Data on medication, tobacco and alcohol use and the 
occurrence of gastrointestinal symptoms were collected at the outpatient clinic, prior to the 
endoscopy. Ability to swallow was assessed from dysphagia scores  supplementary table 6.1 . 
Complaints of GER were defined as chest pain, pyrosis or regurgitation. Data retrieved from 
patient records included type of EA (Gross classification 18), type of primary surgery, and 
additional relevant medical history. 
GER was considered clinically significant if patients needed fundoplication surgery, if 
pH-monitoring showed pathological reflux or if – according to the American College of 
Gastroenterology (ACG) guidelines for GER – upper endoscopy showed typical reflux-induced 
mucosal lesions 19. 
All endoscopic procedures were performed by an experienced gastroenterologist, according 
to a standardized protocol. The mucosa of the esophagus was examined using white light. In 
case of suspicion of BE it was switched to Narrow Band Imaging (NBI). From the age of 25 years 
the esophagus was also stained with Lugol to detect early squamous lesions 20. Endoscopic 
landmarks, such as the squamo-columnar junction (Z-line), the proximal margin of gastric 
folds (GEJ) and the diaphragm, were identified and described. All remarkable findings were 
noted. Esophagitis and Barrett’s epithelium were scored according to the Los Angeles 
Classification 21 and Prague criteria 22. Four random biopsies were taken above the GEJ (if 
end-to-end anastomosis or gastric pull-up had been performed) or above the proximal 
anastomosis (if a colon, jejunal or ileocecal interposition had been performed). In case of BE 
four-quadrant biopsies were taken every 2 cm, according to the Seattle protocol 23. The 
proposed surveillance intervals for BE are in accordance with the ACG guidelines 4. In 
addition, in the absence of BE surveillance intervals of 5 years (age <30 years) or 3 years (age 
≥30 years) were advised  supplementary figure 6.1 . Endoscopic findings were classified 
according to the most severe abnormality found at upper endoscopy.
All deceased and non-responding patients were linked to the Netherlands Cancer Registry, 
managed by the Netherlands Comprehensive Cancer Organisation (IKNL) 24. Since 1989,  
the Netherlands Cancer Registry registers all participants diagnosed with cancer in the 
Netherlands and provides a unique and fully covered database. The 10-years prevalence of 
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ESCC was determined at January 1 2016 (all patients alive at this date, who were diagnosed with 
ESCC in the ten preceding years). The number of persons alive at January 1 2016 in the EA 
cohort and in the general Dutch population were used to calculate the 10-year prevalence of 
ESCC per 100,000 persons in both populations.
Histology and immunohistochemistry
Biopsy specimens were processed at the Pathology department according to standard 
procedures: formalin fixed, paraffin embedded, serially sectioned, and stained with 
hematoxylin & eosin. Biopsies were evaluated by an expert gastrointestinal pathologist for 
the presence of esophagitis, metaplasia, and dysplastic changes  supplementary table 6.2 . 
Numbers of eosinophils per high-power field were counted. In accordance with the ACG 
guidelines, we considered the presence of goblet cells obligatory to confirm the diagnosis of 
BE although malignant transformation in GM has been described 4. Histological results were 
classified according to the most severe abnormality at any biopsy. 
Statistical analysis
Data are expressed as frequencies or medians (minimum; maximum; inter-quartile range 
(IQR)). Characteristics of patients with and without BE were compared using Mann-Whitney U 
tests for continuous variables and Pearson’s chi-square or Fisher’s exact test (if expected 
counts <5) for categorical variables. Because confirmation of BE can be limited by sampling 
error (mosaic pattern of GM and IM 25) and as BE is thought to evolve from GM, findings from 
EA patients with and without metaplasia (GM or IM) were also compared. 
Univariable logistic regression analysis was used to identify predictors of BE and metaplasia. 
To reduce bias due to missing values of weight and length (19% missing weight; 15% missing 
length), multiple imputation was performed for these values in multivariable logistic 
regression analysis. Multivariable logistic regression analysis of the imputed data was used to 
identify potential predictors of metaplasia and results were pooled using Rubin’s rules. 
Relevant predictors were selected using likelihood-ratio tests (stepwise backwards; candidate 
variables: gender, fundoplication surgery, age, (prior) use of alcohol, (prior) smoking and 
BMI). A p-value less than 0.05 was considered statistically significant. Data were analyzed with 
SPSS 21.0 (SPSS Inc., Chicago, IL).
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Figure 6.1 Flowchart of esophageal atresia patients. 
a Esophageal squamous cell carcinoma (ESCC) in a 45-year old male, second primary ESCC at age 60 years. 
b Data (non-traceable match between datasets) provided by the Netherlands Comprehensive Cancer Organisation (IKNL):  
none of these patients developed esophageal cancer. 
c Adenocarcinoma of the thoracic colon interposition in a 48-year old male. 
d Mid-esophageal ESCC in a 42-year old male. 








Table 6.1 Baseline characteristics of 151 participants of the surveillance program
  n (%)
Male gender  85 (56.3)
Type of esophageal atresia Type A 16 (10.6)
 Type C 129 (85.4)
 Type D 4 (2.6)
 Type unknown 2 (1.3)
Type of surgery  [a] Primary end-to-end anastomosis 123 (81.5)
 Delayed end-to-end anastomosis 10 (6.6)
 Gastric pull-up or bowel interposition 18 (11.9)
Associated congenital anomalies  77 (51.0)
Genetic diagnosis  [b]   7 (4.6)
Diagnosis of gastroesophageal reflux prior to surveillance  [c] Yes 71 (47.0)
 Age in years; median 0.5
 (min; max; IQR) (0.1; 54.5; 0.2-7.8)
Diagnosis of Barrett’s esophagus prior to surveillance  [d] Yes 4 (2.6)
Fundoplication surgery  [e] Yes 31 (20.5)
 Age in years; median 0.5 
 (min; max; IQR) (0.1; 7.5; 0.3-1.8)
Dilation of esophageal stenosis Yes 88 (58.3)
 Number of dilations; median 5 
 (min; max; IQR) (1; 35; 3-7)
Age at time of first surveillance endoscopy Age in years; median 25.4 
 (min; max; IQR) (16.8; 68.6; 19.1-36.1)
Body mass index (BMI) Severe underweight (<16 kg/m2) 2 (1.3)
 Underweight (16-18.5 kg/m2) 11 (7.3)
 Normal (18.5-25 kg/m2) 83 (55.0)
 Mild-moderate overweight (25-30 kg/m2) 22 (14.6)
 Severe overweight (30-40 kg/m2) 5 (3.3)
 Missing 28 (18.5)
Anti-reflux medical therapy  [f] Yes, daily use 16 (10.6)
 Yes, when needed 2 (1.3)
 No 124 (82.1)
 Missing 9 (6.0)
Tobacco smoking Yes 24 (15.9)
 Former smoker (quit>2 years) 9 (6.0)
 No 116 (76.8)
 Missing 2 (1.3)
Alcohol consumption ≤7 units/week 68 (45.0)
 ≥8 units/week 10 (6.6)
 Yes, but amount unknown 18 (11.9)
 No alcohol 53 (35.1)
 Missing 2 (1.3)
Dysphagia Grade I  75 (49.7)
 Grade II 1 (0.7)
 Gastrostomy, no oral diet 1 (0.7)
 No dysphagia 70 (46.4)
 Missing 4 (2.6)
Gastroesophageal reflux complaints Yes 47 (31.1)
 No 96 (63.6)
 Missing 8 (5.3)
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a End-to-end anastomosis with Livaditis myotomy (n=9). Gastric pull-up (n=1), colon (n=15), jejunal (n=1) and ileocecal 
interposition (n=1). 
b Klippel-Feil (n=2), Down (n=1), Feingold (n=1), Goldenhar (n=1), Opitz (n=1) and SCIMITAR (n=1) syndrome. 
c Pathological pH-monitoring (n=30), typical reflux induced lesions during endoscopy (n=19), fundoplication surgery performed 
(n=18) and clinical significant gastroesophageal reflux but diagnosis unknown (n=4).
d Age 24.7, 43.7, 45.3 and 56.0 years. 
e Nissen fundoplication (n=30) and Toupet fundoplication (n=1). Redo-fundoplication was necessary in 6 (19.4%) patients at a 
median (range) age of 1.0 (0.6-9.2) years. Median (range) time from initial to redo-fundoplication was 0.7 (0.3-8.0) years. 
Two (6.5%) patients needed a second redo-fundoplication.
f Gastroesophageal reflux symptoms present (n=12). Proton-pump inhibitor (n=13), H2 antagonist ± prokinetic drug (n=4) and 
prokinetic drug (n=1).
Table 6.2 Endoscopic and histological results from the screening and surveillance program in adult 
esophageal atresia patients (N=151) 
Endoscopy  n (%)
Normal esophagus  103 (68.2)
Macroscopic esophagitis  [a] Grade A 8 (5.3)
 Grade B 3 (2.0)
Extension of gastric epithelium above the gastroesophageal junction  [b] with esophagitis Grade A  [a] 6 (4.0)
 without esophagitis 31 (20.5)
Other findings hiatus hernia  [c] 97 (64.2)
 inlet patch 17 (11.3)
 recurrent fistula 1 (0.7)
 esophageal varices 1 (0.7)
Histology above the gastroesophageal junction  n (%)
Normal mucosa  76 (50.3)
Esophagitis mild 29 (19.2)
 moderate 4 (2.6)
 eosinophilic 2 (1.3)
Gastric metaplasia with esophagitis 3 (2.0)
 without esophagitis
 23 (15.2)
Intestinal metaplasia with esophagitis 6 (4.0)
 without esophagitis  [d] 4 (2.6)
No biopsies taken  [e]  4 (2.6)
a Los Angeles Classification.
b Twenty-nine short-segments of <3 cm and eight long-segments of ≥3 cm. Longest circumferential (C) extent of 7 cm and 
longest maximum extent (M) of 7 cm.
c Median (range) length of 2 (1-6) cm.
d In the Barrett’s mucosa of one patient, epithelial changes indefinite for dysplasia were observed.
e Macroscopic normal esophagus (n=3) and gastric epithelium above the gastroesophageal junction (n=1, C3M3).
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results
From the 289 invited patients 151 (52.2%) were willing to participate the screening and 
surveillance program. People in the non-participant group were older, with a median age  
of 38.2 years vs 25.4 years (p<0.001). There was no difference in gender. Three patients were 
not invited, because they had already been diagnosed and treated for cancer in the upper 
gastrointestinal tract. See flowchart in  figure 6.1 . 
Patient characteristics 
A total of 151 patients (85 males) with a median age of 25.4 (range 16.8-68.6) years were 
included in the program. Dysphagia and GER complaints were reported in respectively 50.3% 
and 31.1% of the patients. Nine patients (29.0%) who underwent fundoplication surgery had 
GER complaints. All patients characteristic are depicted in  table 6.1 .
Endoscopy results 
From a total of 158 endoscopies, 147 (93.0%) endoscopies were first surveillance endoscopies. 
More than half (61.4%) of the upper endoscopies were performed under conscious sedation 
(midazolam and fentanyl). Columnar-lined esophagus was seen in 37 (24.5%) patients.  
In eight patients the columnar-lined esophagus extended ≥3 cm above the GEJ with a 
circumferential extent (C) of 0-7 cm and maximum extent (M) of 3-7 cm. Nodular or other 
lesions were absent. We saw macroscopic esophagitis in 11 (7.3%) patients (grade A n=8, grade 
B n=3). In 103 (68.2%) patients no signs of esophagitis or Barrett’s mucosa were found. A 
hiatus hernia was present in 97 (64.2%) patients and an inlet patch in 17 (11.3%) patients.  
One patient had esophageal varices (grade II according to Paquet’s classification26) due to 
non-cirrhotic portal hypertension caused by a portal vein thrombosis. No squamous lesions 
were found  table 6.2 .
Histological results
Of the 37 patients with columnar-lined esophagus, histopathology confirmed IM in ten (6.6%) 
cases (eight men; median age of 34.0 years), all without dysplasia. Features of the ten patients 
diagnosed with BE are summarized in  supplementary table 6.3 . GM was found in 26 (17.2%) 
cases (nine men; median age of 25.7 years). In one patient with columnar-lined esophagus no 
biopsies were taken. Random biopsies above the GEJ revealed active esophagitis in 35 (23.2%) 




Compared to patients without metaplasia BE patients had more often undergone esophageal 
dilations (p=0.04), and had more often a history of fundoplication surgery (p=0.03). Of the  
31 patients who underwent fundoplication surgery metaplasia was found in 10 (32.3%; GM=5 
and IM=5) patients. Patients with metaplasia were more often diagnosed with hiatus hernia 
(p=0.06). None of the 18 patients with a gastric pull-up or bowel interposition developed 
metaplasia  table 6.3 .
Univariable logistic regression analysis of observed data (without imputation) demonstrated 
that fundoplication surgery was significantly associated with BE (OR 4.429; p=0.028)  table 6.4 . 
In the multivariable logistic regression analysis on imputed datasets none of the candidate 
variables – gender, fundoplication surgery, (prior) use of alcohol, (prior) smoking, age and 
BMI (based on imputed length/weight) – were associated with metaplasia. Due to the small 
number of BE cases multivariable analysis to identify risk factors for BE was not feasible. 
Gastrointestinal cancer
Four gastrointestinal cancers were diagnosed before the start of the surveillance program. 
One patient without a history of hereditary colorectal cancer had developed an 
adenocarcinoma in his coloninterposition at the age of 48 years. Three ESCC were diagnosed 
in two men at the age of 42 years, 45 years and the latter patient had developed a second ESCC 
at the age of 60 years in the proximal esophagus, after esophageal resection with gastric tube 
reconstruction. 
The 10-years prevalence of ESCC in EA patients was 685 per 100,000 or 0.7%. Which was 
significantly higher compared to the general population (aged 17-69 years), with a 10-years 
prevalence of ESCC of 6 per 100,000 or 0.006%  table 6.5 .
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Table 6.3 Clinical features of esophageal atresia patients diagnosed with esophageal columnar  
metaplasia/Barrett’s esophagus and without esophageal columnar metaplasia in the screening and  
surveillance program
 No metaplasia Metaplasia (gastric or intestinal)  [a] 
 (N=114) (N=37) 
Characteristics baseline n (%) n (%) 
Male gender 67 (58.8) 18 (48.6) 
Esophageal atresia type A 14 (12.3) 2 (5.4) 
Esophageal replacement 18 (15.8) 0 
Characteristics or symptoms in history
Dilation of esophageal stenosis 64 (56.1) 24 (64.9) 
≥3 dilation procedures 50 (43.9) 18 (48.6) 
Number of dilation procedures; median 1 3  
(min; max; IQR) (0; 15; 0-5) (0; 35; 0-7) 
Fundoplication surgery 21 (18.4) 10 (27.0) 
Prior diagnosis of gastroesophageal reflux 55 (48.2) 17 (45.9) 
Recurrence of trachea esophageal fistula 9 (7.9) 1 (2.7) 
(prior) use of alcohol 76 (66.7) 20 (54.1) 
(prior) smoking 25 (21.9) 7 (18.9) 
Characteristics at time of first diagnosis of metaplasia/Barrett’s esophagus or last diagnosis of no metaplasia
Age in years; median 25.2 25.9 
(min; max; IQR) (16.8; 57.9; 18.4-36.4)  (17.3; 68.6; 19.7-32.8) 
BMI in kg/m2; median  21.9 21.0 
(min; max; IQR) (15.5; 38.0; 20.0-24.7) (15.8; 30.9; 19.4-23.6) 
Hiatus hernia 66 (57.9) 27 (73.0) 
Use of alcohol 74 (64.9) 20 (54.1) 
Smoking 24 (21.1) 7 (18.9) 
Dysphagia complaints 55 (48.2) 21 (56.8) 
Gastroesophageal reflux complaints 31 (27.2) 14 (37.8) 
Proton pump inhibitor usage  6 (5.3) 6 (16.2) 
Anti-reflux medical therapy 10 (8.8) 8 (21.6) 
Non-parametric Mann-Whitney U test for continues variables and Pearson’s chi-square test or Fisher’s exact test for categorical  
variables.
a In one patient with columnar-lined esophagus (C3M3) no biopsies were taken. This patient was included in the metaplasia  
group.
b ‘no metaplasia’ vs. ‘metaplasia’. 




p-value  [b] n (%) p-value  [c]
0.281 8 (80.0) 0.313
0.361 1 (10.0) 1.000
0.007 0 0.355
0.439 9 (90.0) 0.087
0.635 6 (60.0) 0.303
0.270 5 0.038 
 (0; 35; 2-17) 
0.260 5 (50.0) 0.033
1.000 7 (70.0) 0.166
0.452 1 (10.0) 0.583
0.128 7 (70.0) 1.000
0.680 2 (20.0) 1.000
0.945 31.6 0.189 
 (17.9; 56.0; 22.8-47.6) 
0.241 20.1 0.114
 (16.2; 23.6; 16.6-22.5) 
0.057 8 (80.0) 0.153
0.189 7 (70.0) 1.000
0.744 2 (20.0) 1.000
0.385 5 (50.0) 1.000
0.199 2 (20.0) 1.000
0.077 5 (50.0) <0.001
0.078 5 (50.0) 0.003
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Table 6.4 Univariable logistic regression analysis Barrett’s esophagus and metaplasia (gastric or 
intestinal)
 Barrett’s esophagus   Metaplasia
 OR 95% CI p-value OR 95% CI p-value
Male gender 2.806 0.570-13.811 0.204 0.665 0.316-1.400 0.282
Fundoplication surgery 4.429 1.175-16.694 0.028 1.640 0.690-3.901 0.263
(prior) use of alcohol 1.105 0.270-4.525 0.889 0.557 0.261-1.190 0.131
(prior) smoking 0.880 0.176-4.411 0.876 0.821 0.322-2.092 0.680
Age in years  1.038 0.987-1.092 0.150 1.002 0.971-1.034 0.905
BMI in kg/m2 0.755 0.535-1.066 0.110 0.935 0.830-1.052 0.265
Results from analysis of observed data (without imputation).
Table 6.5 Calculation of 10-year prevalence of esophageal squamous cell carcinoma (ESCC)
 Cohort of esophageal atresia patients General Dutch population
 (aged 17-69 years) (aged 17-69 years)
10-year prevalence of ESCC at January 1 2016  2  772
Number of persons alive at January 1 2016 292  [a]  12,140,743
Calculated 10-year prevalence of ESCC 
per 100,000 persons 685 (0.7%) 6 (0.006%)
a Untraceable patients were not included.
discussion
From the 289 EA patients invited 52.2% were willing to participate a surveillance program.  
In adult EA patients both BE (6.6%) and ESCC prevalence (0.7%) were higher compared to the 
general population and at a relatively young age. Fundoplication surgery appeared to be the 
only significant predictor for BE.
In this prospective screening study adult EA patients had a 4-5 fold higher prevalence of BE 
and at a much younger age compared to the general population, 6.6% (95% confidence 
interval 3.9-9.4) vs. 1.3%-1.6% with a median age of 31.6 years compared to 57 years in the 
general population 5, 6. This high prevalence of BE in EA patients is supported by others (up to 
12.5%) 3. Factors associated with BE and EAC are male gender, older age (≥50 years), white race, 
tobacco smoking, obesity, hiatus hernia, and GER 27, 28. In EA patients we found that 
fundoplication surgery – representing patients with a history of severe GER – was associated 
with BE in univariable analysis. As BE is thought to evolve from GM we compared patients with 
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and without metaplasia (GM or IM), but no significant determinants were found. This in 
contrast to a study in 101 EA patients that showed that long gap, age >30 years, recurrent TEF, 
esophageal stricture resection during childhood, esophageal stricture in adulthood, and 
abnormal esophageal manometry were associated with metaplasia 29. It should be noted that 
in the above-mentioned study 10/21 patients were defined as having esophageal metaplasia, 
although no columnar-lined esophagus was observed at endoscopy. Although patients with 
BE in our study were more likely to have a history of anastomotic strictures, we assume that 
strictures should not be considered as an independent risk factor for BE. We speculate that 
patients with anastomotic stricturing more often suffered from GER, which could explain the 
higher prevalence of BE in this group.
In the general Western population GER complaints have been reported in 10-20% 30. In studies 
of EA patients the prevalence ranges widely (18-64%) 3, 31. The use of different definitions of 
GER symptoms and the altered perception of esophageal symptoms in EA patients may 
explain these differences 32. Moreover, in accordance with previous studies we found a weak 
correlation between symptoms and endoscopic and histological findings 33, 34. GER 
complaints were reported in 31.1% of EA patients. GER was diagnosed endoscopically in 17 
(11.3%) patients, but only six patients had symptoms. Fundoplication surgery appeared not to 
protect against esophageal metaplasia at adulthood. Fundoplication failure has been 
reported in 15% and pathological pH-metry was found in 43% of EA patients 10-15 years after 
fundoplication surgery 35, 36. Wrap failures and children outgrowing their fundoplication may 
explain these recurrences, especially in EA patients who undergo fundoplication in the first 
years of life 35.
The high prevalence of BE implies an increased risk to develop EAC in EA patients. In our 
cohort two men were diagnosed with ESCC prior to the start of our surveillance program, 
resulting in a 108-fold higher prevalence of ESCC in EA patients compared to the general 
population. The reason for a possible higher prevalence of ESCC compared to EAC in EA 
patients is still unknown. EA patients could be at higher risk of developing ESCC than EAC. Or 
the time needed for EAC to evolve from BE could be longer than our median follow-up time 
(25.4 years).
Several predictive factors for ESCC have been suggested, such as: low socioeconomic status, 
tobacco smoking, alcohol consumption, dietary factors, achalasia, and human papilloma 
virus 28, 37. In achalasia patients esophageal stasis of food and fluids – causing bacterial over - 
growth with nitrosamine production – is thought to increase the risk to develop ESCC 38, 39.  
The same pathogenesis might explain ESCC development in EA patients. Several authors have 
suggested that esophageal strictures requiring dilation procedures predispose for ESCC 9, 10. 
Therefore during endoscopic surveillance, the squamous epithelium should be examined in 
detail, with Lugol’s staining to detect early squamous lesions 20.
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Esophageal screening for BE and esophageal carcinoma in the general population is not 
recommended 4, 27. Our findings may have important implications for the follow-up of EA 
patients. The high prevalence of BE and ESCC at a young age may warrant lifelong endoscopic 
follow-up. As many EA patients have dysphagia (48-72%) 40, this may be neglected as an early 
warning symptom of esophageal cancer in this population. Routine endoscopy in adult EA 
patients is currently recommended in an ESPGHAN-NASPGHAN guideline 16, but the ideal 
follow-up schedule has yet to be determined. In our follow-up program all participants – 
independent of the presence of metaplasia – are advised to undergo endoscopic surveillance, 
not only to screen for BE and EAC but also for dysplastic squamous epithelium. We 
recommend to perform chromoendoscopy with Lugol’s staining 20 from the age of 25 years 
onwards to detect superficial ESCC. One could consider to take random biopsies mid-
esophageal, preferably from the site of the original TEF or anastomosis. Further long-term 
prospective cohort studies are needed before a more evidence based cost-effective 
surveillance program in EA patients can be implemented.
Our study has several limitations. First, the number of patients with metaplasia did not allow 
identifying clinical predictive factors in multivariable analysis. The response rate in our 
surveillance program (52.2%) was good, but could be better. Besides age and gender we were 
not informed about the reason why people did not participate, or were not able to participate 
because of e.g. disease burden. Second, we included only adults. Although metaplasia has 
been described in children 41, 42, we believe endoscopies in children should only be performed 
in high-risk patients. This is supported by the fact that no long segments of BE nor dysplasia 
was found at the age of 17 years in our follow-up program. Third, the prevalence of 
histological esophagitis could be misinterpreted as being high as there are no normative data 
from the general population. 
In conclusion, the prevalence of BE and ESCC in young adult EA patients is 4-5 and 108-fold 
higher compared to the general population. These results warrant uniform surveillance 
programs for adult EA patients in dedicated centers to facilitate early diagnosis of clinically 
relevant lesions and prevent death from esophageal carcinoma. As fundoplication surgery in 
childhood does not seem to protect against esophageal damage in EA patients, these patients 
should not be excluded from endoscopic surveillance programs.  
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Supplementary table 6.1 Score for severity of dysphagia complaints 
Dysphagia score 
Able to consume a normal diet 0
Dysphagia with certain solid foods 1
Able to swallow semi-solid soft foods only 2
Able to swallow liquids only 3
Unable to swallow saliva (complete dysphagia) 4
Knyrim, K., et al., A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable 
cancer. N Engl J Med, 1993. 329(18): p. 1302-7.
supplementary material
Supplementary figure 6.1 Flowchart of screening and surveillance program in adult esophageal 
atresia patients.
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Supplementary table 6.2 Histological evaluation of esophageal biopsies from the gastroesophageal 
junction
Histopathologic category Criteria
Normal mucosa  Inflammatory cells within normal limits. 
  No morphological changes, minimal basal hyperplasia or subtle reactive changes
Esophagitis mild Slight amount of neutrophils or eosinophils.
  Elongated papillae, basal hyperplasia, no erosions.
 moderate Moderate number of neutrophils or eosinophils.
  Elongated papilla, basal hyperplasia, no erosions.
 erosive Superficially eroded mucosa, no granulation tissue.
 ulcerative Deeply eroded mucosa, granulation tissue, prominent epithelial regeneration.
 eosinophilic pattern  Eosinophilia [a] with eosinophilic microabscesses, degranulated eosinophils.
Metaplasia gastric Columnar epithelium replacing squamous cell epithelium.
  Goblet cells absent.
 intestinal Columnar epithelium replacing squamous cell epithelium.
  Goblet cells present.
Dysplasia non No architectural complexity.
  Normal maturation as the cells progress toward the mucosal surface.
 low grade Preservation or only minimal distortion of crypt architecture.
  Little or no maturation as the cells progress from the crypt bases to the luminal 
  surface.
 high grade Crypt architectural complexity with irregular, branched, cribriform glands.
  Absence of maturation, atypia exceeding that of low grade dysplasia: 
  nuclear-to-cytoplasmic ratio, nuclear size, hyperchromasia, polymorphia.
 indefinite Histologic changes that neither meet the criteria for dysplasia nor for 
  non-dysplasia or absence of representative surface epithelium (technical artifacts).
a Eosinophilia was defined as >15 eosinophils per high-power field.
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Supplementary table 6.3 Clinical features of EA patients diagnosed with BE (n=10)
Patient
Male 1958
- EA type C
- No associated anomalies
- No genetic syndrome
Male 1959 
- EA type C
- No associated anomalies
- No genetic syndrome
Male 1962
- EA type C
- No associated anomalies
- No genetic syndrome
Male 1965
- EA type C
- No associated anomalies
- No genetic syndrome
Female 1977
- EA type C
- Vertebral anomalies, partial 
AVSD, duodenal stenosis, 
jejunal stenosis.
- No genetic syndrome
Surgical history 
- End-to-end anastomosis at day 3.
- No fundoplication.
- End-to-end anastomosis at day 3.
- No fundoplication.
- End-to-end anastomosis at day 1 
with tension at anastomosis.
- Reconstruction of the angle of His 
with correction of a hiatus hernia 
at age 2.8 years.
- End-to-end anastomosis at day 3 
with slight tension at anastomosis.
- Resection of stenotic anastomosis 
at age of 3 months.
- No fundoplication.
- End-to-end anastomosis with 
Livaditis procedure at day 1.
- Nissen fundoplication at age 4.7 
years.
- Resection of strangulated ileum  
at age of 1 month.
Medical history before diagnosis of BE
- History of GER unknown.
- No esophageal stenosis.
- Recurrent bronchitis in childhood.
- History of GER unknown.
- Esophageal stenosis at age of 3 months, number 
of dilations unknown, last dilation at age of 45.3 
years: wide proximal esophagus with stricture in 
distal part.
- Recurrent aspirations first 3 years. Recurrent 
pneumonias child- and adulthood due to 
aspirations, at age of 27 and 41 years resection  
of all segments right lower lobe. 
- Esophageal manometry (age 13.3 years): 100% 
non-transmitted, inactive motor function.
- Clinically significant GER since age of 2.8 years.
- Esophageal stenosis in childhood, multiple 
dilations.
- At age 33.4 years endoscopic sclerosis of arterial 
bleeding from Mallory–Weiss tear in distal 
esophagus.
- Clinically significant GER since age of 8 years.
- No esophageal stenosis.
- At age of 32.9 years reflux esophagitis grade B. 
Extension of gastric epithelium above the GEJ with 
gastric metaplasia without dysplasia at histological 
examination at age of 36.2, 40.2, and 42.6 years.
- Clinically significant GER since birth.
- Esophageal stenosis at age of 3 months,  
25 dilations, last dilation at age of 5 years.
- Endoscopic removal of food stuck in the 
esophagus twice before the age of 4 years.
- At age of 4 years reflux esophagitis. Extension  
of gastric epithelium above the GEJ (C8M8) with 
gastric metaplasia without dysplasia at histological 
examination at age of 19.5, 20.5 and 22.4 years. 
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Features at diagnosis of BE




- Intoxications: Alcohol ≤7 units/week. Non-smoking.
- Family history: negative for cancer.
- Symptoms: dysphagia grade I, seldom food impactions, 
seldom respiratory tract infections.
- Allergy: birch.
- Medication: PPI.
- Intoxications: Alcohol ≤7 units/week. Non-smoking.
- Family history: father bladder cancer at age of 72 years, 
sister rectal cancer at age of 52 years.
- Symptoms: dysphagia grade I, food impactions once  
a week, regurgitation and heartburn.
- Allergy: none.
- Medication: PPI.
- Intoxications: No alcohol . Non-smoking.
- Family history: negative for cancer.
- Symptoms: dysphagia grade I, no food impactions.
- Allergy: none.
- Medication: PPI.
- Intoxications: Alcohol ≤7 units/week. Non-smoking.
- Family history: unknown.
- Symptoms: dysphagia grade I, seldom food impactions.
- Allergy: latex, plasters, dust mites.
- Medication: PPI.
- Intoxications: No alcohol. Non-smoking.
- Family history: unknown.
BE diagnosis
- Age at time of diagnosis 56.0 years. C3M3, no focal lesions,  
no dysplasia. Hiatus hernia (3 cm).
 Follow-up:
- Last evaluation of BE at age of 58.6 years: C3M3, no focal 
lesions, indefinite for dysplasia.
- Age at time of diagnosis 45.3 years. C2M2, no focal lesions,  
no dysplasia. Hiatus hernia (2 cm).
 Follow-up:
- Last evaluation of BE at age of 55.9 years: C2M3, no focal 
lesions, no dysplasia.
- Age at time of diagnosis 54.5 years. C0M1, no focal lesions,  
no dysplasia. Hiatus hernia (4 cm).
- Age at time of diagnosis 43.7 years. C0M2, no focal lesions,  
no dysplasia. Hiatus hernia (2 cm).
 Follow-up:
- Last evaluation of BE at age of 51.7 years, C0M2, no focal 
lesions, no IM in biopsy, no dysplasia. Reflux esophagitis grade 
A. Hemorrhagic gastritis.
- Esophageal stenosis at age of 44.1 years, 3 dilations, last 
dilation at age of 45.2 years. Dysmotility proximal esophagus, 
no obstruction.
- Age at time of diagnosis 24.7 years. C8M8, no focal lesions,  
no dysplasia.
 Follow-up:
- Last evaluation of BE at age of 36.7 years. C5M5, no focal 




- EA type C
- No associated anomalies
- No genetic syndrome
Male 1986
- EA type C




- No genetic syndrome
Male 1989
- EA type C




- EA type C
- Muscular VSD
- No genetic syndrome
Male 1997
- EA type A
- No associated anomalies
- No genetic syndrome
Surgical history 
- End-to-end anastomosis at day 0.
- Recurrent TEF at of age 4 months.
- Nissen fundoplication at age 1 
years and re-Nissen at age of 9.2 
years.
- End-to-end anastomosis at day 1 
with slight tension at anastomosis.
- No fundoplication.
- Kidney transplants at age 2, 22  
and 28 years for end-stage kidney 
failure.
- End-to-end anastomosis at day 2.
- Pyloromyotomy at age of 2 
months.
- Nissen fundoplication at age of 2 
months and re-Nissen at age of 11 
months.
- End-to-end anastomosis at day 1 
with slight tension at anastomosis.
- No fundoplication.
- Gastrostomy at day 2. End-to-end 
anastomosis at day 52.
- Nissen fundoplication at age 6 
months.
Medical history before diagnosis of BE
- Clinically significant GER since birth, at age 9 years 
recurrence of GER despite Nissen fundoplication.
- No esophageal stenosis.
- At age 9 years reflux esophagitis.
- Clinically significant GER at age 10 months, at age 
22.9 and 23.9 years ulcerative esophagitis (grade 
unknown, no microorganism), start PPI.
- Esophageal stenosis at age 1 month, 21 dilations. 
Second erosive and ulcerative stricture at age 22.9 
years, 35 dilations.-Tracheomalacia, frequent lower 
respiratory tract infections.
- Clinically significant GER since birth, at age of 11 
months recurrence of GER despite Nissen 
fundoplication.
- Esophageal stenosis at age of 1 month, 9 dilations, 
last dilation at age of 11 months.
- At age of 11 months reflux esophagitis grade B.
- No history of GER.
- Esophageal stenosis at age of 1 month, 3 dilations, 
last dilation at age of 2 months
- Endoscopic removal of food stuck in the 
esophagus at age of 4 and 13 years.
- Tracheomalacia, frequent lower respiratory 
- Clinically significant GER at age 5 months.
- Esophageal stenosis at age 3 months, 6 dilations, 
last dilation at age of 6 months.
- PEP mask for severe tracheomalacia.
 Complaints of pain, probably due to esophageal 
spasm.
AVSD: atrioventricular septal defect, BE: Barrett’s esophagus; EA: esophageal atresia; GEJ: gastroesophageal junction,  
GER: gastroesophageal reflux; IM: intestinal metaplasia; PPI; proton pump inhibitor; TEF: trachea-esophageal fistula;  
VSD: ventricular septal defect.
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Features at diagnosis of BE
- Symptoms: dysphagia grade I, no food impactions.
- Allergy: none.
- Medication: none.
- Intoxications: Alcohol ≤7 units/week. Active smoking.
- Family history: unknown.
- Symptoms: no dysphagia, no food impactions.
- Allergy: none.
- Medication: PPI.
- Intoxications: No alcohol. Non-smoking. 
- Family history: negative for cancer.
- Symptoms: no dysphagia, no food impactions.
- Allergy: none.
- Medication: none.
- Intoxications: Alcohol ≤7 units/week. Non-smoking.
- Family history: negative for cancer.
- Symptoms: no dysphagia, seldom food impactions.
- Allergy: none.
- Medication: none.
- Intoxications: Alcohol ≤7 units/week. Former smoking 
(quit at age of 19 years).
- Family history: grandfather colorectal cancer at age  
of 67 years.
- Symptoms: no dysphagia, no food impactions, at least 
once a month chest pain during exercise. 
- Allergy: none.
- Medication: none.
- Intoxications: Alcohol ≤7 units/week. No smoking.
- Family history: unknown.
BE diagnosis
- Age at time of diagnosis 32.4 years. C2M3 with ulcerative 
esophagitis, no focal lesions, no dysplasia, at 25cm villous polyp 
(squamous papilloma). Hiatus hernia (4 cm).
- Age at time of diagnosis 30.7 years. C0M5, semi-circular,  
no focal lesions, no dysplasia. Hiatus hernia (2 cm).
- Age at time of diagnosis 23.4 years. C2M6, no focal lesions,  
no dysplasia.
 Wide open pylorus. Hiatus hernia (3 cm).
 Follow-up:
- Last evaluation of BE at age of 27.0 years. C2M5, no focal 
lesions, no dysplasia.
- Age at time of diagnosis 20.9 years. C0M2, no focal lesions,  
no dysplasia. No hiatus hernia.
 Follow-up:
- Last evaluation of BE at age of 23.9 years. C0M1, no focal 
lesions, no IM in biopsy, no dysplasia.
- Age at time of diagnosis 17.9 years. C0M0.5, no focal lesions,  
no dysplasia. Hiatus hernia (3 cm).
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abstract
Esophageal atresia (EA) is one of the most common congenital digestive malformations and 
requires surgical correction early in life. Dedicated centers have reported survival rates up to 
95%. The most frequent comorbidities after EA repair are dysphagia (72%) and gastroesophageal 
reflux (GER) (67%). Chronic GER after EA repair might lead to mucosal damage, esophageal 
stricturing, Barrett’s esophagus and eventually esophageal adenocarcinoma. Several long-
term follow-up studies found an increased risk of Barrett’s esophagus and esophageal 
carcinoma in EA patients, both at a relatively young age. Given these findings, the recent 
ESPGHAN-NASPGHAN guideline recommends routine endoscopy in adults born with EA. We 
report a series of four EA patients who developed a carcinoma of the gastrointestinal tract: 
three esophageal carcinoma and one colorectal carcinoma in a colonic interposition. These 






With a prevalence of 2.43 per 10,000 births, esophageal atresia (EA) with or without a 
tracheoesophageal fistula (TEF) is one of the most common congenital digestive 
malformations 1. Surgical correction needs to be performed shortly after birth. Due to 
advanced surgical techniques and improved perioperative care, survival rate has increased up 
to 95% in dedicated centers 2, 3. Follow-up studies have shown that most EA patients have a 
favourable long-term outcome despite persistant digestive and respiratory problems. 
Common gastrointestinal symptoms after EA repair are dysphagia and gastroesophageal 
reflux (GER) in up to 72% and 67% of the patients, respectively 4, 5. Chronic GER after EA repair 
might lead to mucosal damage, esophageal stricturing, Barrett’s esophagus and eventually 
esophageal adenocarcinoma (EAC) 5-8. Data on incidence and risk factors for esophageal 
carcinogenesis after EA repair are scarce 8-10. The recent ESPGHAN-NASPGHAN guideline 
recommends routine endoscopy in adults born with EA 11. Until now, eight cases of 
esophageal cancer in young EA patients have been described: five esophageal squamous cell 
carcinoma (ESCC) and three EAC 10, 12-15. Here we report four EA patients who developed a 
carcinoma of the gastrointestinal tract: three esophageal carcinoma and one colorectal 
carcinoma in a colonic interposition. These cases emphasize the importance of lifelong 
screening and surveillance of the upper gastrointestinal tract in EA patients. 
Case 1
Patient A presented for the first time with esophageal carcinoma at age 45 years. He was born 
with EA Gross type C (with a distal TEF) which was surgically repaired with closure of the fistula 
and end-to-end anastomosis of the esophagus. In childhood he had undergone a number of 
esophageal dilations to treat an anastomotic stricture.
At the age of 37 years he developed progressive dysphagia. Upper endoscopy showed proximal 
esophagitis and a stenotic anastomosis, which then was dilated. No biopsies were taken. 
Eight years later, dysphagia for solid foods reoccurred with complaints of heartburn and 
weight loss of 6 kg in six months (BMI 21.6 kg/m2). He was a tobacco smoker (at least 27 pack 
years) and used 3-4 alcoholic beverages per day. Upper endoscopy showed a non-stenotic 
anastomosis at 30 cm from the incisors with a ¾ circular growing easily bleeding lesion from 
33-42 cm from the incisors. Biopsies showed chronic inflammation. A chest CT scan revealed a 
stenotic esophagus extending from the aortic arch to the cardia with a malignant appearance 
and mediastinal lymph nodes (pre- and subcarinal). Due to the strong suspicion of 
esophageal cancer an esophageal resection with gastric tube reconstruction was performed. 
Pathology results confirmed the diagnosis of a squamous cell carcinoma (SCC) of the distal 
esophagus (pT2N0M0) which did not need further treatment. 
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Figure 7.1 Chest computed tomography scan (CT scan) (case 1, tumor 2) demonstrating a tumor mass 
in the cervical native esophagus with suspected tumor invasion in the left thyroid gland.
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Fifteen years later, at the age of 60 years, he again developed dysphagia and odynophagia with 
7 kg weight loss (BMI 23.2 kg/m2). Endoscopy revealed a circular tumor (17-21 cm from incisors) 
in the remaining cervical native esophagus eroding the constructed gastric tube and trachea. 
Biopsies showed a well-differentiated SCC. One suspicious supraclavicular and two 
mediastinal FDG-positive lymph nodes were seen on PET-CT scan images and tumor invasion 
in the left thyroid gland was suspected  figure 7.1 . Given the long interval between the two 
malignancies, this new tumor (T4bN2M0) was most likely a second primary tumor in the 
remaining cervical esophagus. In a multidisciplinary team discussion it was decided to treat 
with induction chemotherapy (carboplatin/paclitaxel). Initially the tumor responded well, 
but four months later he suffered from progressive disease with fistula formation to the 
trachea which was a contraindication for additional radiotherapy. An esophageal stent was 
placed to manage progressive dysphagia and palliative radiotherapy (13 x 3 Gy) was started to 
manage neuropathic pain caused by tumor invasion with imminent spinal cord compression. 
He died two days later.
Case 2
Patient B was a 42-year old man born with VACTERL association (acronym: vertebral anomalies, 
anal atresia, cardiac anomalies, TEF, renal anomalies, and limb defects) 16 including EA Gross 
type A (long gap without TEF), anorectal malformation, coccyx agenesis and vertebral 
anomalies. Continuity of the esophagus was restored with a delayed end-to-end anastomosis. 
At 37 years of age he presented with dysphagia. Upper endoscopy revealed a stenotic 
anastomosis at 30 cm from the incisors, which could be easily dilated. In the next two years  
he underwent another three esophageal dilation procedures because of recurrent dysphagia. 
Biopsies revealed chronic and active inflammation with presence of hyphae. At the age of  
42 years he presented with progressive dysphagia, without weight loss (BMI 17.6 kg/m2).  
He smoked tobacco and drank alcoholic beverages only in the weekend. This time upper 
endoscopy revealed a circular stenotic ulcerative ESCC in the proximal esophagus (22-29 cm, 
anastomosis not visible)  figure 7.2a . Endoscopic ultrasound findings were suspicious for 
tumor invasion in the trachea and several potentially malignant regional lymph nodes 
(T4N2M0). The tumor was considered unresectable due to invasion of surrounding vital 
structures (cT4b)  figure 7.2b , lymph node metastases, previous thoracotomies (both sides) 
and intra-mediastinal surgery. Induction chemotherapy (paclitaxel/carboplatin) was started 
to which the tumor evidently had responded after 2 mo. Concomitant chemoradiotherapy 
was given (28 x 1.8 Gy) with curative intent. Six years after treatment he shows no signs of 
recurrent or metastatic disease. 
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Figure 7.2  
Findings at upper endoscopy and chest computed tomography scan (CT scan) (case 2).  
A: Upper endoscopy revealing a stenotic ulcerative tumor in the proximal esophagus, 22-29 cm  
from incisors. Histological examination of esophageal biopsies confirmed the diagnosis esophageal 
squamous cell carcinoma.  
B: Chest CT scan showing a tumor mass in the proximal esophagus with suspected tumor invasion  
in the trachea. 
Figure 7.3  
Initial findings at positron emission 
tomography-computed tomography 
scan (PET-CT scan) (case 3), showing 




Patient C presented at the age of 36 years. She was born with an EA Gross type A which was 
surgically repaired with an end-to-end anastomosis using Livaditis elongation procedure at 
one month of age. At one year of age she underwent a Nissen fundoplication for severe GER. 
At the age of 3 years, an anastomotic stricture developed which was treated with repeated 
esophageal dilations. At the age of 22 years she presented with chronic respiratory symptoms, 
severe pneumonia, persistent GER, and dysphagia complaints. Upper endoscopy with 
esophageal biopsies showed no abnormality. In view of the respiratory and gastrointestinal 
symptoms a duodenal diversion procedure (partial antrectomy with Roux-en-Y gastrojejunal 
anastomosis) was performed at the age of 23 years.
At 36 years of age she presented with food impaction and weight loss of 4 kg (BMI 14.9 kg/m2). 
She did not smoke tobacco and did not drink alcoholic beverages. Upper endoscopy revealed 
a stenotic ulcerative tumor in the distal esophagus with proximal dilation of the esophagus 
(25-32 cm from the incisors, gastroesophageal junction at 34 cm, anastomosis not visible). 
Biopsies revealed a well differentiated SCC. PET-CT scan  figure 7.3  and bronchoscopy did not 
reveal any metastasis. She underwent a subtotal esophagectomy with total gastrectomy and a 
colonic interposition (pT1bN0M0). Within the following month she required reoperation for 
a cervical fistula and mediastinitis and underwent two endoscopic dilations of an anastomotic 
stricture without any evidence of tumor recurrence. Twelve months after surgery she was 
diagnosed with pleural and bone metastases for which she recently has started palliative 
chemotherapy.
Case 4
Patient D presented at the age of 47 years. He was born with VACTERL association 16 (EA Gross 
type C, anorectal malformation, congenital urethral valves with bilateral vesicoureteral reflux 
and hydronephrosis left kidney). At day 5 after birth a thoracotomy was performed with TEF 
closure, gastrostomy and cervical esophagostomy placement. In addition the anorectal 
malformation was corrected. Nine days later a recurrent TEF was ligated. At day 29 the distal 
esophagus was ligated directly above the stomach and after 7 mo a colonic interposition was 
constructed. The spleen was congested and therefore resected during this surgery. Revision 
was needed because of leakage of the proximal anastomosis 19 days later. At 2.5 year of age the 
gastrostomy was closed. Other medical history included asthmatic bronchitis, bilateral 
orchidopexy, transurethral resection of urethral valves and nephrectomy of an afunctional 
infected left kidney.
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At presentation the patient suffered from pneumonia with a density in the lower lobe of  
the right lung. Subsequent PET-scan revealed a PET-positive thickening in the colonic 
interposition for which he had been referred to our center. He complained about progressive 
dysphagia without any weight loss (BMI 18.6 kg/m2). He was a cannabis smoker (2 joints/wk), 
had quit tobacco smoking just before presentation (a few cigarettes per day) and only 
sporadically drank alcoholic beverages. Upper endoscopy revealed the proximal and distal 
anastomosis of the colonic interposition at, respectively, 21 and 47 cm from incisors. From 
26-30 cm from incisors a tumor was visible in the colon interposition which could be easily 
passed with the scope. Histology revealed a moderately differentiated adenocarcinoma. No 
abnormalities were found at colonoscopy. PET-CT scan showed circumferential thickening of 
the colonic interposition over a length of 10 cm, not clearly separated from the thyroid and 
left brachiocephalic vein, a small lesion in the lower right lobe of the lung (PET-negative) and 
a few locoregional lymph nodes (≤ 1 cm, PET-negative)  figure 7.4a and 7.4b . 
Patient D was treated with induction chemotherapy (capecitabine/oxaliplatin) to enable 
maximum tumor regression. After six treatments, the colonic interposition was resected and 
an esophagostomy and jejunal fistula for feeding were created. Pathological examination 
confirmed the diagnosis of colonic adenocarcinoma with a maximum diameter of 4.1 cm, 
tumor free resection margins (≥ 1 cm) and one of 19 lymph nodes positive for metastasis 
(ypT2N1). Family history was negative for Lynch Syndrome. Both pentaplex microsatellite 
instability testing and mismatch repair gene expression analysis for MLH1, MSH2, MSH6 and 
PMS2 were normal. 
Figure 7.4  
Initial findings at positron emission tomography-computed tomography scan (PET-CT scan) (case 4).  
A: Chest CT scan image with a circumferential wall thickening of the thoracic colonic interposition over 
a length of 10 cm, not clearly separated from the thyroid and left brachiocephalic vein. Locoregional 
suspected lymph nodes (< 1 cm).  
B: PET-CT scan showing a PET-positive lesion in the thoracic colonic interposition. No PET-positive lesions 
or lymph nodes.
127chapter 7
After 4 mo continuity was restored by a subcutaneous gastric tube pull-up. At oncological 
follow-up one year after resection of the colonic interposition patient D did not experience 
any dysphagia, weight was stable (BMI 19.7 kg/m2) and ultrasound of the liver and CEA were 
normal (2.72 µg/L).
discussion
We presented four cases of gastrointestinal cancer that have developed more than 30 years 
after surgical treatment of EA: three esophageal carcinoma and one unusual presentation  
of colorectal carcinoma in a colonic interposition. These patients’ relatively young age,  
the fact that only few carcinogenic factors were identified and the high incidence of cancer 
development in a low prevalence disease suggest that EA carries an increased risk for 
esophageal cancer development and therefore screening and surveillance may be warranted, 
as recommended in the ESPGHAN-NASPGHAN guideline 11. 
Esophageal cancer is the 8th most common cancer worldwide, with an incidence rate of 6.4 
and 1.2 per 100,000 males and females, respectively, in developed countries and 10.1 and 4.1 
per 100,000 males and females, respectively, in less developed countries 17. ESCC and EAC have 
different etiologies. ESCC arises from dysplastic squamous epithelium and is associated with  
a low socioeconomic status, use of tobacco or alcohol, several dietary factors, and human 
papilloma virus 18, 19. The main risk factors for EAC are GER, use of tobacco, obesity, and hiatal 
hernia 18. Chronic GER might lead to gastric and intestinal metaplasia of the squamous 
epithelium in the esophagus, known as Barrett’s esophagus, which predisposes to dysplasia 
and EAC. GER is present in up to 67% of the adult EA patients and is likely to contribute to EAC 
development 5. However, in literature – and also in our case series – ESCC is more common 
than EAC in EA patients 10, 12-15. The reason for this high risk of ESCC development has not yet 
been establised. The pathogenesis might be the same as in achalasia, where ESCC is thought 
to result from stasis, causing bacterial overgrowth with nitrosamine production and 
subsequent esophageal inflammation, dysplasia and cancer 20, 21. Most of the ESCC in EA 
patients were found near or at the anastomosis (mid-distal esophagus). It has been suggested, 
therefore, that frequent dilation procedures with associated mucosal tears, scarring and 
inflammation may lead to development of ESCC in this patient group 10, 12. Mitomycin-C, an 
antifibrotic applicant used to prevent recurrence of strictures, may be an additional risk factor 
for ESCC, but this was not used in any of the patients in present case series 22. Moreover, 
genetic predisposition may contribute to esophageal cancer in EA patients and is subject to 
future studies. 
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Endoscopic surveillance of EA patients is advocated to detect lesions at an early stage 11. Those 
treated with a colonic interposition should not be excluded from surveillance, as carcinoma 
could arise in the cervical native esophagus or thoracic colon. More data on the actual 
incidence of esophageal cancer development in adulthood will hopefully become available 
soon when surveillance programs have been implemented. Together with the identification 
of risk factors this will help to optimize surveillance strategies in EA patients. Until then, 
pediatric surgeons and gastroenterologists who are involved in treatment of EA patients 
should be made aware of the cancer risk and be encouraged to reach consensus on optimal 
surveillance. When EA patients reach adulthood, they should be transferred to a 
gastroenterologist for endoscopic surveillance.
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The research described in this thesis concerns gastrointestinal morbidity after esophageal 
atresia (EA) repair in both childhood and adulthood. This thesis aims to optimize long-term 
gastrointestinal follow-up of EA patients.
As survival rates after EA repair are approaching 100%, the focus of medical care for these 
patients has shifted from mortality to long-term morbidity. Gastrointestinal, respiratory and 
neurodevelopmental problems as well as growth impairment are common after EA repair 1-3. 
Some of these morbidities do not only exist in childhood, but persist during adolescence and 
through adulthood and may affect quality of life and survival of EA patients. Multidisciplinary 
follow-up seems necessary after EA repair, however it was not until recently that 
recommendations on gastrointestinal and nutritional management were missing. In the 
recently published ESPGHAN-NASPGHAN guidelines several aspects of gastrointestinal and 
nutritional complications are highlighted 4. Various of these complications are discussed in 
this thesis i.e. growth impairment (Chapter          ), gastroesophageal reflux (GER; Chapter          ), 
esophageal strictures (Chapter          ), Barrett’s esophagus (BE; Chapter          ) and esophageal 
cancer (Chapters            and          )  figure 8.1 .






















In 1999, a longitudinal follow-up program was started at the Pediatric Surgery department of 
our center 5, 6. All children born with a major anatomical malformation (e.g. EA, congenital 
diaphragmatic hernia and omphalocele) have joined this program since. A multidisciplinary 
team runs this program, with scheduled visits until 18 years of age and transfer for adult care 
when the child turns 17 years. The program aims to reduce overall morbidity associated with 
these anatomical malformations and has resulted in valuable long-term follow-up data for 
these specific patient groups. Chapters          and          evaluated data obtained from EA patients 
participating in this longitudinal follow-up program. 
Feeding difficulties and growth impairment
The first years of life are crucial for normal development of the brain and immune system 7, 8. 
With a brand new connection between the native esophagus and stomach, neonates treated 
for EA are confronted with the first gastrointestinal challenges in life. Accompanied by 
dysphagia, regurgitation, burping, vomiting, coughing, and choking it is a challenge for these 
neonates to achieve required nutritional intake. Feeding difficulties after EA repair are the 
result of oropharyngeal dysfunction, esophageal dysfunction and/or behavioral disorders, 
and reduce with age 9-11.
A study in 56 children born with EA (median age 3.7 years; range 0-16.8 years) showed that 54% 
of children were not eating age appropriate textures (72% of children aged 0-2 years) 10. 
Another study comparing 124 children treated for EA with 50 control patients, found late 
introduction of solid foods, prolonged meal times, more episodes of chocking/coughing 
during meals, and more refusal of meals in EA patients 12. In 40 children treated with delayed 
primary repair for long-gap EA, normal development of feeding skills were found despite the 
late onset of feeding in these patients 13. Although feeding difficulties are common after EA 
repair 11, children with the most common type of EA (Gross type C) seem to have mild 
(subclinical) feeding difficulties, while severe problems are observed in patients with Gross 
type A EA and extreme prematures 14. Early dietary management to achieve a good nutritional 
status seems warranted in these patients. 
Low birthweight is a risk factor to develop underweight and a short stature 15. As many EA 
patients are born small for gestational age (30%) or prematurely (36%-39%), these children 
– compromised by feeding problems and recurrent infections − are at risk of growth 
impairment 16-19. 
To date, studies on growth in children born with EA are mainly cross-sectional or retrospective 
10-12, 20-28. Several studies found a reduced height in children with EA 10-12, 20, 22-24, 27, 28. In the 
Rotterdam EA cohort, we published two longitudinal studies found impaired growth (height) 
2 4
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in the first five years of age with catch-up growth between two and five years 29, 30. In Chapter  
          we longitudinally evaluated growth in children born with EA up to the age of 12 years.  
Up to the age of five years, these children had a significantly lower weight (weight-for-height) 
compared to the general population. Height (height-for-age) was significantly lower up to the 
age of eight years. At 12 years of age weight and height had normalized. In the future, we will 
continue to follow this group during adolescence to evaluate whether nutritional 
intervention is needed to obtain a normal growth spurt in puberty. 
Target height and its SD score (SDS) can be calculated with parental heights 31. This can be 
useful to discriminate the influence of disease on growth 32. When we corrected height for 
individual target height, the SDS for height (SDS for distance-to-target-height) improved in 
our study. This finding shows the importance of structurally recording parental height, as a 
child’s nutritional status can be underestimated when only interpreting SDS for height-for-
age.
Previous studies found several explanatory variables for growth impairment in EA patients, 
such as long-gap EA, esophageal substitution, and a history of GER 12, 21, 22. In Chapter           we 
also evaluated these factors, but did not find associations with growth impairment. We found 
two of the studied explanatory variables to be negatively associated with growth: low birth - 
weight and a history of fundoplication surgery. Children with a low birthweight were more 
likely to have a short stature and to be underweight, this was previously described by others 15. 
Fundoplication surgery was mostly performed before the age of six months. Many children 
who underwent fundoplication surgery had height and weight below the reference norm after 
surgery. We suspect that these children have persistent feeding problems preventing catch-up 
growth. Moreover, they may have had more extreme disease severity posing a risk for failure 
to thrive. The SDS weight-for-height of these children increased from 1-2 years, which we 
assume can be ascribed to adequate treatment of severe GER. 
We found that number of surgeries and history of pulmonary infections were positively 
associated with weight (weight-for-height) in EA patients. We speculate that children with 
recurrent hospitalizations more often received dietary interventions. In congenital 
diaphragmatic hernia patients close involvement of multidisciplinary nutrition support 
teams was indeed found to prevent failure to thrive 33. It is worth recommending to have such 
teams, including dieticians and speech-language pathologists, available to support 
hospitalized children in general, and continue supporting high-risk-patients after discharge 
to home. These multidisciplinary teams can optimize nutritional status in early years, which 
is crucial for normal brain and immune system development 7, 8. Future multicenter studies 
should focus on optimization of nutritional intake and on the effects of growth problems on 




Prevalence and risk factors of gastrointestinal problems  
in esophageal atresia patients
Gastroesophageal reflux
GER is a physiologic phenomenon. When GER causes troublesome symptoms interfering with 
daily life or complications it is referred to as GER disease (GERD) 34. GERD – a motility disorder 
– is common (up to 67%) in EA patients, both in early childhood and adulthood 4, 35. It results 
in respiratory and gastrointestinal problems in the short and long term, e.g. aspiration 
pneumonia, apparent life-threatening events, dysphagia, feeding problems, chronic 
respiratory symptoms, esophageal strictures, esophagitis, BE and esophageal cancer 4, 36-39. 
Given the high prevalence of GERD, early diagnosis and management of GERD is important  
to reduce GERD associated morbidity. 
When GERD is clinically suspected, several diagnostic tools can help to diagnose GERD: e.g. 
barium imaging, esophagogastroduodenoscopy, manometry, scintigraphy, pH monitoring, 
and combined pH and impedance (pH-MII) monitoring. pH monitoring detects pH changes of 
esophageal contents, but lacks the ability to detect weakly and non-acid boluses 40. pH-MII 
monitoring can detect both acid and non-acid reflux, but is not available in all medical centers 
and underestimates GER events in patients with esophagitis or motility disorders as a result of 
low baseline impedance values 34, 41-43. Besides, reference values are lacking and inter- and 
intra-observer agreement studies show diverging results 44-47. Because of this, the recent 
ESPGHAN-NASPGHAN Guideline on pediatric GERD (2018) dissuades use of pH-MII monitoring 
alone for diagnosing GERD in infants and children 34. It should only be considered to 1) 
correlate persistent symptoms with (non-)acid GER, 2) evaluate the role of (non-)acid GER in 
esophagitis and other symptoms suggestive for GERD, 3) determine the efficacy of anti-acid 
therapy, and 4) differentiate children with hypersensitive esophagus, functional heartburn 
and non-erosive reflux disease 34.
Although many children with EA are exposed to chronic GER, only a few experience 
troublesome symptoms. Both pH-MII monitoring results suggestive for GERD and endoscopic 
abnormalities have been described in asymptomatic children with EA 48-51. The discrepancy 
between symptoms and GER makes it difficult to decide in which patients GER should be 
monitored. The ESPGHAN-NASPGHAN Guideline (2016) for EA patients recommends to 
routinely treat all EA patients with anti-acid treatment in the neonatal period and to monitor 
GER using pH-MII monitoring and/or endoscopy at time of discontinuation (regardless of 
symptoms) and during long-term follow-up in symptomatic children with EA 4.
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In Chapter            we evaluated GER symptoms in 8-year old children with EA using the GER 
questionnaire developed by Manterola et al. 52. The questionnaire was suggestive for GERD 
(score >3) in 29% (n=7), but in only two of these children a high reflux index (>7%) was found. 
pH-MII parameters were similar in children with low and high Manterola scores. This may 
have been the result of day-to-day variability of pH-MII measurements in EA patients, or 
perhaps disturbed impedance patterns make pH-MII studies unsuitable for GER detection in 
EA patients 53. Dysphagia – which may be associated with dysmotility, eosinophilic esophagitis 
or strictures rather than GER – was mentioned by 5/7 children. Regurgitation was scored in 6/7 
children with a high Manterola score, which – in children with EA – can also be regurgitation 
from the esophagus rather than the stomach. It may therefore be that the Manterola 
questionnaire is not suitable for EA patients. Development of an appropriately validated 
questionnaire for children with EA to determine which child benefits from preventive 
measures to prevent complications from GER (e.g. acid-suppression, prokinetics, 
fundoplication) and how is important.
Reference values for pH-MII monitoring in symptomatic children without EA have been 
published, but due to ethical issues true normal values in healthy asymptomatic children 
cannot be established 54-57. Several groups have reported their experiences with pH-MII 
monitoring in post-EA repair children of different ages, but cut-off values for pathological 
results remain unknown 48, 49, 58-63. Moreover, differences in study protocols makes 
comparing results difficult.
Bolus retention, abnormal motility patterns during swallowing and decreased baseline 
impedance caused by GER and dysmotility are frequently observed in EA patients. As these can 
disturb automated reflux detection in pH-MII measurements, manual evaluation of bolus 
events is necessary for accurate identification of GER in EA patients. 
In Chapter            we evaluated acid and non-acid GER in 57 EA patients aged ≤18 months and 
8-years old using pH-MII monitoring. All reflux events were manually reviewed and modified 
or deleted in case of incorrect identification of the reflux event. In both infants and school-
aged children non-acid and mixed refluxes were more frequently observed than acid and 
liquid refluxes, respectively. We found similar results for reflux index (acid exposure index 
(%)), number of retrograde bolus movements (RBM) and bolus clearance time compared to 
available reference values in children without EA (asymptomatic neonates or children with 
gastrointestinal, pulmonary or neurological symptoms) 54, 56, 57, 64. Compared to available 
pH-MII results in children born with EA, number of RBM in our cohort of infants was high 
compared to a small Dutch cohort 58, but similar to other cohorts 48, 63. Results in 8-year old 
children were comparable. We found a lower reflux index compared to most cohorts of EA 




We found a large overdetection of reflux events in automated analysis of pH-MII 
measurements in EA patients. After manual evaluation 39% of reflux events was deleted from 
the tracings. These were mainly non-acid swallows which the software incorrectly identified 
as reflux events. We found two main reasons for modification of retrograde boluses after 
visual evaluation: correction of incorrect identification of proximal bolus events and 
correction of bolus clearance time. The software misclassified swallows to clear retrograde 
boluses as proximal boluses. This was caused by air in the esophagus after a swallow.  
In several children, stasis of fluids was present in channel Z3 and Z4, at the level of the 
esophageal anastomosis. The software did not recognize this stasis and measured a shorter 
bolus clearance time. This was also observed in 118 adults (without EA) with endoscopy-
negative heartburn 65. This raises the question whether automated analysis is accurate enough 
to identify GER in EA patients. We believe the percentage of overdetection of reflux events in 
automated analysis of pH-MII measurements in EA patients is too high to ignore and to 
perform automated analyses without manual revision. Manual revision, however, carries the 
risk of greater inter-observer variability. Refinement of automated software is needed to 
identify impedance reflux patterns in patients with complex motility disorders such as EA. 
Although the ESPGHAN-NASPGHAN Guideline for EA patients recommends to prescribe 
anti-acid therapy in all neonates with EA, a recent systematic review found prophylactic 
anti-reflux treatment not to prevent stricture formation after EA repair (low quality of 
evidence) 4, 66. As described in Chapter           , reflux in EA patients is mainly non-acid. An  
Italian study found that symptoms in infants (<12 months) were mainly associated with 
non-acid reflux, while symptoms in older children were mainly caused by acid reflux 62. 
Currently there are no effective medications available to treat non-acid GER in children.  
A small double-blinded placebo RCT in children without EA showed that Baclofen inhibits 
transient lower esophageal sphincter relaxation and accelerates gastric emptying, but is 
dissuaded in guidelines as a first-choice therapy in children because of known side effects  
in adults 34, 67. Future studies in EA patients assessing the usefulness of anti-acid therapy in 
preventing complications from GER are needed.
Surgical intervention (e.g. fundoplication surgery) is considered when medical therapy fails in 
children with severe GERD. The recent clinical Guidelines for the diagnosis and management 
of GERD in children recommend to consider anti-reflux surgery in children with GERD and 
one of the following: 1) life threatening complications of GERD after failure of optimal 
medical treatment; 2) symptoms refractory to optimal therapy after appropriate evaluation  
to exclude other underlying diseases; 3) chronic conditions with a significant risk of GERD-
related complications; or 4) the need for chronic pharmacotherapy for control of signs and/or 
symptoms of GERD 34. However, no controlled trials have been published to evaluate the role 
of anti-reflux surgery in EA patients. In EA patients with esophageal dysmotiliy, surgical 
intervention might worsen stasis of food and fluids. Studies in patients without EA have 
4
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shown that fundoplication surgery does not necessarily protect against aspiration pneumonia 
68, 69. The Guideline for EA patients states that EA patients – despite the risk of post-
fundoplication complications – might benefit from anti-reflux surgery, especially those with 
severe refractory esophageal strictures 4. Future controlled trials should focus on the role of 
fundoplication surgery in EA patients. 
Anastomotic strictures
Anastomotic stricture formation is the most frequent post-operative complication after EA 
repair (17%-59%), occurring mostly in the first year of life 70, 71. Several factors are thought to 
contribute to stricture formation after EA repair, such as long gap EA with consequent 
anastomotic tension, anastomotic leakage and GER 71-79. These anastomotic strictures should 
not be confused with congenital esophageal stenosis, which are frequently found in neonates 
born with EA (3%-47% compared to 1:25,000/1:50,000 in the general population), but have a 
different etiology 4.
In Chapter            we describe a large multicenter study in 454 Dutch children born with EA 
(median follow-up of 6.6 years; range 0.6-16.9 years). Dilations of an anastomotic stricture 
were performed in 58% of children. Reported incidence rate of strictures after EA repair ranges 
widely (9%-79%) 80. A uniform definition of an esophageal stricture after EA repair is lacking, 
which makes it difficult to compare the results between studies. 
An esophageal stricture is mostly defined as any narrowing of the esophagus requiring at least 
one dilation 71, 76, 77. However, definitions vary based on frequency of dilations 81-86, luminal 
diameter 73, or symptomatology 72, 75. In several centers clinicians decide to surgically 
intervene already after three consecutive dilation procedures. Because of this, a clinically 
significant esophageal stricture is often defined as a stricture requiring ≥3 or ≥4 dilations 84-86. 
Based on the definition in the international Guideline on pediatric endoscopy, we defined the 
following definition of a refractory esophageal stricture: an anastomotic stricture requiring 
≥5 dilations at maximally four-week intervals 87. This definition distinguishes refractory 
strictures from so called recurrent strictures. In our study we found refractory strictures of an 
end-to-end anastomosis in 7.3% of children. Isolated EA, anastomotic leakage and early 
stricture (≤28 days after anastomosis) were associated with refractory stricture development.
Others also found isolated EA to be associated with stricture formation 72-74. The large 
esophageal gap often requires staged surgery or esophageal replacement (e.g. gastric pull-up, 
jejunal/colonic interposition). Although primary repair of a large gap is thought to result in 
anastomotic tension with subsequent stricture formation, literature is contradictory 83, 88. 
Current practice in children born with an isolated EA is performing a primary anastomosis of 
the esophagus. In our study, we found a high percentage of refractory strictures in these 
5
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children (27%), which is important information for pre-operative parental counseling. 
We believe that anastomotic leakage enhances inflammation and scarring of the anastomotic 
area, with subsequent stricture formation. This association was also found by others 78, 79.
We found esophageal dilation within 28 days postoperatively (‘early stricture’) to be 
associated with refractory strictures. A possible explanation is that more severe (refractory) 
strictures may occur in the first weeks after esophageal anastomosis. However, in those first 
weeks postoperatively the anastomosis is still vulnerable and early anastomotic dilation 
might be an independent risk factor for refractory strictures. Our data did not allow to draw 
any conclusions on this subject. Most refractory strictures developed within four months 
postoperatively. We assume that refractory strictures after this period (‘late onset’) are related 
to altered food consistency as more solid formulas can cause dysphagia, food impaction, 
stasis, aspiration or vomiting.
We hypothesized that thoracoscopic EA repair increases refractory esophageal stricture 
formation, however we could not confirm this in our study (only 54 thoracoscopic procedures 
in two centers). In thoracoscopic EA repair visualization is better and the dissection is usually 
more limited compared to open corrections. A recent study found thoracoscopic and staged 
EA repair to be associated with clinically relevant stricture formation (≥4 dilations) 85, however 
two reviews found comparable stricture rates after open and thoracoscopic EA repair 89-91. 
Another factor thought to increase esophageal stricture formation is anastomotic tension 72, 
74-78. Since anastomotic tension is a subjective observation which is often poorly documented 
in surgery reports, we choose to include anastomotic leakage as a predictor for refractory 
strictures in our study instead. 
Although others have identified GERD as a risk factor for esophageal stricture development  
71, 74, 78, 79, studies in EA patients have shown that prophylactic anti-acid therapy did not always 
protect against stricture development 92-94. Moreover, studies are hard to compare since 
different protocols and definitions are used. In our study anti-reflux surgery was more 
frequently performed in patients with a refractory stricture. This surgery should be considered 
as being a therapeutic intervention rather than a risk factor for stricture development, since it 
was mostly performed after a refractory stricture had developed. 
Although literature on esophageal stricture formation in EA patients is scarce, other reported 
risk factors for post EA repair stricture development are prematurity, birthweight and cardiac 
anomalies 72, 85, 93. We could not confirm this in our study. 
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Future studies can hopefully answer the question whether adequate acid suppression aiming 
to protect the anastomotic area in high risk patients (e.g. children with isolated EA, 
anastomotic leakage, early strictures) is effective in reducing refractory stricture formation. 
Multicenter studies focusing on adjuvant treatments for esophageal strictures (e.g. stent 
placement, intralesional steroids injection, mitomycin C application, endoscopic needle 
knife incision and resection surgery) are needed to evaluate the effectiveness of these 
methods in reducing refractory stricture development. To compare results from different 
studies, we recommend to use a uniform definition for refractory anastomotic strictures:  
‘an anastomotic stricture requiring ≥5 dilations at maximally four-week intervals’. 
Esophagitis and Barrett’s esophagus (BE)
Chronic GER may lead to esophageal mucosal damage such as esophagitis and BE, which are 
both frequent in EA patients. During endoscopy esophagitis is found in 25.1% of EA patients 
(12%-15% in general population)(see overview of literature in Chapter          ) 95, 96. BE is 
diagnosed if gastric epithelium is observed in the esophagus and metaplasia is confirmed in 
the biopsy 97. In accordance with the ACG guidelines (2008), we considered the presence of 
goblet cells – present in intestinal metaplasia (IM) and absent in gastric metaplasia (GM) – 
obligatory to confirm the diagnosis of BE although malignant transformation in GM has  
been described 97. 
In the general adult population the prevalence of BE is 1.3%-1.6% and is predominantly 
diagnosed in middle-aged white males 95, 98, 99. In EA patients BE is described in up to 12.5% 35. 
Since BE is a premalignant lesion which predisposes to esophageal adenocarcinoma (EAC) 
with an annual risk of 0.5%, endoscopic surveillance in EA patients was recently 
recommended in an ESPGHAN-NASPGHAN guideline (2016) 4, 100. 
In Chapter           we describe the first results of a screening and surveillance program in adult EA 
patients. Since 2013, all EA patients aged 17 years or older have been referred to the 
Gastroenterology department of our center for endoscopic screening and surveillance of the 
esophagus. From the 289 invited EA patients, 151 (52%) were willing to participate in the 
surveillance program. We found a prevalence of BE (IM) of 6.6%, which is 4-5 fold higher 
compared to the 1.3%-1.6% in the general population population 95, 98. 
In the general population BE is associated with several risk factors such as male gender, older 
age (≥50 years), white race, tobacco smoking, obesity, hiatus hernia, and GER 101, 102. In the 
general population BE is diagnosed at a median age of 57 years 95, 98. We found BE at a much 
younger age (median of 31.6 years), with our youngest patient diagnosed at 19 years of age. 




In our study fundoplication surgery – representing patients with a history of severe GER – 
appeared to be the only significant predictor for BE. A high percentage of fundoplication 
failure after EA repair and children outgrowing their fundoplication may explain the 
recurrence of GER in these patients 104, 105.
We also evaluated possible determinants for esophageal metaplasia (both GM and IM) as BE is 
thought to evolve from GM and diagnosis of BE can be limited by sampling error (mosaic 
pattern of GM and IM) 106. None of the factors were significant. In contrast, a study in 101 EA 
patients found the following risk factors for esophageal metaplasia (GM and IM): long gap EA, 
age >30 years, recurrent TEF, esophageal stricture resection during childhood, esophageal 
stricture in adulthood, and abnormal esophageal manometry 107. However, in half of the 
patients diagnosed with metaplasia no columnar-lined esophagus was observed at 
endoscopy. The same discrepancy between histological evidence of metaplasia and suspected 
BE (columnar-lined esophagus) at endoscopy was present in another study 108. It seems that 
biopsies were taken from the cardia instead of the (absent) metaplastic columnar epithelium 
in the esophagus, which highlights the importance of accurate recognition of endoscopic 
anatomical landmarks in the diagnosis of BE 109. If done not correctly, it may lead to 
inaccurate prevalence data of BE in EA patients.
Esophageal cancer
Esophageal cancer is the 8th most common cancer worldwide, with an incidence in developed 
countries of 6.4 (♂) and 1.2 (♀) per 100,000 110. The two commonest types of esophageal 
cancer are EAC deriving from the columnar mucosa and esophageal squamous cell carcinoma 
(ESCC) originating from the squamous mucosa. 
Over the last decades, survival of EA patients has increased and many more patients reach 
adulthood. To date – together with the cases reported in Chapter           – 11 cases of esophageal 
carcinoma in adult EA patients have been reported at an alarmingly young age: three EAC and 
eight ESCC 37, 111-115. The youngest was nearly 20 years old 113.
As above mentioned BE is a premalignant lesion which predisposes to EAC. In the general 
population GER, use of tobacco, obesity, and hiatal hernia are the major risk factors for EAC 
102. ESCC has several other risk factors such as low socioeconomic status, tobacco smoking, 
alcohol consumption, dietary factors, achalasia, and human papilloma virus 102, 116.
However, ESCC – which is not directly related to reflux – is seen more often than EAC in EA 
patients. In our screening and surveillance program described in Chapter            we found ESCC 




The relatively young age at time of cancer diagnosis, the presence of only a few carcinogenic 
factors and the high cancer incidence in EA patients suggests an increased risk for 
carcinogenesis after EA repair. The reason for a possible higher prevalence of ESCC compared 
to EAC in EA patients is still unknown. EA patients could be at higher risk of developing ESCC 
than EAC. Or the time needed for EAC to evolve from BE could be longer than our median 
follow-up time (25.4 years).
In achalasia patients esophageal stasis of food and fluids – causing bacterial overgrowth with 
nitrosamine production – is thought to increase the risk to develop ESCC 117, 118. The same 
pathogenesis might explain ESCC development in EA patients. As most ESCC had developed at 
or near the anastomosis (mid-distal esophagus), several authors have suggested that frequent 
dilation procedures with associated mucosal tears, scarring and inflammation predispose for 
ESCC 111, 112. Prospective data from multicenter collaborative initiatives are needed to further 
evaluate carcinogenesis in EA patients. 
Screening and surveilllance programs
Detecting potential pathological lesions at the earliest possible stage can perhaps prevent 
mortality from esophageal carcinoma at a young age, which is why endoscopic surveillance of 
EA patients at a young age is currently advocated 4. Yet the ideal follow-up schedule has to be 
determined. It is important to identify patients who are at risk for carcinogenesis and will 
need the most intensive surveillance.
As it is still unclear which EA patients are at risk for esophageal cancer development, we 
started screening all EA patients in our center from the age of 17 years onwards. Our proposed 
surveillance intervals for BE are in accordance with the ACG guidelines 97. In addition, in the 
absence of BE surveillance intervals of 5 years (age <30 years) or 3 years (age ≥30 years) are 
advised  figure 8.2 .
Figure 8.2 Flowchart of screening and surveillance program in adult esophageal atresia patients.
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We recommend to perform chromoendoscopy with Lugol’s staining from the age of 25 years 
onwards to examine the squamous epithelium in detail 119. As most ESCC were found near or 
at the anastomosis one could consider to take random biopsies mid-esophageal at the site  
of the original TEF or anastomosis. Further long-term prospective cohort studies are needed 
before a more evidence based cost-effective surveillance program in EA patients can be 
implemented.
Since EA is a rare disease and only a few clinicians are involved in medical care for EA patients, 
a minority of clinicians are aware of the increased risk for carcinogenesis after EA repair. 
Moreover, since most EA patients do not experience dysphagia or GER related symptoms as 
troublesome, only a small percentage of adult EA patients visit their general practitioner.  
This illustrates the need for more awareness among general practitioners, for multicenter 
collaboration and for initiation of national surveillance programs.  
conclusions
In conclusion, there is a high need for multicenter research to optimize long-term 
gastrointestinal follow-up of EA patients. Since EA is a rare condition, multicenter 
collaborative initiatives (international and national) are essential, preferably randomized 
trials. Standardized treatment protocols and uniform definitions to report clinical parameters 
are essential to compare different patient cohorts. Consensus meetings are needed to achieve 
consensus on and formulate recommendations for the care of EA patients. Hence, the 
International Network on Esophageal Atresia (INoEA) was formed in 2013 to help formulate 
clinical practice guidelines for the care of these patients 4. Family support groups from all over 
the world are united in the European federation of Esophageal Atresia and Tracheoesophageal 
fistula support groups (EAT). EAT focusses on sharing knowledge, experience and resources to 
improve management of EA and promotes scientific research and awareness of EA. They 
collaborate with the medical community through organizations such as INoEA.  
In 2016 the Dutch Consortium of Esophageal Atresia (DCEA) was established, with members 
from all six university hospitals involved in neonatal surgery in the Netherlands and board 
members of the active Dutch patient support group ‘Vereniging voor Ouderen en Kinderen 
met een Slokdarmafsluiting’ (VOKS). In this thesis, we have shown the first publication of the 
DCEA study group involving 5/6 university hospitals (Chapter          ). 
Since 2016 the European Commission installed 25 European Reference networks for 7,000 rare 
diseases. The European Reference Network on rare intestinal, Inherited and Congenital 
Anomalies (ERNICA) is a multidisciplinary network of highly specialized healthcare 
professionals focusing on congenital gastrointestinal diseases such as EA and several acquired 
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gastrointestinal diseases 120. For EA, both patient support groups and medical centers are 
represented at international level in the workstream of diseases of the esophagus, which 
allows establishment of international protocols and definitions.
Structural follow-up of all children with EA should be considered up to adulthood, since  
it is unknown whether growth remains normal during puberty. Dieticians, as part of a 
multidisciplinary team, should be involved during (initial) hospitalization and follow-up  
to optimize nutritional status in early years, which is crucial for normal brain and immune 
system development. 
Transition of adolescents from pediatric care to adult Gastroenterology departments is 
important to provide life-long endoscopic follow up to facilitate early diagnosis of relevant 
esophageal lesions. Since fundoplication surgery is a risk factor for both growth impairment 
and BE, structural follow-up in both child- and adulthood seems particularly important in this 
group of patients. Risk stratification in patients with EA is important to define which 
subgroup of patients should receive endoscopic follow-up and at which frequency. 
Development of a predictive score, incorporating clinical, endoscopic, biochemical and 
genetic factors, is required to risk stratify patients with EA. This would allow focusing of 
surveillance endoscopy on patients deemed to be at a higher risk of progression to 
esophageal cancer, making this strategy more cost-effective. 
Genetic studies may serve to develop optimal risk stratification for carcinogenesis in EA 
patients and contribute to development of an evidence-based surveillance program from 
birth into adulthood. We hypothesize that chronic GER resulting in BE is not the only risk 
factor for esophageal carcinogenesis in EA patients as ESCC – which has an etiology unrelated 
to GER – is more often reported in EA patients than EAC. We believe the following genetic 
studies are needed:
•	 Whole	genome	sequencing	to	identify	somatic	gene	mutations	in	EA	patients	who	
developed BE/EAC or ESCC and evaluate whether they differ from control patients without 
EA. 
•	 Targeted	sequencing	to	evaluate	germline	variants	(single	nucleotide	polymorphisms;	
SNPs) near genes that are important for both foregut development and development of  
BE/EAC or ESCC – FOXF1, BARX1, FOXP1, TBX5, GDF7 genes – in EA patients. 
In 2016, we started to prospectively collect esophageal biopsies and blood samples of adult EA 
patients in a Biobank. In the future, these materials can be used to search for predictors of 
malignant progression in EA patients. 
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This thesis aimed to optimize long-term gastrointestinal follow-up of esophageal atresia (EA) 
patients. In this chapter, the main findings and conclusions of our studies will be summarized. 
Since gastrointestinal problems can compromise growth, Chapter            describes longitudinal 
evaluation of growth in 126 EA patients from infancy up to school age. Compared with the 
general population, EA patients had a significantly lower weight up to five years of age. A 
significantly lower height was found in the first eight years of life. Both weight and height had 
normalized, however, at 12 years of age. Two of the studied explanatory variables − low birth 
weight and a history of fundoplication surgery − were associated with lower standard 
deviation scores for both height and weight. 
Chapter            provides an overview of the current knowledge regarding long-term gastro-
intestinal morbidity after EA repair. Nowadays survival after EA repair is approaching 100%  
in dedicated centers. In almost all EA patients esophageal motility is disturbed and 
gastroesophageal reflux (GER) is prevalent in both children and adults. GER results in 
gastrointestinal problems such as dysphagia, esophageal strictures, esophagitis, Barrett’s 
esophagus (BE), and esophageal cancer. Structured follow-up programs run by 
multidisciplinary teams may help to reduce morbidity in EA patients. Guidelines on 
esophageal follow-up in EA patients were missing at time of writing this chapter. The few 
strategies for esophageal surveillance programs suggested in literature are shortly 
mentioned.
The results of routine evaluation of GER in EA patients aged ≤18 months and 8-years old using 
combined pH and impedance monitoring are evaluated in Chapter           . Both infants and 
school-aged children experience non-acid refluxes more frequently than acid refluxes. After 
manual revision of the tracings a high percentage of reflux events was deleted. This raises the 
question whether automated analysis is accurate enough to identify impedance reflux 
patterns in patients with complex motility disorders such as EA.
Chapter            describes the incidence of refractory strictures of the esophageal anastomosis in 
a large national multicenter cohort of 454 children born with EA. Determinants of refractory 
stricture formation (isolated EA, anastomotic leakage and the need for esophageal dilation 
within 28 days after EA repair) are discussed in more detail in this chapter.
In Chapter            we describe the first results of a screening and surveillance program in EA 
patients. Since 2013, all adult EA patients (≥17 years) have been referred to the Gastroenterology 
department of our center for endoscopic screening and surveillance of (pre)malignant 







In 6.6% the premalignant lesion BE was present, which is 4-5 fold higher compared to the 
general population. Of the studied explanatory variables only a history of fundoplication 
surgery was associated with BE. Esophageal squamous cell carcinoma (ESCC) developed in 
0.7%, which was 108-fold higher compared to the general population. Recent guidelines 
(2016) recommend surveillance endoscopy in EA patients, however the ideal surveillance 
strategy has yet to be determined.
Chapter            describes four EA patients who developed a gastrointestinal cancer at a relatively 
young age. Three patients developed an esophageal carcinoma and one patient developed a 
colorectal carcinoma in a colonic interposition. The relatively young age at time of cancer 
diagnosis, the presence of only a few carcinogenic factors and the high cancer incidence in EA 
patients suggests an increased risk for carcinogenesis after EA repair.  
The general discussion in Chapter            addresses the research described in this thesis in 
connection with the literature, describes the strengths and limitations of the studies 
presented in this thesis and highlights directions for further research. The major 
recommendations are the following:
•	 Structural follow-up of all children with EA – especially those who underwent fundoplication 
surgery – should be considered up to adulthood, since it is unknown whether growth 
remains normal during puberty. Dietitians, as part of a multidisciplinary team, should be 
involved during (initial) hospitalization and follow-up to optimize nutritional status in 
early years, which is crucial for normal brain and immune system development. 
•	 A	large	overdetection	of	retrograde	bolus	movements	is	present	in	automated	analysis	of	pH	
and impedance measurements in EA patients, which emphasizes the need for refinement  
of automated software for the use in infants and children with EA. The high number of 
non-acid retrograde bolus events with a normal reflux index (acid index) in infants and 
children with EA questions the need for standard anti-acid therapy in these patients.
•	 To	further	elucidate	the	mechanisms	involved	in	refractory	anastomotic	stricture	
formation, studies focusing on different surgical techniques should be performed. Research 
with pH and impedance monitoring and/or esophageal biopsies (histological esophagitis) 
could investigate the role of GER in refractory stricture formation.
•	 Transition	of	adolescents	from	pediatric	care	to	adult	Gastroenterology	departments	is	
important to receive life-long endoscopic follow up to facilitate early diagnosis of relevant 
esophageal lesions. Since fundoplication surgery is a risk factor for both growth 
impairment and BE, structural follow-up in both child- and adulthood seems particularly 
important in this group of patients.
•	 Multicenter	collaboration,	the	use	of	uniform	definitions	to	report	clinical	parameters	 
(e.g. esophageal gap length, GER, esophageal strictures) and longitudinal data collection is 
needed to answer the question ‘How to optimize gastrointestinal long-term follow-up in  
EA patients?’.
•	 Collecting	esophageal	biopsies	and	blood	samples	in	a	Biobank	is	needed	to	search	for	





Dit proefschrift richt zich op het optimaliseren van de lange termijn zorg voor maagdarm-
problemen bij patiënten geboren met een slokdarmatresie. In dit hoofdstuk worden de 
belangrijkste bevindingen en conclusies van onze studies samengevat en besproken. Verder 
zullen suggesties voor toekomstig onderzoek worden gepresenteerd.
Slokdarmatresie (oesofagusatresie) is een relatief veelvoorkomende aangeboren afwijking 
(congenitale aandoening / geboortedefect) waarbij de slokdarm (oesofagus) en luchtpijp 
(trachea) betrokken zijn. Het is de meest voorkomende aangeboren afwijking van de slok-
darm. In Europa is één op de 4.000 pasgeborenen geboren met een slokdarmatresie. In 
Nederland worden er jaarlijks 35-55 kinderen geboren met slokdarmatresie (1 per 4.000 
geboortes). 
Atresie is de term die gebruikt wordt om een aangeboren afwijking te beschrijven waarbij een 
natuurlijke lichaamsopening afgesloten is of geheel ontbreekt. In kinderen geboren met 
slokdarmatresie is het middelste gedeelte van de slokdarm afwezig en niet verbonden met het 
onderste gedeelte van de slokdarm, welke verbonden is met de maag. Een kind geboren met 
slokdarmatresie heeft last van teruggeven van voeding en speeksel doordat dit niet naar de 
maag kan passeren. Kinderen geboren met een slokdarmatresie hebben vaak ook een 
verbinding tussen de slokdarm en luchtpijp, een zogeheten tracheo-oesofageale fistel. Deze 
fistel – afhankelijk van de precieze locatie in de slokdarm – zorgt ervoor dat voeding, speeksel 
en maagzuur in de luchtpijp en longen terecht komt. Als de tracheo-oesofageale fistel niet 
snel na geboorte opgespoord en behandeld wordt, kan het pasgeboren kind ademhalings-
problemen, een luchtweginfectie (longontsteking) of zelfs een acute obstructie van de 
bovenste luchtwegen met een daaropvolgende acute ademstop ontwikkelen.
Een kind kan geboren worden met een geïsoleerde slokdarmatresie, een geïsoleerde tracheo-
oesofageale fistel of een combinatie van de twee (meest voorkomend). Via het classificatie-
systeem van Gross wordt slokdarmatresie onderverdeeld in vijf types: type A (geïsoleerde 
slokdarmatresie), type B (slokdarmatresie met fistel hoog in de slokdarm), type C (slokdarm-
atresie met fistel laag in de slokdarm), type D (slokdarmatresie met twee fistels) en type E 
(geïsoleerde tracheo-oesofageale fistel)  figuur 1.1 . 
Aangezien maagdarmproblemen de groei negatief kunnen beïnvloeden beschrijft Hoofdstuk
          de groei van geboorte tot aan de schoolleeftijd van 12 jaar in 126 kinderen met slokdarm-
atresie. In vergelijking met de algemene populatie hadden kinderen met slokdarmatresie een 
significant lager gewicht tot aan de leeftijd van vijf jaar. Een significant kleinere lengte werd in 
de eerste acht levensjaren gezien. Zowel gewicht als lengte waren bij 12 jaar genormaliseerd. 
Twee van de bestudeerde potentieel verklarende variabelen – laag geboortegewicht en 
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anti-reflux chirurgie (operatie tegen het omhoogkomen van maagzuur in de slokdarm) – 
waren geassocieerd met het achterblijven van gewicht en lengte.
Hoofdstuk            beschrijft de huidige kennis over maagdarmproblemen die op de lange 
termijn ontstaan na operatief herstel van een slokdarmatresie. De overleving na een herstel-
operatie nadert 100% in gespecialiseerde centra. In bijna alle slokdarmatresiepatiënten zijn 
de ritmische bewegingen van de slokdarm – bijvoorbeeld tijdens het slikken – verstoord en 
komt omhoogkomend maagzuur (reflux) veel voor bij zowel kinderen als volwassenen. Reflux 
zorgt voor maagdarmproblemen zoals slikklachten, vernauwingen van de slokdarm, 
slokdarmontsteking, Barrettslokdarm en slokdarmkanker. Bij een Barrettslokdarm is het 
slijmvlies in de slokdarm veranderd, waarbij er een verhoogde kans is op het ontstaan van 
slokdarmkanker. Gestructureerde follow-up programma’s met multidisciplinaire teams 
kunnen de problemen bij slokdarmatresiepatiënten mogelijk verminderen. Ten tijden van het 
schrijven van dit hoofdstuk ontbraken richtlijnen voor periodieke controle van de slokdarm 
in slokdarmatresiepatiënten. De paar strategieën voor slokdarm surveillance programma’s 
die in de literatuur beschreven zijn worden kort genoemd.
In Hoofdstuk            worden de resultaten van pH-impedantie metingen bij kinderen van ≤18 
maanden en 8 jaar oud beschreven. Bij zowel de baby’s als bij de oudere kinderen kwam 
niet-zure reflux vaker voor dan zure reflux. Na handmatige revisie van de metingen werd een 
hoog percentage refluxmomenten verwijderd. Het is dus de vraag of automatische analyse van 
deze metingen accuraat genoeg is om refluxpatronen te kunnen identificeren bij patiënten 
met complexe motiliteitsstoornissen zoals slokdarmatresie.
Hoofdstuk            beschrijft de resultaten van een grote nationale multicenterstudie in 454 
kinderen met slokdarmatresie, waarin het ontstaan van hardnekkige terugkerende slokdarm-
vernauwingen werd onderzocht. Risicofactoren voor het krijgen van een hardnekkige 
terugkerende slokdarmvernauwing zijn: een slokdarmatresie zonder fistel (Gross type A), 
naadlekkage na de slokdarmoperatie en een slokdarmvernauwing binnen 28 dagen na de 
slokdarmoperatie. 
Om (kwaadaardige) afwijkingen van het slokdarmslijmvlies tijdig op te sporen wordt in 
recente richtlijnen (2016) aangeraden om de slokdarm van volwassenen geboren met een 
slokdarmatresie regelmatig te controleren, echter moet de ideale surveillancestrategie nog 
bepaald worden. Het Erasmus MC is sinds 2013 gestart met een screening en surveillance 
programma, waarbij patiënten vanaf 17 jaar oud bij de MDL-arts op de polikliniek gezien 
worden. Na overleg wordt er middels een kijkonderzoek in de slokdarm (gastroscopie) het 
slokdarmslijmvlies beoordeeld. De resultaten hiervan worden beschreven in Hoofdstuk           . 
Van de 151 patiënten werd er in 6,6% Barrettslokdarm gevonden, dit is 4-5 keer hoger dan te 






variabelen was enkel anti-reflux chirurgie geassocieerd met het ontwikkelen van Barrett-
slokdarm. Van alle patiënten ontwikkelde 0,7% slokdarmkanker (plaveiselcelcarcinoom),  
wat 108-maal hoger is dan in de algemene populatie te verwachten valt. 
In Hoofdstuk            worden vier slokdarmatresiepatiënten beschreven die op jonge leeftijd 
kanker van het bovenste deel van het maagdarmkanaal hebben ontwikkeld. Drie patiënten 
kregen slokdarmkanker en een patiënt kreeg dikke darmkanker in een stuk dikke darm wat op 
kinderleeftijd gebruikt was om de slokdarm met de maag te verbinden (colon-interpositie). 
De relatief jonge leeftijd waarop de kanker werd gevonden, de aanwezigheid van maar een 
paar bekende risicofactoren voor kanker en de hoge kankerincidentie bij slokdarmatresie-
patiënten suggereert een verhoogd risico op ontstaan van kanker na herstellen van 
slokdarmatresie.
De algemene discussie in Hoofdstuk            behandelt de volgende punten: de onderzoeken uit  
dit proef schrift in relatie tot de literatuur, de sterke en zwakke punten van de onderzoeken uit 
dit proefschrift en de richtingen voor toekomstig onderzoek. De belangrijkste aanbevelingen 
zijn de volgende:
•	 Structurele	follow-up	van	alle	kinderen	met	slokdarmatresie	–	in	het	bijzonder	diegene	 
die een anti-reflux operatie hebben gehad – dient tot de volwassen leeftijd overwogen  
te worden, aangezien het onbekend is of groeiontwikkeling normaal blijft tijdens de 
pubertijd. Diëtisten, als onderdeel van een multidisciplinair team, dienen betrokken te zijn 
tijdens (initiële) ziekenhuisopname en follow-up om de voedingsstatus in de vroege jaren te 
optimaliseren, wat cruciaal is voor normale ontwikkeling van hersenen en immuunsysteem.  
•	 Met	automatische	analyse	van	pH-impedantie	metingen	in	slokdarmatresiepatiënten	vindt	
overdetectie van reflux plaats. Dit laat de noodzaak zien voor het verfijnen van automatische 
software voor het gebruik bij kinderen met slokdarmatresie. Het hoge aantal niet zure 
refluxmomenten bij een normale refluxindex (zuurindex) bij kinderen met slokdarmatresie 
stelt de noodzaak voor standaardbehandeling met zuurremmers in deze patiënten ter 
discussie. 
•	 Studies	die	zich	focussen	op	verschillende	operatietechnieken	voor	herstellen	van	
slokdarmatresie zijn nodig om het mechanisme achter het ontwikkelen van een 
hardnekkige terugkerende slokdarmvernauwing verder te bekijken. Onderzoeken met 
pH-impedantie metingen en/of slokdarmbiopten (histologische oesofagitis) kunnen de  
rol van reflux bij het ontstaan van hardnekkige terugkerende slokdarmvernauwing 
onderzoeken.
•	 Overgang	van	Kindergeneeskunde	naar	de	volwassen	Maag-darm-leverziekten	afdeling	is	
belangrijk voor levenslange endoscopische follow-up om relevante slokdarmafwijkingen in 
een vroeg stadium op te sporen. Aangezien anti-reflux chirurgie een risicofactor voor zowel 
groeiachterstand als Barrettslokdarm is, lijkt structurele follow-up in zowel kinderen als 





het vastleggen van klinische parameters (bijv. lengte slokdarmatresie, reflux, 
slokdarmvernauwingen) en longitudinale dataverzameling is noodzakelijk voor  
het beantwoorden van de vraag ‘Hoe optimaliseer je de lange termijn zorg voor 
maagdarmproblemen bij patiënten geboren met een slokdarmatresie?’.
•	 Om	naar	voorspellers	van	kwaadaardige	progressie	bij	patiënten	geboren	met	een	




list of abbreviations      161
contributing authors      163
bibliography      166
phd portfolio      167
acknowledgements dankwoord      170




 BE Barrett’s esophagus
 BCT bolus clearance time
 BMI body mass index
 CI confidence interval
 CT scan computed tomography scan
 DTH distance-to-height
 EA esophageal atresia
 EAC esophageal adenocarcinoma
 ESCC esophageal squamous cell carcinoma
 GEJ gastroesophageal junction / gastric folds
 GER  gastroesophageal reflux
 GERD  gastroesophageal reflux disease
 GM gastric metaplasia
 GOR gastro-oesophageal reflux
 GORD gastro-oesophageal reflux disease
 HFA height-for-age
 IM intestinal metaplasia
 IQR inter-quartile range
 ISFET  ion-sensitive field-effect transistor
 MMS  Medical Measurement Systems
 OA oesophageal atresia
 PET-CT scan positron emission tomography-computed tomography scan
 pH-MII monitoring pH and impedance monitoring
 PPI proton pump inhibitor
 RBM retrograde bolus movements
 RI  reflux index
 SAP  symptom association probability
 SD standard deviation
 SI  symptom index for reflux
 SDS standard deviation score
 SGA small for gestational age
 TEF tracheoesophageal fistula
 TH target height
 TOF tracheo-oesophageal fistula 




 CHARGE coloboma, heart defects, atresia of the choanae, retardation  
of growth, genital and urinary abnormalities, ear abnormalities 
and/or hearing loss
 VACTERL vertebral anomalies, anal atresia, cardiac anomalies, 
tracheoesophageal fistula, renal anomalies, and limb defects
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Het boek is af! Na 3 jaar full-time onderzoek in het Erasmus MC en de afrondingsfase tijdens 
mijn werk als aios MDL ligt hij er dan eindelijk. Wat ben ik blij en trots op dit boek. Deze thesis 
was er niet gekomen zonder de steun en hulp van velen. In dit laatste (en meest gelezen) 
hoofdstuk wil ik graag een aantal van hen in het bijzonder bedanken. 
Allereerst wil ik graag mijn promotor vanuit de afdeling Maag-, Darm- en Leverziekten, Prof. 
dr. M.J. Bruno, bedanken. Beste Marco, precies 6 jaar geleden in mei 2014 mocht ik na het 
sturen van een open sollicitatiebrief bij jou op gesprek komen. Vier maanden later begon ik 
als kersverse onderzoeker aan mijn onderzoek over patiënten geboren met slokdarmatresie: 
de eerste onderzoekssamenwerking tussen de afdeling Maag-, Darm- en Leverziekten en 
afdeling Kinderchirurgie in het Erasmus MC. Bedankt voor het vertrouwen in mij, de 
begeleiding bij mijn projecten en kritische feedback op mijn stukken. Ik heb hier veel van 
geleerd en kijk ernaar uit om straks als aios MDL in het Erasmus MC meer van je te kunnen 
leren. 
Als tweede wil ik graag mijn promotor vanuit de afdeling Kinderchirurgie, prof. dr. R.M.H. 
Wijnen, bedanken. Beste René, wat vond ik het leuk om een kijkje bij de kinderchirurgie te 
mogen nemen. In 2006 begon ik geneeskunde met het idee chirurg te worden. Dat is in de 
loop van de jaren veranderd, maar ik blijf het een mooi vak vinden. Ik weet nog goed dat ik 
met je mee naar OK ging, om mee te kijken bij een slokdarmatresiecorrectie bij een 
pasgeborene. Wat een bewondering heb ik voor jou en je collega’s hoe je dit bij zo’n kleintje 
voor elkaar krijgt. En dan te bedenken dat ik volwassen patiënten op de poli zag en dat een 
groot deel nog geeneens slikklachten had! Ik wil je bedanken voor je steun de afgelopen  
jaren bij het opzetten van projecten binnen het EMC en (inter-)nationale samenwerking,  
je feedback op mijn manuscripten en de gezellige en leerzame tijd in Sydney.  
Mijn co-promotoren prof. dr. M.C.W. Spaander en dr. H. IJsselstijn, ik had me geen beter 
duo kunnen bedenken! Wat ben ik enorm blij met jullie fijne begeleiding van de afgelopen 
jaren. Lieve Manon, hoe jij je staande houdt met al je activiteiten blijft me verbazen: (poli-)
kliniek, diensten, protocollencommissies, congressen, landelijk bevolkingsonderzoek 
darmkanker, een tiental PhD-ers begeleiden en natuurlijk je gezin. En dat allemaal met een 
glimlach en oprechte interesse in de ander. Naast sociale en politieke vaardigheden bevat jij 
ook de gave om elk manuscript om te vormen in een betere versie. Ik heb veel van je geleerd 
de afgelopen jaren en wil je bedanken voor je humor, eerlijkheid, steun en het vertrouwen in 
mij. Ik kijk er enorm naar uit om over een paar jaar in het Erasmus MC samen met je te werken 
en nog meer van je te leren. Lieve Hanneke, wat heb ik genoten van jouw begeleiding. Je bent 
een ontzettend positieve vrouw die politiek heel sterk is en zich staande houdt in een (toch 
wel) mannenwereld. De (inter-)nationale samenwerkingsverbanden zoals ze er nu zijn waren 
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geresulteerd heeft in minder vragen van kritische reviewers. Je was overal van op de hoogte  
en ik kon altijd met een vraag bij je terecht. Bedankt voor je fijne begeleiding de afgelopen 
jaren, ik vind het jammer dat deze leerzame en gezellige periode na vandaag beëindigd is! 
 
Geachte leden van de leescommissie: prof. dr. J.C. Escher, prof. dr. M.P. Peppelenbosch  
en prof. dr. R. Emblem, dank voor het beoordelen van mijn proefschrift / thank you for 
reviewing my thesis. Prof. dr. M.P. Peppelenbosch, prof. dr. J.C. Escher, dr. R.H.J. Houwen, 
prof. dr. R.M.W. Hofstra en prof. dr. L.W.E. van Heurn: ik ben vereerd dat u zitting wilt 
nemen in de promotiecommissie van mijn proefschriftverdediging.
Beste prof. dr. C.J. van der Woude, opleider in het Erasmus MC, bedankt voor het vertrouwen 
in mij door mij op te leiden tot Maag-, Darm- en Leverarts.
Beste dr. H. Boom, dr J.T. Brouwer, dr. B.J. Veldt en alle overige stafleden en collega 
arts-assistenten in het Reinier de Graaf Gasthuis, bedankt voor de warme start in Delft. Ik 
ben blij dat ik in deze fijne plek mijn vooropleiding mocht starten en kijk uit naar de komende 
opleidingsjaren op de afdeling Maag-, Darm- en Leverziekten. 
Zonder mijn collega’s van ‘het dak’ was mijn PhD-tijd nooit zo leuk geweest. Al die gezellige 
momenten op de kamers, bij journal clubs, buiten-de-deur-lunches (BDDL), borrels, diners, 
congressen en ski-weekenden, dank voor deze onvergetelijke tijd! Sil en Esmée, mijn eerste 
kamergenootjes. Bedankt voor alle gezelligheid, jullie steun en luisterend oor bij frustratie-
momenten die ik gelukkig altijd bij jullie kwijt kon. Ik heb me vanaf moment één welkom 
gevoeld en kijk met plezier terug op deze tijd. Lieve dakduifjes (Els, Margo, Sil, Esmée, 
Louisa, Sophia, Joany, Maren, Shannon en Eline), dank voor alle onvergetelijke avonden, 
gesprekken en steun de afgelopen jaren. Ik heb zin in ons volgende dakduivendiner en kijk  
uit naar de periode dat we weer mdl-collega’s in het Erasmus MC zijn!  
Lieve Rianne en Margo, wat ben ik blij dat jullie vandaag als paranimfen naast mij staan.  
Lieve Rianne: van studiegenootje, naar huisgenootje en goede vriendin. Wat hebben wij  
veel gedeeld de afgelopen jaren. Van vrolijke momenten tot verdrietige, we kunnen altijd  
bij elkaar terecht. Ik heb genoten van onze themafeestjes, de geslaagde avonden met de 
kookclub, alle goede gesprekken en ook van je hulp en je kritische blik bij mijn vragen. 
Bedankt voor deze hechte vriendschap. Lieve Margo, wat ben ik blij dat wij samen in het 
Reinier de Graaf werken. Van PhD-collega naar goede vriendin en collega in Delft. Bedankt 
voor alle gezellige momenten en steun de afgelopen periode. Als ik het nodig had stond jij 
klaar met een luisterend oor en opbeurende woorden. Ik kan goed met je lachen en een 
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avondje met jou in de kroeg of op een festival is gegarandeerd geslaagd. Ik kijk uit naar alle 
gezellige etentjes, borrels, feestjes in de toekomst en hoop dat we nog lang collega’s en 
vriendinnen zullen blijven. 
Lieve vriendinnen, bedankt voor alle gezellige momenten en steun tijdens moeilijke tijden. 
Eva, vriendin vanaf toen we nog kleine meiden waren. Wat fijn om zo’n goede vriendin te 
hebben die als familie aanvoelt. Esmee en Maartje, na de middelbare school zijn we alle drie 
een andere kant op gegaan, maar ik ben blij dat we toch nog zulke goede vriendinnen zijn. 
Astrid en Hilal, mijn maatjes uit Tergooi Ziekenhuis, bedankt voor alle fijne momenten toen 
in het ziekenhuis en nu daarbuiten! Lieve Berthe, Floor, Linda, Marieke, Marjolein en 
Rianne, na 14 jaar zijn we van geneeskunde studiegenootjes uitgegroeid naar een hechte 
vriendinnengroep. Wat heb ik genoten van onze zangkunsten tijdens de Singstar-avonden,  
de creaties tijdens het spelen van Charades (vooral het uitbeelden van de ziektebeelden ter 
voorbereiding van ons KLOP-tentamen was legendarisch!), de Sinterklaasgedichten, 
weekendjes weg en al die andere gezellige middagen/avonden. De meiden van ‘De 
Spaansekraag’, opgericht na onze verpleeghulpstage in het 1e jaar. Ik ben onwijs blij met  
jullie en vind het jammer dat ik niet meer bij jullie in de buurt in Amsterdam woon. 
Beste Ko, wat fijn dat je mijn manuscripten altijd snel en uitgebreid van commentaar op het 
Engels hebt willen voorzien. Ik heb veel geleerd van je duidelijke feedback, bedankt hiervoor! 
Beste Joost en Nicole, bedankt voor jullie hulp bij het uitvoeren van de statistische analyses 
voor mijn studies. Beste Marjolein en John, bedankt voor jullie hulp en feedback om de 
manuscripten over respectievelijk groei en strictuurvorming tot het niveau te brengen van  
wat ze nu zijn. Ook zou ik graag alle co-auteurs willen bedanken voor de fijne samenwerking 
en hoop dat er in de toekomst nog meer mooie studies samen uitgevoerd zullen worden. 
Over de toekomst gesproken, mijn opvolgster Chantal, wat ben jij met enthousiasme en 
energie aan je onderzoeksperiode begonnen. Leuk om te zien hoe jij je onderzoeksprojecten 
binnen de drie afdelingen Klinische Genetica, Kinderchirurgie en Maag-, Darm- en Lever-
ziekten tot een succes weet te brengen. Met een gerust hart heb ik dan ook de Biobank 
Slokdarmatresie aan jou over gedragen. Inmiddels ben je alweer aan het laatste jaar van je 
promotietraject begonnen. Ik wil je heel veel succes wensen met de afronding van je 
manuscripten en hopelijk zal na een periode als anios een mooie opleidingsplek tot chirurg 
voor je wachten. 
Beste prof. dr. J.C. Molenaar en zuster Leni, dankzij jullie zorgvuldige verslaglegging in de 
operatie logboeken van het Sophia Kinderziekenhuis (in sierlijk handschrift van zuster Leni)  
is het mij gelukt om bijna alle volwassenen die ooit in het Sophia voor slokdarmatresie 
geopereerd zijn aan te schrijven en uit te nodigen voor ons follow-up programma.  
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Een aantal van hen hoorden van mij op de polikliniek voor het eerst waarvoor zij ooit op 
kinderleeftijd geopereerd waren en waarvoor zij dus dat litteken hadden! 
Nermin en Ronald, hartelijk dank voor de prettige samenwerking en voor al jullie hulp bij het 
inplannen en oproepen van patiënten op de polikliniek. Adriana en Petra, na het uitpluizen 
van de oude handgeschreven logboeken van de operaties in het Sophia Kinderziekenhuis was 
het nog een flinke klus om deze patiënten geboren met slokdarmatresie aan te kunnen 
schrijven. Dank voor jullie hulp bij het opvragen van de adresgegevens en versturen van onze 
informatiebrieven. 
Marja, Carla, Berna en Andrea, wat moet een promovendus zonder zulke fijne secretaresses 
als jullie! Ik wil jullie bedanken voor jullie hulp bij het inplannen van afspraken, verzamelen 
van handtekeningen, hulp bij praktische zaken en ook vooral voor alle gezellige praatjes 
tussendoor.
JoAnne en Joost, wat zou een patiëntenvereniging zonder zulke enthousiaste bestuursleden 
als jullie moeten. Bedankt voor de fijne samenwerking met VOKS.
Lieve tante Tess, wat vind ik het enorm leuk dat jij mijn proefschrift zo mooi hebt vorm-
gegeven. Dank voor deze creatieve bijdrage aan mijn proefschrift! 
Lieve Inge, mijn grote zus die mij een kijkje op het werk in de operatiekamer gaf. Bedankt 
voor je goede voorbeeld!
Lieve Sas, lieve zus, wat ben ik trots op jou. Super om te zien wat je op je werk hebt bereikt.  
Je bent sterk, lief en positief, een combinatie waarmee je ver komt in het leven! 
Lieve pap en mam, wat ben ik blij met zulke lieve ouders. Dank voor al jullie steun en liefde, 
jullie hebben het mogelijk gemaakt dat ik hier vandaag sta. 
Lieve Mark, bedankt dat jij al 10 jaar naast mij staat. Het is lastig hier te beschrijven hoe 
ontzettend veel jij voor mij betekent. Jouw liefde, vertrouwen, flexibiliteit en steun gaven mij 
de mogelijkheid om mijn proefschrift naast een drukke baan als aios af te ronden. Bedankt 
dat je mij al deze jaren hebt gesteund. Het voltooien van dit proefschrift was niet gelukt 
zonder jou. Hoe langer we bij elkaar zijn, hoe duidelijker het wordt: met jou wil ik oud 
worden. Ik kijk uit naar alle avonturen, reizen en andere mooie momenten in ons verdere 
leven samen!
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